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Hypoglycaemia is the commonest complication of insulin-treated diabetes. In the initial Chapters of this
thesis, the physiological and clinical aspects of hypoglycaemia are described, and the literature examining the
effects of both acute and recurrent hypoglycaemia on cognitive function in humans is reviewed. The
remaining Chapters describe original experimental studies in which the neuro-cognitive sequelae and the
prevention of insulin-induced hypoglycaemia were examined.
Acute hypoglycaemia was induced in 16 non-diabetic subjects using a modified hyperinsulinaemic glucose
clamp technique and caused predictable decrements in cognitive performance. However, acute
hypoglycaernia had no effect on the function of the peripheral nervous system, as assessed by nerve
conduction studies performed on the dominant median and common peroneal nerves. This lack of effect of
acute hypoglycaemia on peripheral nerve function suggests that peripheral neurones do not have the same
obligate requirement for glucose as a metabolic fuel as neurones of the central nervous system.
The temporal changes in mood states and cognitive functions following a single, spontaneous episode of
severe hypoglycaemia in 20 people with insulin-treated diabetes were examined. Recovery from any acute
cognitive decrement following severe hypoglycaemia'was complete by 1.5 days, although decreased levels of
'happiness' and 'energy' appeared to take longer to recover. Compared to 'control' subjects who had not
experienced severe hypoglycaemia for over one year, the 'hypo' subjects had persistent cognitive decrements
and altered mood states which may have been a consequence of previous exposure to recurrent episodes of
severe hypoglycaemia.
The identification of serum markers that could predict the degree of neuronal damage and prognosis of
patients after severe hypoglycaemia would have considerable clinical value. Neurone-Specific Enolase (NSE)
and Protein S-100 (S-100) are markers of acute neuronal damage in various neurological disorders. Serum
concentrations of these markers did not rise in 16 diabetic subjects who experienced an episode of severe
hypoglycaemia and who made a complete neurological recovery. However, serum concentrations of the
markers did rise in two of three patients who died following an episode of severe hypoglycaemia. These
preliminary results suggest that measurement of serum concentrations of NSE and S-100 may have a future
role in evaluating clinical outcome following an episode of severe hypoglycaemia which is associated with
neurological damage.
Insulin lispro is a rapid-acting analogue of human insulin which is associated with a diminished frequency of
nocturnal hypoglycaemia. With certain meal types, however, the use of lispro could theoretically be
associated with an increased risk of post-prandial hypoglycaemia. The glucodynamics of pre- and post-
prandially administered lispro were examined following test meals in which the proportion of the
carbohydrate and fat, and liquid and solid constituents was varied. The optimum timing of injection of lispro
was, in part, dependent on the constituents of the test meals. Optimum glucodynamics for a high
carbohydrate/low fat meal were obtained with pre-prandial administration of lispro. However, large
decremental glucose excursions were seen when lispro was injected before meals with a high fat/low
carbohydrate content, resulting in an increased risk of post-prandial hypoglycaemia. A more favourable
glucodynamic pattern was observed when lispro was injected after high fat/low carbohydrate meals.
ABSTRACT OF THESIS
>GS/ABST/94 Use this side only
ACKNOWLEDGEMENTS
I gratefully acknowledge the enormous help, support and guidance provided by Dr
Brian Frier and Professor Ian Deary, who acted as co-supervisors during my research
fellowship. They gave dynamic leadership to our research team and provided a
potent stimulus for my development as a clinical researcher. Dr Frier has an
encyclopaedic knowledge of the clinical aspects of hypoglycaemia and, under his
auspices, I learnt about study design, the nuances of patient recruitment, and the finer
aspects of the English language. Professor Deary gave me an insight into the
complicated worlds of psychometric testing and statistical analysis, and was always
on hand to discuss the wider implications of the research findings. I am also grateful
to my co-research fellows, Dr Fiona Ewing and Dr Stewart Ferguson, who helped out
with my clamp studies and who were there to share the successes, and the failures!
Eli Lilly and Company provided financial support towards my research fellowship
and, in particular, I would like to thank Dr Jonathan Janes, Ms Jyothi Lakhanpal and
Ms Sharon McCarthy. Dr Roy Sherwood and Ms Hagosa Abraha, from the
Department of Clinical Biochemistry at King's College, London, performed the NSE
and S-100 assays and also provided much needed background information on these
serum markers. Dr Alistair Lammie, from the Department of Pathology at the
University of Edinburgh, educated us all in the neuropathology of hypoglycaemic
brain damage and provided detailed neuropathological reports on two of the cases in
Study 3. Dr Petros Perros, from the Freeman Flospital, Newcastle, kindly provided
me with the clinical details of one of the patients presented in Study 3, and arranged
for blood samples to be sent to London. Dr Matthew Young, from the Department of
Diabetes at the Royal Infirmary of Edinburgh, expertly taught me the subtleties of
peripheral nerve conduction studies.
Finally I would like to thank all the staff and patients of the Department of Diabetes
at the Royal Infirmary of Edinburgh who supported me throughout and were willing






ABSTRACT OF THESIS 4
ACKNOWLDEGEMENTS 5
INDICES 6
SUMMARIES OF STUDIES 11
CHAPTER 1: PATHOPHYSIOLOGICAL AND CLINICAL ASPECTS OF 19
HYPOGLYCAEMIA
1.1 Historical Background 20
1.2 Definitions of Hypoglycaemia 21
1.3 Physiological Responses to Hypoglycaemia 24
1.4 Neurobiochemical and Neuropathological Effects of Hypoglycaemia 30
1.5 Frequency of Hypoglycaemia 34
1.6 Risk Factors for Severe Hypoglycaemia 35
1.7 Morbidity and Mortality of Severe Hypoglycaemia 41
1.8 Reducing the Frequency of Severe Hypoglycaemia 43
1.9 Summary 50
CHAPTER 2: EFFECTS OF HYPOGLYCAEMIA ON COGNITIVE FUNCTION 51
2.1 Effects of Acute Hypoglycaemia on Cognitive Function 52
2.2 Effects of Recurrent Severe Hypoglycaemia on Cognitive Function 71
CHAPTER 3: HYPOTHESES FOR STUDIES 81
3.1 Acute Hypoglycaemia, the Peripheral Nervous System and Information 82
Processing
3.2 Recovery from Severe Hypoglycaemia 83
3.3 Determining Prognosis after Severe Hypoglycaemia 83
3.4 Insulin Lispro and Post-Prandial Hypoglycaemia 84
CHAPTER 4: METHODS: COGNITIVE FUNCTION TESTS AND NERVE 85
CONDUCTION STUDIES
4.1 Cognitive Function Tests 86
4.2 Methodological Issues in the Measurement of Peripheral Motor Nerve Function 94
6
CHAPTER 5: STUDY 1 - EFFECTS OF ACUTE HYPOGLYCAEMIA ON THE 98
PERIPHERAL NERVOUS SYSTEM AND THE INFORMATION PROCESSING





CHAPTER 6: STUDY 2 - RECOVERY OF COGNITIVE FUNCTION AND 129





CHAPTER 7: STUDY 3 - EVALUATION OF SERUM MARKERS OF NEURONAL 158





CHAPTER 8: STUDY 4 - DETERMINATION OF THE OPTIMAL TIME FOR 177






CHAPTER 9: CONCLUSIONS AND FUTURE RESEARCH 201
9.1 Acute Hypoglycaemia, the Peripheral Nervous System and Information 202
Processing
9.2 Recovery from Severe Hypoglycaemia 204
9.3 Determining Prognosis after Severe Hypoglycaemia 205








1.1: Glucose Thresholds of the Physiological and Neurological Effects of Acute 23
Hypoglycaemia
1.2: Schematic Representation of Glycolysis and Oxidative Phosphorylation 25
1.3: Physiological Responses to Acute Hypoglycaemia 28
1.4: Relationship between Glycaemic Control and Severe Hypoglycaemia in 37
the DCCT.
1.5: Amino Acid Sequence of Insulin Lispro 46
1.6: Time-Action Profiles of Soluble Insulin and Insulin Lispro 48
4.1: The Hick Reaction Time Paradigm 93
5.1: Schematic Representation of Study Design 105
5.2: Blood Glucose Profiles during the Euglycaemic and Hypoglycaemic Clamp 114
Studies
5.3: Effects of Acute Hypoglycaemia on the Decision Time Component of 118
Choice Reaction Times
5.4: Effects of Acute Hypoglycaemia on the Movement Time Component of 119
Choice Reaction Times
6.1: Graphic Representation of the Hypothesised 'Hangover' Effect of Severe 138
Hypoglycaemia on Cognitive Function
7.1: Section of CA4 Zone of the Hippocampus from Patient 1 168
7.2: Section of the Superficial Cortex (Layer 2) from Patient 2 168
7.3: Serum Concentrations of NSE in the 'Hypo' and 'Control' Subjects, and 169
in Patients 1 and 2
7.4: Serum Concentrations of S-100 in the 'Hypo' and 'Control' Subjects, and 170
in Patients 1 and 2
7.5: Serum S-100 Concentrations in Patient 3 171
8.1: Glucose Excursions Following the High Carbohydrate Liquid (CL) Meal 190
8.2: Glucose Excursions Following the High Carbohydrate Solid (CS) Meal 191
8.3: Glucose Excursions Following the High Fat Liquid (FL) Meal 192




2.1: Cognitive Tasks Impaired during Acute Hypoglycaemia 56
5.1: Results of Cognitive Function Tests and Symptom Scores During 115
Euglycaemia and Hypoglycaemia
5.2: Choice Reaction Times during Euglycaemia and Hypoglycaemia 116
5.3: Median and Common Peroneal Motor Nerve Conduction Velocities and 117
Amplitudes
6.1: History of Severe Hypoglycaemia 142
6.2: Clinical Characteristics of Subjects 143
6.3: Cognitive Test Results 144
6.4: Mood Scale Results 148
6.5: Cognitive Function Self-Appraisal Scale - 'Change' Scores 149
6.6: Standardised Residuals (Z-score format) of Significant Cognitive Tasks 150
and Mood Scales after Adjustment for Severe Hypoglycaemia History
7.1: Clinical Characteristics of Subjects and Timing of Blood Samples 167
8.1: Clinical Characteristics of Subjects 184
8.2: Constituents of Test Meals 185
8.3: Baseline Blood Glucose Concentrations 189
10
SUMMARY OF STUDY 1
Background and Aims
Acute hypoglycaemia causes impairment of cognitive function in people with and
without diabetes. There is evidence that profound and prolonged acute
hypoglycaemia can facilitate the development of a peripheral neuropathy. However,
few controlled studies have assessed the impact of a more moderate degree and
duration of acute hypoglycaemia on the function of the peripheral nervous system.
This study assessed the impact of 60 minutes of acute hypoglycaemia on parameters
of peripheral neural function.
It has also been suggested that individual differences in intelligence and speed of
information processing may be mediated by the speed of nerve conduction within the
central nervous system, and that an indirect measure of this can be obtained by
measuring peripheral nerve conduction velocities. Therefore, a secondary aim of the
investigation was, within a single study, to examine comprehensively the effects of
controlled hypoglycaemia on different levels of human information processing. By
testing all such levels during hypoglycaemia in the same group of subjects, it was
possible to investigate the lower level processes that may contribute to the
decrements in higher-level mental performance.
Methods
Sixteen non-diabetic humans underwent two separate hyperinsulinaemic glucose
clamp procedures on different study days, in a counterbalanced fashion. On one
occasion euglycaemia was maintained (blood glucose 5.0 mmol/1) and on the other
occasion hypoglycaemia was induced (blood glucose 2.6 mmol/1). During each
condition, subjects performed a combined psychometric, cognitive-experimental and
psychophysical test battery. Nerve conduction studies were also performed on the
dominant-side median and common peroneal nerves and measurements were made
of the motor nerve conduction velocities, the amplitudes of the motor action
potentials, and the ratios of the amplitudes after proximal and distal stimulation (a
measure of conduction block).
Results
Hypoglycaemia caused impaired performance of general cognitive and information
processing tasks at the cognitive-experimental and psychophysical level (p<0.05).
However, peripheral motor nerve conduction velocities and the amplitudes of motor
action potentials were unaffected (p>0.05). In addition there was no evidence of
peripheral neural conduction block. The common peroneal nerve conduction
velocities reduced with time in both conditions (p<0.01), but no effect of time was
observed with any of the other neurophysiological parameters.
Conclusions
Multiple levels of information processing in the brain were altered while peripheral
nerve function remained intact. This implies that peripheral neural function may not
be used as a surrogate marker of speed of neuronal conduction within the central
nervous system in future studies attempting to determine the underling neural
mechanisms of intelligence. The lack of effect of acute hypoglycaemia on peripheral
nerve function also suggests that peripheral neurones do not have the same obligate
requirement for glucose as a metabolic fuel as neurones of the central nervous
system. The change in common peroneal nerve conduction velocities requires
further investigation, but may indicate an effect of hyperinsulinaemia on peripheral
neural function.
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SUMMARY OF STUDY 2
Background and Aim
Acute hypoglycaemia in non-diabetic and diabetic humans impairs cognitive
functions and alters mood states. There is considerable evidence from experimental
studies that cognitive decrements induced by moderate degrees and durations of
acute hypoglycaemia, and probably alterations in mood state, return to baseline
parameters within 45 - 60 minutes of restoration of normoglycaemia. However, no
previous studies have examined the time required for cognitive functions and moods
to return to normal after an acute episode of severe hypoglycaemia. The aim of the
present study was, therefore, to examine the temporal changes in mood states and
cognitive functions following a single, spontaneous episode of severe hypoglycaemia
occurring in people with insulin-treated diabetes.
Methods
Cognitive functions and moods were studied prospectively in 20 subjects with
insulin-treated diabetes who had experienced a spontaneous episode of severe
hypoglycaemia ('hypos'), and 20 matched subjects with insulin-treated diabetes who
had not experienced severe hypoglycaemia in the preceding year ('controls'). A
detailed battery of cognitive function tests and mood scales was administered at 1.5,
9 and 30 days following the severe hypoglycaemia, and at similar intervals for the
'controls'.
Results
The 'hypo' subjects had a history of a greater number of episodes of severe
hypoglycaemia (p<0.01). For the majority of cognitive tests, no evidence was
observed of a 'hangover' effect of acute hypoglycaemia on cognitive function
(p>0.05). A trend was noted for levels of Hedonic Tone (p=0.08) and Energetic
Arousal (p=0.05) to improve with time in the 'hypo' subjects, but not in the 'controls'.
However, the 'hypo' subjects had chronically elevated levels of depression (p=0.01)
and anxiety (p<0.05) and persistently performed more poorly in several cognitive
tests such as the Digit Symbol (p<0.01) and the Stroop (p<0.01) tasks. The
13
differences in cognitive performance between the groups disappeared after statistical
adjustment for previous severe hypoglycaemia history.
Conclusions
These results suggest that, in the main, recovery from any acute cognitive decrement
following severe hypoglycaemia was complete by 1.5 days, although decreased
levels of 'happiness' and 'energy' may take longer to recover. The persistent
cognitive decrements and altered mood states noted in the 'hypo' subjects may be a
consequence of previous exposure to recurrent episodes of severe hypoglycaemia.
14
SUMMARY OF STUDY 3
Background and Aim
The ability of severe hypoglycaemia to induce both transient and permanent
neurological abnormalities, and rarely death, is well recognised. Clinicians often
have difficulty in determining the prognosis of unconscious patients admitted
following an episode of severe hypoglycaemia. The identification of serum markers
that could predict the degree of neuronal damage and prognosis of patients after
severe hypoglycaemia would have considerable clinical value. Neurone-Specific
Enolase (NSE) and Protein S-100 (S-100) are markers of acute neuronal damage in
patients with various neurological disorders. The aim of the present study was to
determine if these proteins have a role in predicting clinical outcome following
severe hypoglycaemia by measuring changes in their serum concentrations with time
in patients who did and did not make a complete neurological recovery following
severe hypoglycaemia.
Methods
Serum concentrations of NSE and S-100 were measured at various time intervals in
16 patients with insulin-treated diabetes following an episode of severe
hypoglycaemia, which did not cause permanent neurological impairment (the 'hypo'
subjects), and in three diabetic patients who died following an episode of severe
hypoglycaemia. The proteins were also measured in 10 insulin-treated diabetic
subjects who had not experienced an episode of severe hypoglycaemia for at least
one year (the 'control' subjects).
Results
No difference in serum concentrations of NSE and S-100 was observed between the
'hypo' and 'control' subjects at either 36 hours or seven days after the episode of
severe hypoglycaemia (p>0.05). However, in two of the three subjects who died,
NSE and S-100 concentrations were markedly elevated.
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Conclusions
These preliminary results suggest that any neuronal injury occurring during an
episode of severe hypoglycaemia, which is not associated with permanent
neurological deficit, is insufficient to provoke elevation of these markers. However,
measurement of serum concentrations of NSE and S-100 may have a role in
evaluating clinical outcome following an episode of severe hypoglycaemia that is
associated with neurological damage.
16
SUMMARY OF STUDY 4
Background and Aim
Insulin lispro is an analogue of human insulin, which has a rapid onset of action and
a relatively short duration of action, allowing administration immediately before
food. Global studies, in patients with Type 1 diabetes, have suggested that therapy
with insulin lispro is associated with a diminished frequency of hypoglycaemia.
However, the Scottish diet has a much higher content of fat than is ingested in many
other European countries. In the context of a high fat diet, the rapid onset of action
of pre-prandially administered insulin lispro could result in early post-prandial
hypoglycaemia. In such circumstances, post-prandial injection of lispro may be
more appropriate. The aim of the present study was to compare the glucodynamics
of pre- and post-prandially administered lispro following test meals in which the
proportions of the carbohydrate and fat, and liquid and solid, constituents were
varied.
Methods
20 subjects with Type 1 diabetes were allocated into two groups. Group 1 subjects
(n=10) received isocaloric high carbohydrate/low fat breakfasts and high fat/low
carbohydrate breakfasts which had a marked liquid component. Group 2 subjects
(n=10) received isocaloric test meals with equivalent carbohydrate and fat
proportions to those in Group 1, but with a more marked solid phase. For each test
meal, lispro was injected pre-prandially (10 minutes before) on one occasion and
post-prandially (20 minutes after) on another. Blood glucose levels were measured
every 15 minutes for a two hour period, and the glucose excursions (difference in
blood glucose levels from baseline) calculated.
Results
For all meal types studied, pre-prandially administered lispro produced significantly
smaller glucose excursions (p<0.05). In the case of the high carbohydrate/low fat
breakfasts, the excursions observed following pre-prandial lispro were incremental,
although a small negative excursion occurred in the first 45 minutes after ingestion of
17
the more solid meal. Pre-prandial lispro produced decremental excursions after
consumption of the high fat/low carbohydrate breakfasts and in the case of the more
solid meal this was particularly marked. Post-prandially administered lispro resulted
in incremental glucose excursions after the high fat meals.
Conclusions
The optimum timing of injection of lispro is, in part, dependent on the constituents of
the meal to be ingested. If a high carbohydrate/low fat meal is to be consumed, pre-
prandial administration of lispro is superior. However, the large decremental glucose
excursions seen when lispro was injected before meals with a high fat/low
carbohydrate content (particularly when the food was mainly in the solid phase)
would result in an increased risk of early post-prandial hypoglycaemia. In such
circumstances, post-prandial administration of lispro may be more appropriate.
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CHAPTER 1





In 1910, Porges reported the earliest biochemically-confirmed observation of
hypoglycaemia in humans. He described the histories of three patients with
Addison's disease in whom blood glucose concentrations fell below 0.067%
(approximately 3.7 mmol/1)1. However, it was not until the pioneering work of
Frederick Banting, Charles Best, James Collip and John Macleod in Toronto in the
early 1920's2 that hypoglycaemia became firmly recognised as a clinical entity.
These investigators were responsible for the isolation, purification and subsequent
clinical application of insulin in the treatment of diabetes mellitus. In early
experiments, the Toronto investigators noted that rabbits injected with insulin
became increasingly hungry as their blood glucose concentrations fell, often to the
point that the animals would eat wood shavings or paper'. The rabbits would
eventually go on to develop convulsions and lapse into unconsciousness and, if left
untreated, would ultimately die3. Such 'hypoglycaemic reactions' could be reversed
following the injection of a solution of glucose.
Hypoglycaemia was also observed in some of the first human diabetic patients
treated with insulin4 and indeed several patients who were administered these early
insulin preparations died from what were later demonstrated to be 'hypoglycaemic
reactions'2. This led the pre-eminent diabetologist of the era, Elliott P. Joslin, to
observe that "insulin is not a cure for diabetes, but is a potent preparation, alike for
evil and for good"\
Over the last 80 years there have been considerable advances in insulin therapy.
Isophane and lente insulins, with a much more prolonged duration of action than
soluble insulin, were developed in the middle of the last century. There were
subsequent improvements in the purity of pork and beef insulin preparations and, in
the 1980's, advanced molecular genetic techniques lead to the introduction of insulins
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with the human amino acid sequence. These human insulins have largely replaced
animal insulins in the first-line management of people with Type 1 diabetes.
However, none of these advances have addressed the fundamental inadequacies of
exogenous insulin therapy. The concentrations of insulin that are administered
peripherally are far in excess of those seen physiologically within the hepatic portal
circulation. Moreover, while exogenous insulin regimens attempt to mimic the
pattern of insulin release observed in the non-diabetic state, they do so poorly and
clearly are not able to respond in a physiological manner to variations in blood
glucose concentrations. Consequently, hypoglycaemia is still the commonest
complication of insulin-treated diabetes6 and generates as much anxiety in patients as
the threat of advanced diabetic complications such as blindness or renal failure7. In
an attempt to reduce the frequency of hypoglycaemia, genetically engineered
analogues of human insulin have been developed, whose time-action profiles are
more representative of physiological insulin secretion. However, the magnitude and
consequences of hypoglycaemia remain immense. Few people with insulin-treated
diabetes escape intermittent exposure and, as a consequence, hypoglycaemia remains
the principal limiting factor in achieving good glycaemic control in patients with
o
diabetes .
1.2 DEFINITIONS OF HYPOGLYCAEMIA
1.2.1 Problems with Biochemical Definitions of Hypoglycaemia
It is not possible to provide a precise biochemical criterion for the diagnosis of
hypoglycaemia. A progressive decline in blood glucose triggers a hierarchy of
events that occur at individual glycaemic thresholds (Figure 1.1), commencing with
counterregulation (arterial blood glucose ~3.8 mmol/1), impairment of different
cognitive functions (-3.2-2.6 mmol/1) and the onset of symptoms and
neurophysiological dysfunction (-3.2-2.4 mmol/1). In clinical practice, however, it is
usual only for venous blood glucose levels to be measured, and in the main these are
lower than contemporaneous arterialised blood glucose concentrations (which tend to
be measured in research studies involving hypoglycaemia)9. Venous plasma glucose
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concentrations below 3.0 mmol/1 may occur readily following an overnight fast or
during the course of a prolonged glucose tolerance test10. Moreover, as will be
described later, thresholds for the onset of symptoms and counterregulation in
patients with Type 1 diabetes may vary depending on preceding glycaemic control.
Thus, patients with preceding poor glycaemic control may experience symptoms of
hypoglycaemia at venous plasma glucose concentrations substantially in excess of
3.0 mmol/111. Patients with preceding strict glycaemic control may not experience
the onset of symptoms of hypoglycaemia until venous plasma glucose concentrations
have fallen below 2.0 mmol/112. In terms of clinical practice. Diabetes UK has
recommended that individuals with diabetes should strive wherever possible to
13
ensure that blood glucose concentrations are always greater than 4.0 mmol/1 .
1.2.2 Clinical Definitions of Hypoglycaemia
Episodes of hypoglycaemia may be usefully subdivided into asymptomatic
(biochemical) hypoglycaemia, mild symptomatic hypoglycaemia and severe
hypoglycaemia. Severe hypoglycaemia is defined as an episode of hypoglycaemia in
which assistance from a third party is required to effect treatment. The definition
does not specify a threshold level below which blood glucose concentration must fall
before an episode of hypoglycaemia can be considered severe, nor does it specify
any particular modalities of treatment.
22
FIGURE 1.1: Glucose Thresholds of the Physiological and Neurological









































The earliest manifestation of a falling blood glucose level is the inhibition of
endogenous insulin secretion. Thereafter, as blood glucose falls, counterregulatory
hormones are released and symptoms are generated. With increasing depth of
hypoglycaemia, cognitive impairment develops and ultimately coma, convulsions
and death will supervene.
Reproduced, with the permission of the authors and publishers, from: Frier BM,
Fisher BM. Impaired Hypoglycaemia Awareness. In: Hypoglycaemia in Clinical
Diabetes. Frier BM and Fisher BM eds. Chichister: John Wiley and Sons; 2000.
Copyright© 2000 John Wiley and Sons. All rights reserved.
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PART B: PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL
RESPONSES TO HYPOGLYCAEMIA
1.3 PHYSIOLOGICAL RESPONSES TO HYPOGLYCAEMIA
1.3.1 Central Nervous System Energy Metabolism
An insight into normal central nervous system energy metabolism is
understanding the physiological responses to, and the neuropathological
hypoglycaemia.
Glucose Metabolism
Despite the fact that it performs no mechanical or osmotic activities and constitutes
only 2% of normal body weight, the human brain has an enormous metabolic
requirement. On average, the brain utilises 20% of the body's oxygen supplies and
receives 15% of cardiac output14. The processes that consume this large amount of
energy include the generation of neuronal action potentials and the maintenance of
ionic homeostasis, neurotransmitter re-uptake, axoplasmic flow and protein
synthesis
Glucose is the principal metabolic fuel of the brain and its oxidation therefore
accounts for effectively all of the oxygen consumed by the brain (Figure 1.2).
Oxidation of one molecule of glucose yields an energy equivalent of 42 molecules of
adenosine triphosphate (ATP) while the anaerobic metabolism of glucose, by
glycolysis alone, generates only 2 molecules of ATP. However, the brain can neither
synthesise nor store glucose and is entirely dependent apon the cerebral circulation
for maintaining its constant supply of fuel. Glucose is transported across the blood-
brain barrier and into the brain by specific glucose transport proteins (GLUT 1) 16'17.
These molecules act as 'carriers' rather than 'pumps', in that they transport glucose
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Other glucose transport proteins have been identified in brain tissue (GLUT 3, 4 and
5), and these may be responsible for allowing entry of glucose into neurones and
17
glial cells . Under normal circumstances, the facilitated transport of glucose into the
brain does not limit the rate of intracellular brain metabolism. However, during
hypoglycaemia, glucose transport becomes rate limiting and neuroglycopenia quickly
develops18.
Glucose extraction from the cerebral circulation depends not only on the number and
activity of GLUT 1 transporters, but also on the surface area of the cerebral
circulation and cerebral blood flow19. The nature of changes in cerebral blood flow
may be important in determining its impact on glucose extraction. For example, if
cerebral blood flow increases as a consequence of greater capillary recruitment,
glucose extraction may be significantly enhanced because of the increased
cerebrovascular surface area available for glucose transport. By contrast, increases
in linear cerebral blood flow may have a smaller impact on glucose extraction during
hypoglycaemia because of the rate-limiting effect of glucose diffusion across the
blood-brain barrier19.
Other Cerebral Energy Sources
The brain has a limited capacity to utilise other energy sources such as ketone bodies,
lactate, amino acids and free fatty acids '\ Ketone bodies (B-hydroxybutyrate,
acetoacetate and acetone) are short-chain fatty acids that provide up to 65% of brain
oxidative energy metabolism during periods of fasting or carbohydrate deprivation,
and so spare the progressive catabolism of muscle proteins that would otherwise be
70
required to maintain endogenous gluconeogenesis . Lactate may also be used as a
metabolic fuel by the brain, through its ability to be converted to pyruvate by the
enzyme lactate dehydrogenase (Figure 1.2). In certain forms of neonatal
hypoglycaemia, lactate is known to provide up to 30-40% of cerebral energy
requirements21.
The brain does not appear to require a prolonged period to adapt to use alternate
22 23
energy sources, since the intravenous infusion of either ketone bodies or lactate
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can ameliorate the symptomatic and hormonal responses to insulin-induced
hypoglycaemia and prevent cognitive dysfunction. However, outwith the laboratory,
the role of ketone bodies and lactate in protecting the brain from the deleterious
effects of insulin-induced hypoglycaemia may be more limited, since plasma
concentrations are generally low and their rate of uptake by the brain is modest1".
1.3.2 Counterregulation
Because of the reliance of the central nervous system on glucose as a metabolic fuel,
multiple mechanisms have evolved to maintain glucose homeostasis (Figure 1.3). A
fall in blood glucose is detected by glucose sensors within the brain, located mainly
in the ventromedial nuclei of the hypothalamus24, and the hepatic portal system2".
Activation of these glucose sensors instigates a cascade of responses to raise blood
glucose26. These responses include:
1. The release of counterregulatory hormones which antagonise insulin action and
suppress its endogenous secretion.
2. Stimulation of the autonomic nervous system (principally the sympathetic
division) which not only promotes counterregulation, but also induces important
haemodynamic and other end-organ effects.
3. The generation of warning symptoms that alert the individual to the development
of hypoglycaemia and the need to take corrective action.
The principal counterregulatory hormones are glucagon (secreted by pancreatic alpha
cells independently of control by the brain), and adrenaline (epinephrine) secreted
secondary to sympathetic neural stimulation. Other counterregulatory hormones
(Cortisol and growth hormone), released through activation of the hypothalamic-
pituitary axis, are less powerful. These hormones stimulate the immediate provision
of stored glucose from glycogen within the liver (hepatic glycogenolysis) and
encourage the synthesis of glucose (gluconeogenesis) within the liver and kidney
(Figure 1.3).
27
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■ Rise in biood glucose
Acute hypoglycaemia causes activation of the sympathetic nervous system and the
release of glucagon from the pancreas, as well as anterior and posterior pituitary
hormones. These act in concert to raise blood glucose concentrations and to generate
warning symptoms of hypoglycaemia. Sympathetic activation results in the
stimulation of adrenaline secretion from the adrenal medulla and in the release of
noradrenaline from sympathetic nerve endings.
Reproduced, with the permission of the author and publisher, from: Frier BM.
Hypoglycaemia. In: Pickup J and Williams G eds. Textbook ofDiabetes. 2nd Edition.
Oxford: Blackwell Science; 1997; 40.1-40.23. Copyright© 1997 Blackwell Science
Ltd. All rights reserved.
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1.3.3 Symptoms of Hypoglycaemia
The symptoms of hypoglycaemia are generated directly by neuroglycopenia, and also
via acute autonomic stimulation. Common autonomic symptoms are sweating,
trembling, pounding heart, hunger and anxiety, while neuroglycopenic symptoms
include inability to concentrate, drowsiness, confusion, difficulty with speech and
incoordination. Common non-specific symptoms are nausea, tiredness and
27headache . The symptom profile differs with age. Behavioural changes are
observed in children28, while the elderly report more neurological symptoms of
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hypoglycaemia . The early recognition of the onset of symptoms of hypoglycaemia
('awareness') is vital for people with insulin-treated diabetes.
1.3.4 Hypoglycaemia and Cerebral Blood Flow
Autonomic activation and secretion of catecholamines provoke haemodynamic
changes that modify regional blood flow and increase the circulation of many organs,
including the heart, liver and skeletal muscles (Figure 1.3). Most19'30"32, but not all33,
studies in humans have demonstrated that acute hypoglycaemia also causes an
increase in cerebral blood flow. Tallroth et al demonstrated, in non-diabetic subjects,
that acute hypoglycaemia promoted not only an overall increase in cerebral blood
flow, but also a significant alteration in the relative distribution of cerebral blood
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flow, with the highest increments being found in the frontal and parietal lobes . In
patients with Type 1 diabetes, the magnitude of the response was less and the
increased regional blood flow was more uniform . MacLeod et al also reported
alterations in regional blood flow during acute hypoglycaemia in patients with Type
1 diabetes"'4. There were significant increments in relative cerebral blood flow to
both superior frontal cortices and the right thalamus, and significant decrements in
cerebral blood flow to the right posterior cingulate cortex and the right putamen34.
In theory, the increased cerebral blood flow that occurs during acute hypoglycaemia
would be consistent with a physiological attempt to increase substrate delivery to the
central nervous system at a time of maximum need. Evidence in support of this
premise has come from studies in which cerebral blood flow has been manipulated
pharmacologically. Increasing cerebral blood flow with the carbonic anhydrase
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inhibitor acetazolamide, reduces the symptomatic and adrenaline responses to
hypoglycaemia19, while reducing cerebral blood flow with caffeine, markedly
increases the symptomatic and counterregulatory hormonal responses to
hypoglycaemia35'3 .
However, the rise in cerebral blood flow during hypoglycaemia only occurs at very
low blood glucose concentrations (less than 2.0mmol/l), i.e. well below the threshold
for the development for cognitive dysfunction'2. This appears to be a maladaptive
response to hypoglycaemia, since it might be imagined that the whole purpose of
increasing substrate delivery would be to preserve cognitive function. However,
increasing cerebral blood flow with acetazolamide does not actually reduce the
degree of cognitive impairment that occurs during mild hypoglycaemia19. Thus, the
brain appears to be differentially sensitive to increased substrate delivery, with the
glucose-sensing areas demonstrating much greater responsiveness to increased
cerebral blood flow than the cerebral cortex.
1.4 NEUROBIOCHEMICAL AND NEUROPATHOLOGICAL EFFECTS OF
HYPOGLYCAEMIA
1.4.1 Differences Between Hypoglycaemic and Hypoxic Brain Injury
For many years, hypoglycaemia was thought to harm the brain by simply starving
neurones of their energy supply. Such a theory would, therefore, imply that identical
neurobiochemical and neuropathological changes would occur during periods of
either oxygen or glucose deprivation. Recent research has shown that this is not the
case. Energy failure of cerebral neurones appears to be less marked during
hypoglycaemia than during periods of hypoxia-ischaemia. Brain glucose utilisation
decreases almost linearly as the blood glucose concentration falls below normal
levels, but cerebral oxygen consumption does not fall as much as would be predicted
by the reduction in glucose utilisation'7. Neuronal ATP levels are reduced to just
over one third of the normal value during severe hypoglycaemia whereas, by
37
contrast, ATP levels fall to less than 5% of normal in ischaemic neurones . These
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findings presumably reflect the ability of cerebral neurones to utilise other
endogenous substrates as fuels during periods of profound glucose deprivation and
account for the ability of the brain to withstand longer periods of hypoglycaemia than
of hypoxia-ischaemia, before permanent damage ensues. Nevertheless, the partial
energy failure that occurs during mild to moderate hypoglycaemia presumably
accounts for the impaired neuronal function that ensues (see Chapter 2).
The development of hypoglycaemia heralds the onset of a variety of other ion and
chemical changes within cerebral neurones. Activity of ionic pumps, such as the
sodium/potassium ATPase pump, cannot be maintained because of the energy deficit
and consequently ions run down their concentration gradients15'38. Increased protein
and lipid catabolism occurs and flux through the glycolytic pathway is reduced,
resulting in diminished tissue concentrations of lactate and pyruvate (Figure 1.2).
The generation of protons by the Krebs cycle is reduced and when this is coupled
with a lack of organic acids, tissue alkalosis ensues"'4. This is in direct contrast to the
situation during hypoxia-ischaemia where anaerobic metabolism of glucose results in
increased tissue concentrations of lactate and where the resultant tissue acidosis is
TO TQ
thought to exert a direct 'acidotoxic' effect on neurones ' .
1.4.2 Excitotoxic Brain Injury
Aspartate and glutamate are excitatory neurotransmitters that bind to TV-methyl-D-
aspartate (NMDA) receptors on the dendrites of neurones. In high concentrations,
these neurotransmitters can cause neuronal death that is characterised by destruction
of dendrites, axonal sparing and, ultimately, necrosis of the nerve cell body
(perikaryon)"'7""'9. Such a pattern of 'excitotoxic' cell death is seen in neurones
following hypoglycaemia"'7"'9 and can be prevented by pre-treatment with NMDA
receptor antagonists40. The key factor in the development of increased levels of
aspartate and glutamate is the decrease in glycolytic flux which reduces
concentrations of acetyl co-enzyme A and results in increased concentrations of
oxaloacetate (acetyl co-enzyme A normally condenses with oxaloacetate as the first
reaction in the Krebs cycle; Figure 1.2) . Oxaloacetate can combine with glutamate






According to Le Chetalier's principle, the excess oxaloacetate drives the chemical
reaction to the right resulting in proportionately greater levels of aspartate than
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glutamate . This is again in direct contrast to the pattern seen in cerebral ischaemia
where glutamate predominates41. The mechanisms behind 'excitotoxic' neuronal
death remain to be clearly elucidated but probably involve excitotoxic-mediated
calcium influx into neurones with subsequent activation of lipolysis, the generation
of free radicals and cell membrane breakdown41.
1.4.3 Neuropathological Features of Hypoglycaemic Brain Injury
The striking feature of hypoglycaemic brain damage is 'selective neuronal necrosis'
i.e. neurones are affected while other cell types, such as blood vessels and glial cells
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are not . Hypoxia-ischaemia may cause either selective neuronal necrosis or 'pan-
necrosis', in which all cell types are affected39. Pathogenetically, it is generally
accepted that excitatory amino acids lead to selective neuronal necrosis, while tissue
39acidosis results in pan-necrosis . In the rat, neuronal necrosis does not start to occur
until cessation of electrical activity in the brain, as measured by
electroencephalography (EEG), has been present for up to 10 minutes42. The extent
of neuronal necrosis increases as the duration of EEG 'isoelectricity' increases and
while, initially, only selective neuroanatomical cell types are affected, ultimately all
will be involved if hypoglycaemia is of sufficient severity and duration42.
The neuropathology of hypoglycaemic brain damage is similar to that of hypoxia-
ischaemia but, in the early stages, the pattern of neuronal involvement may allow a
distinction between the two neurotoxic mechanisms to be made. In both animal and
human brains, neurones in the superficial cerebral cortex tend to be involved more
than deeper neurones in hypoglycaemia ,7-4,_4\ Necrosis of neurones within the
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dentate gyrus of the hippocampus l7'39'46, with relative sparing of cerebellar Purkinje
cells43"45'47, is also considered to be characteristic of hypoglycaemia. The
mechanisms behind the selective pattern of neuronal damage remain to be firmly
elucidated, but may reflect differential efficiencies of neuronal glucose transporters39
and the accumulation of excitotoxins within the CSF37. The importance of this latter
phenomenon is supported by time course observations of hypoglycaemic neuronal
damage in rats. These have demonstrated that areas exposed to the subarachnoid
spaces (i.e. cerebral cortex and hippocampus) are affected early, with regions




PART C: CLINICAL ASPECTS OF HYPOGLYCAEMIA
1.5 FREQUENCY OF HYPOGLYCAEMIA
Over 100, mostly rare, causes of hypoglycaemia have been identified in humans10.
In Western clinical practice, the overwhelmingly most common form encountered is
hypoglycaemia associated with the treatment of diabetes mellitus with insulin, and it
is consideration of this form of hypoglycaemia that will form the basis of this thesis.
Hypoglycaemia in diabetic patients is also less frequently related to the use of
sulphonylurea drugs, particularly long-acting agents such as glibenclamide48'49.
1.5.1 Frequency of Mild Hypoglycaemia
The true frequency of hypoglycaemia in insulin-treated diabetic patients is difficult
to estimate accurately because of differences in definitions of hypoglycaemia. In
addition, assessment of hypoglycaemia frequency is hampered because most
episodes occur in the community without any input from medical, nursing or
paramedical staff, and recall by patients of such episodes is generally poor. This
highlights the importance of prospective recording of episodes of hypoglycaemia in
clinical research studies.
The average patient with insulin-treated diabetes will probably experience several
thousand episodes of mild symptomatic hypoglycaemia over a lifetime with diabetes.
In a study of 441 patients with Type 1 diabetes, managed primarily with a
conventional insulin regimen of twice daily soluble and isophane insulin, an average
of 1.8 episodes of mild symptomatic hypoglycaemia occurred per patient per week7.
Asymptomatic hypoglycaemia, detected on routine home blood glucose monitoring,
is likely to be even more common, particularly at night and if overall glycaemic
control is strict. Thorsteinsson et al demonstrated that 10% of blood glucose levels
were less than 3.0 mmol/1 in patients who had a median blood glucose concentration
of 5.0 mmol/1 r,°. In a separate study of nocturnal blood glucose profiles in 31
patients with Type 1 diabetes (mean HbAlc 8.6%), 29% experienced nocturnal
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hypoglycaemia (blood glucose less than 3.0 mmol 1/1) and 67% of these episodes
were asymptomatic31.
1.5.2 Frequency of Severe Hypoglycaemia
Surveys of frequency of severe hypoglycaemia in unselected northern European
populations with insulin-treated diabetes have documented rates of 1.0 to 1.6
episodes per patient per year7"32'53. In any particular year, around 30% of patients
treated with insulin experience one or more episodes of severe hypoglycaemia32'54.
1.6 RISK FACTORS FOR SEVERE HYPOGLYCAEMIA
1.6.1 Conventional Precipitating Factors for Severe Hypoglycaemia
Traditionally, severe hypoglycaemia has been ascribed to relative or absolute insulin
excess, with the conventional precipitating factors being grouped into main six
categories26:
1. Inappropriate insulin injection - e.g. excessive dose, inappropriate time,
inappropriate insulin formulation
2. Inadequate exogenous carbohydrate - e.g. missed meal or snack, overnight fast
3. Increased carbohydrate utilisation - e.g. exercise
4. Decreased endogenous glucose production - e.g. excess alcohol consumption
5. Increased insulin sensitivity - e.g. exercise, weight loss
6. Decreased insulin clearance - e.g. renal failure
1.6.2 Severe Hypoglycaemia in the Diabetes Control and Complications
Trial
While the above factors undoubtedly contribute to many episodes of severe
hypoglycaemia, the results of the Diabetes Control and Complications Trial (DCCT)
have suggested that investigators must look beyond these conventional risk factors in
an attempt to understand the pathogenesis of severe hypoglycaemia. In the DCCT,
1441 patients with Type 1 diabetes were randomly assigned to either intensive
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insulin therapy (based on multiple injection insulin regimens or continuous
subcutaneous insulin infusion therapy with an external pump) or conventional insulin
therapy (one or two insulin injections daily)6. The subjects, particularly in the
intensive group, were highly motivated and received significant levels of
professional support. Subjects were excluded if, in the previous two years, they had
experienced more than one episode of severe neurological impairment without
warning symptoms of hypoglycaemia, or more than two episodes of seizure or coma,
regardless of attributed cause. Over 6.5 years of follow-up, the average glycated
haemoglobin (HbAlc) concentration in the intensive group was approximately 7.0%
and in the conventional group approximately 8.8%6.
During the study, the occurrence of an episode of severe hypoglycaemia in an
individual patient prompted a review of conventional risk factors and, in instances
where probable causes were identified, corrective actions such as re-educating the
patient were undertaken". Despite this, 3788 episodes of severe hypoglycaemia
occurred in the 1441 patients over the course of the study".
The main risk factor for severe hypoglycaemia in the DCCT was a history of
previous episodes of severe hypoglycaemia". Other high risk groups included
males, adolescents, C-peptide negative individuals and subjects administering a high
total daily insulin dose (>0.6 units/kg)". Moreover, subjects in the intensive group
were three times more likely to experience severe hypoglycaemia, compared with
subjects in the conventional group. At the end of the study, 65% and 35%,
respectively, of subjects in the two treatment groups had experienced an episode of
severe hypoglycaemia. In both groups, there was a quadratic relationship between
HbAlc and risk of severe hypoglycaemia (Figure 1.4), with risk of hypoglycaemia
increasing as HbAlc decreased. However, the attained HbAlc did not account for
all the difference in risk of severe hypoglycaemia, as subjects in the intensive group
still had an excess risk of severe hypoglycaemia after statistical adjustment for
HbAlc concentration.
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FIGURE 1.4: Relationship between Glycaemic Control and Severe
Hypoglycaemia in the DCCT.
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In the DCCT, there was a quadratic relationship between glycated haemoglobin concentration and
severe hypoglycaemia, with rate of severe hypoglycaemia rising significantly as HbAlc
concentrations fell. The pale line is a regression line estimated as a function of the logarithm of the
glycosylated haemoglobin value; the dark lines represent the 95% confidence intervals. The circles
indicate the crude rates, within deciles, of the mean HbAlc concentrations during the trial. The
arrows mark the mean HbAlc levels attained by subjects in the intensive- and conventionally-treated
arms of the study.
Reproduced, with the permission of the authors and the Massachusetts Medical Society from: The
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of
diabetes on the development and progression of long-term complications in insulin-dependent
diabetes mellitus. New Eng J Med 1993; 329: 977-986. Copyright© 1993 Massachusetts Medical
Society. All rights reserved.
This revised version of the Figure was copied, with the permission of the author and publisher, from:
Frier BM. Hypoglycaemia. In: Pickup J and Williams G eds. Textbook of Diabetes. 2nd Edition.
Oxford: Blackwell Science; 1997; 40.1-40.23.
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1.6.3 Risk Factors for Severe Hypoglycaemia in Other Studies
The above association between severe hypoglycaemia and HbAlc has been
replicated in some34, but not all36'57, studies. In a prospective evaluation of the
implementation of an intensive insulin therapy programme in 636 patients with Type
1 diabetes, a lower mean HbAlc during the period of the study was associated with
severe hypoglycaemia, but there was no linear or quadratic relationship between
HbAlc and severe hypoglycaemia36. Other risk factors for severe hypoglycaemia in
this study were comparable with some of those identified in the DCCT and included
previous severe hypoglycaemia, higher daily insulin doses, increased duration of
diabetes, younger age at onset of diabetes, lower emotional coping abilities and C-
peptide negativity36. A recent systematic review has found no evidence to support
the premise that treatment with human, as opposed to animal, insulins, is associated
58with an increased risk of hypoglycaemia" .
The role of peripheral autonomic neuropathy in increasing the risk of severe
hypoglycaemia has been considered in several studies. In the EURODIAB IDDM
Complications Study, the presence of abnormal cardiovascular reflexes was
associated with a 1.7-fold increased risk of severe hypoglycaemia39. Gold et al also
demonstrated that autonomic neuropathy was associated with a small increased risk
of severe hypoglycaemia in 60 patients with Type 1 diabetes" , but no relationship
was demonstrated in the DCCT60. The mechanism underlying this association
remains to be fully elucidated. Peripheral autonomic neuropathy often co-exists with
impaired hypoglycaemia awareness in patients with Type 1 diabetes, presumably
because both conditions are associated with diabetes of long duration61, but impaired
61 63
awareness can readily occur in the absence of peripheral autonomic neuropathy " .
1.6.4 Acquired Hypoglycaemia Syndromes
Citing the results of the DCCT, Cryer has suggested that the integrity of the glucose
counterregulation system may be a pivotal factor in determining whether the relative
or absolute hyperinsulinism that frequently occurs in insulin-treated diabetes,
ultimately results in the development of hypoglycaemia26. The three main acquired
syndromes that are associated with an increased risk of severe hypoglycaemia and
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impaired glucose counterregulation in patients with Type 1 diabetes are described
below.
Counterregulatory Hormonal Deficiencies
Hypoglycaemia-induced secretion of glucagon declines in most patients within five
years of developing Type 1 diabetes64'65. The cause of the defective glucagon
response to hypoglycaemia in Type 1 diabetes is not known, but is presumably
mediated by a second messenger as the pancreatic a-cells react appropriately to other
stimuli. Later on in the course of Type 1 diabetes, a defective adrenaline response to
hypoglycaemia may also develop65"67. As with the glucagon response, the impaired
adrenaline response is hypoglycaemia-specific but, in contrast to glucagon, the
adrenaline response exhibits a threshold effect - i.e. an adrenaline response can still
be elicited by hypoglycaemia, but only at a lower blood glucose concentration67. If
hypoglycaemia develops in patients who have this combined counterregulatory
hormonal deficiency, glucose recovery may be seriously compromised. Subjecting
such patients to intensified insulin therapy increased the risk of severe
hypoglycaemia by 25 times, compared with subjects with an intact adrenaline
response68.
Impaired Awareness of Hypoglycaemia
In many patients with insulin-treated diabetes, the hypoglycaemia symptom profile
alters with time, resulting in impaired perception of the onset of hypoglycaemia.
Commonly, autonomic warning symptoms are lost and in their place
neuroglycopenic symptoms come to predominate. Around 25% of people treated
with insulin develop impaired awareness of hypoglycaemia (IAH) and the prevalence
of this problem increases with the duration of insulin treatment7'61'69. Prospective
studies have demonstrated that the frequency of severe hypoglycaemia is increased




Altered Glycaemic Thresholds Following Intensive Insulin Therapy
Strict glycaemic control modifies the glycaemic thresholds for counterregulation72'73
and the onset of symptoms74. The threshold for autonomic symptoms and the
counterregulatory response is therefore set at a much lower blood glucose than usual.
1.6.5 Hypoglycaemia-Associated Central Autonomic Failure
The above acquired hypoglycaemia syndromes tend to segregate together clinically.
Patients with glycated haemoglobin concentrations near the non-diabetic range have
an increased risk of developing IAH7^"77, while the glycaemic thresholds for the onset
I ^ 78 79of symptoms and responses are altered in patients with IAH ' ' ' . Cryer has
suggested that these acquired abnormalities represent a form of central
'hypoglycaemia-associated autonomic failure' in Type 1 diabetes, speculating that
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recurrent severe hypoglycaemia is the primary cause . If hypoglycaemia is the
precipitant, then it is possible to see how a vicious cycle may become established
with the development of the acquired hypoglycaemia syndromes promoting further
episodes of severe hypoglycaemia.
Evidence supporting the role of antecedent hypoglycaemia in the pathogenesis of
acquired hypoglycaemia syndromes has come from studies demonstrating that the
glycaemic thresholds for autonomic and symptom responses to an episode of
hypoglycaemia are reduced by exposure to a preceding episode of hypoglycaemia in
both healthy individuals81"84 and subjects with Type 1 diabetes67'85'86. The duration
and depth of antecedent hypoglycaemia determines the responses to a subsequent
87decline in blood glucose . In animals, the counterregulatory hormonal response to
systemic hypoglycaemia can be reduced if the brain is infused with glucose, i.e. if the
88 89cerebral glucose supply is maintained despite peripheral hypoglycaemia ' . In
vitro, the transcription90 and translation91 of GLUT 1 protein (the blood-brain barrier
glucose transport protein) is increased in brain capillary endothelial cells which are
deprived of glucose. Moreover, prolonged hypoglycaemia in rats increases the
92
number of GLUT 1 transporters in the blood-brain barrier and increases the
QT
extraction of glucose from the cerebral circulation . In humans, glucose uptake into
the brain is enhanced during acute hypoglycaemia, in non-diabetic subjects subjected
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to chronic hypoglycaemia (blood glucose 2.9 mmol/1 for 56 hours)94, and in diabetic
subjects with strict glycaemic control7'. These studies provide a mechanism
whereby acquired hypoglycaemia syndromes could develop: repeated severe
hypoglycaemia causes upregulation of GLUT 1 transporters in the brain, as a
compensatory adaptive mechanism to preserve neuronal energy supplies when
circulating glucose levels are low. However, the response may be considered
maladaptive since glucose sensors in the hypothalamus may not detect the systemic
hypoglycaemia until much lower blood glucose concentrations are achieved,
resulting in elevated glycaemic thresholds for the release of counterregulatory
hormones and the development of symptoms.
Other mechanisms whereby antecedent hypoglycaemia may mediate the
development of hypoglycaemia-associated autonomic failure have been postulated.
Davis et al reported that the infusion of Cortisol the day before a hypoglycaemic
clamp study resulted in comparable blunted counterregulatory hormone responses to
those observed following antecedent hypoglycaemia9'. Moreover, Tkacs et al found
that recurrent hypoglycaemia in male Sprague-Dawley rats, lowering blood glucose
to levels that impaired counterregulatory responses without the induction of coma,
caused apoptotic cell death in the arcuate nucleus of the hypothalamus and reduced
expression of neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) mRNA96.
The loss of arcuate nucleus NPY and POMC neurones could result in defective
counterregulatory responses to hypoglycaemia since they project both rostrally and
caudally to brain areas involved in the autonomic and pituitary components of
counterregulation96.
1.7 MORBIDITY AND MORTALITY OF SEVERE HYPOGLYCAEMIA
Fortunately, the overwhelming majority of patients make a complete recovery
following an episode of hypoglycaemia. Aside from cognitive dysfunction and
coma, the commonest complication of acute hypoglycaemia is likely to be the
precipitation of focal or generalised convulsions. Failure to recognise the occurrence
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of hypoglycaemia may lead to an erroneous diagnosis of idiopathic epilepsy being
made and the prescription of anticonvulsant drugs which are ineffective in preventing
hypoglycaemia-induced convulsions97.
Rarely, severe and protracted hypoglycaemia can cause permanent brain damage,
and this often occurs in the context of excessive consumption of alcohol or insulin
overdosage (either deliberate or accidental) . These patients usually present in a
coma and cerebral oedema may be present". Survivors of protracted hypoglycaemic
coma may develop cortical and hippocampal atrophy with ventricular enlargement,
often associated with a chronic vegetative state100. Transient and permanent focal
neurological deficits, such as hemiparesis, 'locked in' syndrome, ataxia, severe
amnesia101 and cortical blindness102, have been described following severe
hypoglycaemia.
Hypoglycaemia is a relatively rare cause of death in insulin-treated patients but the
frequency may be underestimated. The 1979 joint survey, by the Medical Services
Study Group and the British Diabetic Association, of factors contributing to the
deaths of people with diabetes under the age of 50, identified hypoglycaemia as a
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cause of death in 4% of the 448 deaths recorded . More recently, in the British
Diabetic Association Cohort Study, hypoglycaemia accounted for 4% of deaths in
men with Type 1 diabetes aged 20 to 49 years and 1% of deaths in women in the
same age group104. Aside from its direct effects on brain metabolism,
hypoglycaemia could precipitate death by a variety of mechanisms. In patients with
macrovascular disease, the profound haemodynamic and haemorrheological changes
of severe hypoglycaemia10' may provoke acute vascular sequelae such as cardiac
arrhythmia, myocardial ischaemia and cerebrovascular insufficiency. Cardiac
arrhythmia, induced by nocturnal hypoglycaemia, has also been implicated in rare
cases of sudden death during sleep in otherwise healthy, young patients with Type 1
diabetes (the 'dead in bed syndrome')106'107.
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1.8 REDUCING THE FREQUENCY OF SEVERE HYPOGLYCAEMIA
1.8.1 Hypoglycaemia Recognition and Avoidance Strategies
There is no clear consensus on the optimum strategy to manage patients at increased
risk of severe hypoglycaemia.
Home Blood Glucose Monitoring
No trials have demonstrated that increased use of home blood glucose monitoring
reduces the occurrence of severe hypoglycaemia. However, common sense would
indicate that patients at risk should be advised to monitor blood glucose
concentrations on a regular basis to detect asymptomatic biochemical
hypoglycaemia. Indeed, home blood glucose monitoring profiles can predict patients
who are at increased risk of severe hypoglycaemia, i.e. those with frequent and
extreme low blood glucose readings, and with pronounced variability in day-to-day
readings'08.
The majority of episodes of severe hypoglycaemia tend to occur at night70'109,
presumably because sleep reduces the ability to recognise the symptoms of
hypoglycaemia. In theory, monitoring of bedtime and fasting blood glucose
measurements may help reduce the risk of nocturnal hypoglycaemia. Vervoort et al
demonstrated that fasting glucose levels of less than 5.5 mmol/1 were predictive of
preceding 'early morning' hypoglycaemia (between 4.00 and 7.30am) and that 'early
nocturnal' hypoglycaemia (between 11.00pm and 1.00am) never occurred if blood
glucose concentrations before bedtime were greater than 7.5 mmol/l"1.
Lifestyle and Dietary Measures
All patients with insulin-treated diabetes should be educated about the need for
regular meals and snacks and about the adjustment of carbohydrate intake and insulin
dosage before and after exercise. The risks of hypoglycaemia associated with excess
alcohol consumption should also be regularly reinforced. The frequency of nocturnal
hypoglycaemia may be reduced by the ingestion of a bedtime snack of complex
carbohydrate, such as uncooked cornstarch, that is slowly digested and which may
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maintain blood glucose concentrations for several hours110. Including protein with
the complex carbohydrate at bedtime may be beneficial109'111, although this has been
disputed112.
Increasing Awareness of Hypoglycaemia and Counterregulatory Hormonal
Responses
If glycated haemoglobin concentrations are within or near the non-diabetic range,
relaxation of glycaemic control will restore symptomatic and counterregulatory
hormonal responses to hypoglycaemia101. IAH (and possibly counterregulatory
deficiencies) may be reversed through a total avoidance of hypoglycaemia and, with
meticulous diabetic management, this has been achieved in research studies for
periods varying from three weeks to one year114-116. Although complete avoidance of
hypoglycaemia is clearly beneficial, to attempt this is time-consuming and labour-
intensive, and beyond the resources of most specialist centres. As an alternative,
Blood Glucose Awareness Training (BGAT) has been developed in the USA for
patients with IAH. This involves an intensive period of re-education in which
patients are taught to recognise neuroglycopenic cues117"119 and initiate appropriate
treatment responses. In unaware patients, BGAT reduces the number of episodes of
undetected biochemical hypoglycaemia, but does not appear to alter the overall
prevalence of hypoglycaemia119'120.
The bedtime administration of the glucagon-releasing amino acid alanine, or the
adrenaline-stimulating p2-adrenergic agonist terbutaline is more effective than a
conventional bedtime snack in reducing the occurrence of nocturnal
hypoglycaemia121. Moreover, the frequent ingestion of caffeine augments the
symptomatic and counterregulatory hormonal responses to hypoglycaemia in non-
diabetic and diabetic subjects"'6. Concerns about the long-term safety and practicality
of these pharmacological agents has limited their clinical role to date, but they do
introduce the concept of identifying therapeutic agents that may reduce the risk of
severe hypoglycaemia in patients with diabetes.
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Altering Insulin Regimens
Reducing total daily insulin dosage is a simple means of avoiding hypoglycaemia,
but clearly this may be at the expense of suboptimal glycaemic control. Splitting the
evening dose of soluble and intermediate-acting insulin (such that soluble insulin is
administered before the evening meal and intermediate insulin before bed) is
commonly recommended to patients experiencing frequent nocturnal
hypoglycaemia109. Reductions in severe hypoglycaemia have also accrued by
replacing multiple daily injection regimens of insulin with continuous subcutaneous
199 . . . ...
insulin infusions (CSII) , or indeed by substituting bedtime isophane insulin with
the overnight use of CSII12"'. However, in the United Kingdom, at least, cost
implications have meant that CSII is not a practical option for most patients.
Other potentially significant resources in the management of patients at risk of severe
hypoglycaemia are the new rapid-acting insulin analogues, insulin lispro (Humalog)
and insulin aspart (Novorapid). In particular a large body of evidence has emerged
about the role of insulin lispro in reducing the frequency of episodes of
hypoglycaemia and this will be considered in detail in the following section.
1.8.2 Insulin Lispro
Insulin lispro is a genetically modified form of human insulin in which the sequence
of amino acids in the P-chain has been altered, such that the natural sequence of
proline at position B28 and lysine at position B29 has been reversed (Figure
1.5)124'125.
Conventional soluble insulin molecules form dimers in solution, and aggregate
further into hexamers in the presence of zinc ions. The relatively delayed onset and
prolonged duration of action of soluble insulins is, therefore, explainable by the fact
that, following subcutaneous injection, the insulin hexamers have to dissociate before
diffusion into the circulation can occur126'127. As a consequence, it is recommended
that soluble insulin is injected at least half an hour before food to limit post-prandial
glucose excursions128"1"'0. By contrast, the altered amino acid sequence of insulin
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FIGURE 1.5: Amino Acid Sequence of Insulin Lispro
Compared with human insulin, the positions of proline at B28 and lysine at B29 of
the C-terminal end of the p-chain are reversed.
Reproduced, with the permission of the authors and the Massachusetts Medical
Society from: Holleman F, Hoekstra JBL. Insulin Lispro. New EngJMed 1997; 337:
176-183. Copyright© 1997 Massachusetts Medical Society. All rights reserved.
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lispro leads to a conformational shift in the C-terminal end of the (3-chain that
sterically hinders the ability of the insulin lispro molecules to form dimers126'127.
Therefore, compared to conventional soluble insulins, the onset of action of insulin
lispro is quicker and the overall duration of action is shorter (Figure 1.6)124'12?. In
practical terms this means that insulin lispro can be injected just before meals.
Insulin lispro underwent extensive Phase III clinical trials in over 4000 patients with
diabetes before a product licence was granted in April, 1996. Because of the
differences in the timing of pre-meal injections of insulin lispro and soluble insulin,
the majority of the trials were open-label. The consistent finding of these early trials
was that, compared with soluble insulin, insulin lispro did not improve overall
glycaemic control (as assessed by glycated haemoglobin concentrations), but did
reduce post-prandial glucose excursions by 1.0 - 4.0 mmol/l123'131'132. However, its
shorter duration of action meant that fasting and pre-prandial glucose concentrations
tended to be higher during treatment with insulin lispro than with soluble
insulin125'131'132. More recent studies have suggested that improvements in glycated
haemoglobin concentrations can be achieved by optimisation of basal insulin
133,134
regimens
The effects of insulin lispro on the frequency of hypoglycaemia have received
considerable attention. Therapy with insulin lispro does not impair counterregulatory
1 T r
hormonal and symptomatic responses to hypoglycaemia . In the largest open-label,
crossover study of 1008 patients with Type 1 diabetes, three months treatment with
insulin lispro was associated with a 12% reduction in the frequency of
i
hypoglycaemia . The greatest proportional reduction occurred in the frequency of
• 132 •nocturnal hypoglycaemia . This pattern of results has been borne out in several
other studies131'136 and has a plausible physiological explanation. Nocturnal
hypoglycaemia was thought to be associated with the nocturnal hyperinsulinaemia
caused by intermediate or long-acting insulins taken before bed or teatime.
However, soluble insulin injected before the evening meal, because of its relatively
long duration of action (Figure 1.6), may exacerbate early nocturnal
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FIGURE 1.6: Time-Action Profiles of Soluble Insulin and Insulin Lispro
0 "T 1 1 1 1 1 1 1 1 1 1 1 1
0 1 23456789 10 11 12
Hours
Following subcutaneous injection, levels of insulin lispro peak in the circulation after
approximately one hour, and fall rapidly thereafter. By contrast, levels of soluble
(regular) insulin rise more slowly, peak between one to three hours and, thereafter,
gradually fall to basal levels.
Reproduced, with the permission of the authors and the Massachusetts Medical
Society from: Holleman F, Hoekstra JBL. Insulin Lispro. New EngJMed 1997; 337:
176-183. Copyright© 1997 Massachusetts Medical Society. All rights reserved.
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hyperinsulinaemia and so contribute to the development of nocturnal
137
hypoglycaemia * . The frequency of nocturnal hypoglycaemia may be reduced by
insulin lispro because its shorter time-action profile diminishes early nocturnal
hyperinsulinaemia.
However, it is important to recognise that a fairly broad definition of hypoglycaemia
was utilised by the insulin lispro investigators: "patients recorded an episode of
hypoglycemia when they experienced a sign or symptom that they normally
associated with hypoglycemia. In addition a blood glucose measurement during
routine blood glucose testing <3.5 mmol/l was counted as hypoglycemiaj2. This
definition would clearly have had the potential to include significant numbers of
episodes that either may not have been true hypoglycaemia or may have been of
limited clinical relevance. A more robust meta-analysis of the data on episodes of
severe hypoglycaemia (defined strictly as episodes of coma requiring treatment with
glucagon or intravenous glucose) from eight trials studying 2576 patients with Type
I T8
1 diabetes was, therefore, performed . The total number of episodes of severe
hypoglycaemia was small (233) and only 4.4% of patients receiving soluble insulin
experienced such an episode. Therapy with insulin lispro was associated with about
a 30% reduction in the number of patients who developed severe hypoglycaemia, but
the absolute reduction was small, with 3.1% of insulin lispro-treated patients
affectedlj8.
Insulin lispro probably does offer lifestyle benefits to people with Type 1 diabetes, in
terms of the potential convenience of being able to administer insulin immediately
before food. The data on the ability of insulin lispro to reduce the frequency of
hypoglycaemia is of reasonable quality, but is not compelling. Further studies are
needed in patients who are at particularly high risk of hypoglycaemia, such as those
with IAH, to clarify its role in strategies to reduce the incidence of severe
hypoglycaemia. In addition, the rapid onset of action of insulin lispro could,
theoretically, result in an increased risk of early post-prandial hypoglycaemia,
particularly if the normal rise in blood glucose concentrations after a meal were
delayed (such as after a meal with a high fat content). Therefore, further research
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into the effects of insulin lispro on blood glucose concentrations following various
different meal types is required so that patients can be advised on the optimal timing
of administration of insulin lispro.
1.9 SUMMARY
Glucose is the predominant metabolic fuel of the brain, and neuroglycopenia quickly
ensues when blood glucose concentrations fall below normal limits. The prevention
of hypoglycaemia is, therefore, crucial to survival. As a consequence, blood glucose
concentrations are normally maintained within a very narrow range by powerful
neuro-hormonal mechanisms. Several large trials have elucidated the major risk
factors for hypoglycaemia but, even with modern insulin therapies, hypoglycaemia
remains the commonest complication of insulin-treated diabetes and forms the major
barrier to achieving 'normal' blood glucose concentrations.
In recent years, our understanding of the effects of hypoglycaemia on the brain has
increased significantly. In Chapter 2, the literature examining the impact of insulin-
induced hypoglycaemia on cognitive function will be reviewed in detail. In
particular the impact of recurrent episodes of hypoglycaemia on cerebral function
will be considered, as well as the evidence from experimental studies that have
examined the effects of acute hypoglycaemia on cognitive performance.
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CHAPTER 2
EFFECTS OF HYPOGLYCAEMIA ON COGNITIVE FUNCTION
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2.1 EFFECTS OF ACUTE HYPOGLYCAEMIA ON COGNITIVE FUNCTION
Examination of the reproducible effects of acute hypoglycaemia on cognitive
performance became feasible in the 1980's, when experimental procedures such as
the hyperinsulinaemic glucose clamp and the bedside measurement of blood glucose
concentration were widely available. Prior to this, observations had been made that
blood glucose levels below 3.0 mmol/1, as a consequence of either natural glucose
fluctuations139 or bolus injection of insulin140, were associated with impaired motor
co-ordination, mental speed, concentration and memory. Since then, a large
literature on the cognitive effects of acute hypoglycaemia has developed with recent
interest focusing on the particular cognitive domains that are affected, factors which
moderate individual susceptibility to hypoglycaemia, and the clinical relevance of the
cognitive decrements that occur.
2.1.1 Methodological Considerations
The literature examining the effects of acute hypoglycaemia on cognitive function is
large and diverse. Before considering the results in detail, it is important to consider
the methodological differences that exist between many of the studies and the
limitations of some the procedures employed9.
Limitations of Neuropsychological Testing
All studies examining cognitive performance during acute hypoglycaemia utilise
neuro-cognitive tests of one form or another. Although much of the variance in
human mental abilities is attributable to general intelligence, in clinical practice it is
useful to employ tests to examine the various cognitive domains141'142. These
domains include attention and concentration, memory (both verbal and non-verbal),
abstract thinking, constructional ability and speed of information processing. Full
assessment of cognitive function requires, therefore, the administration of a battery
of psychometric tests to ensure that sufficient cognitive domains are examined to
detect any decrements. However, a bewildering range of psychometric tests is
available141. The format of individual tests is very variable, ranging from the relative
simplicity of paper and pencil tasks, such as Trail-Making B (from the Halstead-
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Reitan battery)14, and Digit Symbol (from the Wechsler Adult Intelligence Scale)144,
to the electronic complexity of driving simulators l4\ The lack of'gold standards' for
the validation of psychological tests means that multiple tests of differing nature and
complexity are available to examine the parameters of any given cognitive domain.
The situation is made more complex since many tests measure more than one aspect
of cognitive ability, so that the results from two different tests purporting to examine,
for example, 'verbal memory' may not be directly comparable. Thus, comparisons
between studies that have used different batteries of cognitive tests must be made
with caution, even though they may have been attempting to examine the same
nominal cognitive domains146.
The use of large batteries of psychological tests also increases the risk of a type 1
statistical error, i.e. that a statistically significant result will occur by chance. The
difficulties associated with this approach have recently been highlighted by Ryan
who has advocated the employment of multivariate statistical procedures in the
analysis of study results147. Unfortunately, this approach can only effectively be
used if sample sizes are large and the outcome measures are statistically interrelated.
Cognitive tasks are also subject to the effects of practice, i.e. performance improves
with repeated administration. Many studies have failed to account for this and have
compared cognitive performance during acute hypoglycaemia with that measured
during a preceding period of euglycaemia. This may lead to underestimation of the
magnitude of cognitive decrements occurring during hypoglycaemia''. Comparing
cognitive performance during acute hypoglycaemia with that measured during a
separate euglycaemia study day may control the effects of practice. Crucially, the
order of the experimental study sessions must be counter-balanced, i.e. half of the
subjects must undergo the hypoglycaemia study session first followed by the
euglycaemia control session, and the other half must undergo the study sessions in
the reverse order. Such a study design may be further refined by including periods of
euglycaemia prior to each experimental condition, to take account of day-to-day
148variations in cognitive performance .
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Few studies have reported the order in which cognitive tasks are administered within
a given test battery or have provided reassurance that the order has remained
consistent. This is clearly important, since fatigue of the subject and the potential for
a lag between changing blood glucose concentrations and an effect of cognitive
function mean that performance of cognitive tasks may be affected by the duration of
the experimental study9.
Methods of Inducing Hypoglycaemia
Two main techniques have been employed to induce hypoglycaemia experimentally:
the insulin infusion technique and the hyperinsulinaemic glucose clamp. The former
involves the intravenous infusion of insulin at variable rates to reach the desired
blood glucose concentration, while the latter employs a fixed intravenous infusion
rate of insulin with a variable intravenous infusion of dextrose to maintain blood
glucose concentrations at the appropriate level149. The clamp technique has gained
considerable popularity because of the relative ease and speed at which fine
adjustments in blood glucose concentrations can be made, allowing measurement of
the thresholds of various physiological responses to hypoglycaemia.
However, both techniques have disadvantages. In the insulin infusion technique, the
plasma concentrations of insulin vary, while the clamp procedures employ very high
concentrations of insulin. Insulin itself has generally been regarded as having no
effect on brain tissue, as glucose uptake into neurones was thought to be wholly
insulin-independent. However, the insulin-responsive glucose transporter, GLUT 4,
has been identified in brain endothelial tissue17. Moreover, insulin receptors are
found both in the brains of animals150'151 and of humans152, especially in the
hippocampus, hypothalamus and olfactory bulb1 11IM. Insulin can act as a
153 • •neuromodulator in the brain, inhibiting synaptic activity " , while alterations in
plasma insulin concentrations can be related to, or even directly regulate, changes in
cognitive function in non-diabetic humans134"1'"'6. A degree of reassurance about the
validity of utilising pharmacological doses of insulin to assess cognitive responses to
hypoglycaemia has been provided by two studies in humans. In these studies, the
infusion of differing concentrations of insulin did not affect cognitive responses to
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comparable levels of hypoglycaemia1^7'1^8, although higher infusion rates did affect
neuroendocrine l57>158 and symptomaticly7 responses. In a separate study, using more
physiological concentrations of insulin, higher plasma insulin concentrations were
associated with more pronounced cognitive impairment during hypoglycaemia1 ?9.
Measurement of Blood Glucose Concentrations
Knowledge of the nature of blood samples analysed for glucose concentration
(plasma or whole blood; arterialised or venous blood) is important in the
interpretation of results from hypoglycaemia studies. Plasma glucose concentrations
are 10-20% higher than contemporaneously measured whole blood glucose
concentrations9. In certain circumstances, notably post-prandially, there are also
significant differences between arterial and venous blood glucose concentrations160.
2.1.2 Cognitive Processes Impaired by Acute Hypoglycaemia
Numerous experimental studies have considered the impact of acute hypoglycaemia
on cognitive function and many of these have been subject to detailed review9'161. A
summary of some of the studies that have examined the cognitive decrements that
occur at specific blood glucose concentrations is provided in Table 2.1. The Table is
not meant to provide a comprehensive account of all studies that have examined
acute hypoglycaemia and cognitive function, and indeed studies that are discussed in
later sections are not included. Instead, it is designed to allow an insight into the
glucose thresholds at which decrements occur in the various cognitive domains.
The cognitive tests examined in individual studies have been broadly grouped in
Table 2.1 according to the criteria described by Lezak141. The Table clearly
illustrates that cognitive function becomes progressively impaired as blood glucose
falls and that no cognitive domains are spared. Although individual studies have
demonstrated cognitive decrements at glucose concentrations between 3.0-3.4
mmol/1, measures of cognitive function appear to be consistently impaired at blood
glucose concentrations of 2.9 mmol/1 and below. It has been repeatedly asserted that,
during hypoglycaemia, accuracy of performance of a given task tends to be preserved
55

















































































































































































































FootnotestTabl2.1 'ND' -non-diabeticsubjects 'I' -performanceofthecognitivaskwassi if cantlyimpaireddur gacuthypoglyc mia 'NFperformanceofthecognitivaskwasn tsi ificantlyimpaireddur gacuthyp glyca mia 'a' -arterialisedbloodsample V-venousbloodsample 'b' -wholebloodsamp 'p' -plasmasample 's' -simplereactionti e 'c' -choicereactiontime 'B' -backwarddigitsp n 'F-forwarddigitspan *8subjectsunderwentahypoglyca miccl pnd8tunderwenteuglyca micc p
57
at the expense of speed. Moreover, cognitive tasks which are complex and attention-
demanding are disrupted more by milder levels of hypoglycaemia than simple motor
tasks, such as finger tapping or digit span recall9"161. This latter assertion is not
completely borne out by the studies cited in Table 2.1, since few experimental
studies have actually examined aspects of motor function at blood glucose
concentrations between 2.0-3.0 mmol/1.
2.1.3 Moderators of Cognitive Function during Acute Hypoglycaemia
Several studies have demonstrated a substantial degree of variability in individual
responses to the effects of acute hypoglycaemia16"'166'171'174'179"182. Some subjects
demonstrate profound impairment of cognitive function during mild hypoglycaemia,
while others remain unaffected at the lowest concentrations of blood glucose that can
safely be induced in the laboratory. There has, therefore, been considerable interest
in factors that moderate individual susceptibility to acute hypoglycaemia.
183 • • ... .... .Gonder-Frederick et al confirmed the wide inter-individual variability in
performance of several cognitive tasks (examining motor function, attention and
verbal fluency) during hypoglycaemia. Important cognitive decrements occurred at a
venous plasma glucose of 2.6 mmol/1 in 50% of subjects, but 15% showed little or no
disruption of performance. Variations in the glycaemic thresholds for the onset of
cognitive impairment, as well as the degree of dysfunction experienced in most tasks,
were stable in individual subjects on re-testing three months later. However,
paradoxically, individual variations in performance of simple and complex reaction
time tasks were not consistent with time and did not correlate with any biological
182variable measured . No other studies have examined the repeatability of responses
to hypoglycaemia in individuals, and this clearly limits the ability to draw firm
conclusions from studies that have examined specific moderators of hypoglycaemia
susceptibility. The individual moderators that have been investigated, and which will
be considered in turn, include: age, sex, intelligence, the presence or absence of
diabetes, glycaemic control, antecedent hypoglycaemia, impaired awareness of
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hypoglycaemia (IAH), previous severe hypoglycaemia and duration of
hypoglycaemia.
Age
Matyka et al compared the effects of acute hypoglycaemia on performance of a four-
choice reaction time task in seven non-diabetic men aged 22-26 years and seven non-
diabetic men aged 60-70 years184. Compared with the younger men, reaction time
deteriorated more profoundly in the older men and at a higher glycaemic threshold
(arterialised plasma glucose of 3.0 mmol/1 in the older men compared with 2.6
mmol/1 in the younger men). By contrast, in several other studies, there was no
correlation between age and change in cognitive performance during
180 181 183
hypoglycaemia ' " , although the age-range of subjects studied was more limited
1 O A
than in the investigation by Matyka et al .
Sex
Significant gender differences in cognitive function during hypoglycaemia were
181
reported in one study . At an arterialised venous glucose of 2.2 mmol/1, women
with Type 1 diabetes exhibited less of a performance decrement from baseline than
men in measures of attention and mental flexibility. There were no significant
gender differences in other cognitive measures, and the differences persisted after
181
adjustment for other potential confounding factors . Somewhat paradoxical results
were observed in a further study in which women performed better during mild
hypoglycaemia (venous plasma glucose 3.6 mmol/1), but demonstrated comparable
cognitive performance to men during more moderate hypoglycaemia (venous plasma
glucose 2.6 mmol/1)183.
Intelligence
It has frequently been asserted that people with a higher IQ level possess more 'brain
reserve capacity' in cognitive processing, which may offer a degree of protection
185from cerebral insults such as hypoglycaemia . This concept was directly
investigated by Gold et al186, who studied the effects of acute hypoglycaemia on the
cognitive performance of 24 non-diabetic individuals who were divided into high and
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average IQ groups. As expected, the high IQ group had significantly better
performance at baseline in most of the cognitive tasks but, overall during
hypoglycaemia, there were few differences in deterioration in performance between
the two groups. Following multiple univariate analyses (with the attendant risk of a
type 1 statistical error), the high IQ group performed relatively more poorly during
hypoglycaemia during two cognitive tasks assessing attention and information
processing.
Other studies have also failed to demonstrate a relationship between intelligence (or
surrogate markers such as education) and change in cognitive performance during
hypoglycaemia180-183.
Diagnosis of Diabetes
Wirsen et al examined 10 men with Type 1 diabetes and 12 non-diabetic men, and
found that the cognitive performance of the former group was more affected than the
latter by acute hypoglycaemia (arterialised venous glucose 2.0 mmol/1). However,
the results of this study must be interpreted with caution as the diabetic subjects
started at higher blood glucose concentrations (and therefore had a proportionately
greater fall in glucose concentrations). Moreover, although the groups were matched
for baseline performance on a battery of cognitive tests, no assessment was reported
of pre-morbid cognitive ability. The groups came from different occupational
backgrounds (the diabetic men were white collar workers and the non-diabetic men
were medical students) and had different durations of education.
There were no differences between diabetic and non-diabetic subjects in
deterioration in cognitive performance during acute hypoglycaemia in two other
studies74'179. In a third study where diabetic and non-diabetic subjects were studied,
there were baseline differences in cognitive performance of the groups which
187
preclude further interpretation of the impact of diabetes per se
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Other Diabetes-Related Clinical Variables
Several studies have found no relationship between degree of cognitive dysfunction
during acute hypoglycaemia and variables such as duration of diabetes164'179'181'183
182 183
age of onset of diabetes ' and the magnitude of counterregulatory response to
179 181
hypoglycaemia " . Increased deterioration in cognitive performance during acute
hypoglycaemia was associated with a history of coma due to severe hypoglycaemia
in one study18"1.
Strict Glycaemic Control, Recent Antecedent Hypoglycaemia and Impaired
Awareness of Hypoglycaemia
The effects of IAH, strict glycaemic control and recent antecedent hypoglycaemia on
the cognitive response to hypoglycaemia have been of considerable research interest.
However, the inter-relation of these factors makes the field complex and difficult to
interpret.
Strict Glycaemic Control
In several studies, there was no correlation between glycated haemoglobin levels and
cognitive performance during acute hypoglycaemia74'164'179"183. However, in one
early study, lower HbAlc levels were associated with poorer performance on an
auditory reaction time task, although subjects with stricter glycaemic control had also
experienced significantly more previous episodes of unconsciousness secondary to
severe hypoglycaemia166. The interpretation of these studies is limited because a
relatively small number of subjects were studied, so increasing the risk of a type 2
statistical error.
In the study by Widom and Simonson74, there was no difference in the median
threshold for cognitive dysfunction during hypoglycaemia between diabetic patients
with well-controlled (mean total HbAl 8.0%) and poorly controlled (mean total
HbAl 11.8%) diabetes. Similar results were observed by Maran et al in an
examination of the thresholds for deterioration of four-choice reaction time during
acute hypoglycaemia in eight intensively-treated diabetic subjects (mean HbAlc
188
7.7%) and ten conventionally-treated subjects (mean HbAlc 10.1%) . By contrast,
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Ziegler et al studied seven diabetic subjects with strict glycaemic control (mean
HbAlc 6.3%) and 11 with less strict control (mean HbAlc 9.1%) and found that the
threshold for prolongation for the latency of the P300 wave (a 'cognitive' brain
electrical event-related potential) occurred at a significantly lower glucose
concentration in the former group than the latter. Comparable results were obtained
in another study of P300 potentials in intensively and conventionally-treated diabetic
subjects189.
Antecedent Hypoqlycaemia
It is difficult to obtain an overall perspective of the impact of antecedent
hypoglycaemia on cognitive performance during subsequent episodes of
hypoglycaemia, because different degrees and durations of antecedent
hypoglycaemia have been studied. Moreover, there is no consistent pattern for the
duration of the time period between the antecedent hypoglycaemia (or the control
euglycaemia condition) and the subsequent hypoglycaemia study. In the following
section study results are summarised in order of increasing duration of this time
period.
Mellman et al induced hypoglycaemia in nine non diabetic subjects, 90 minutes after
a two hour period of antecedent hypoglycaemia (arterialised plasma glucose 3.2
mmol/1) 19°. Two cognitive tasks were utilised - Logical Memory and Digit Symbol
Substitution (a psychomotor test); performance of the former task was preserved
following antecedent hypoglycaemia, but Digit Symbol Substitution test scores
deteriorated equally whether there had been antecedent hypoglycaemia or
euglycaemia190.
The impact of antecedent nocturnal hypoglycaemia has been considered in two
separate studies. Veneman et al demonstrated in 10 non-diabetic volunteers that a
single episode of moderate asymptomatic nocturnal hypoglycaemia (plasma glucose
2.4 mmol/1 for two hours) diminished the degree of cognitive dysfunction (as
assessed by a comprehensive battery of cognitive tasks) during subsequent
84
hypoglycaemia the following day . Fanelli et al also found that antecedent
nocturnal hypoglycaemia (arterialised plasma glucose 2.8 mmol/1 for 3.5 hours)
62
reduced overall cognitive dysfunction during subsequent hypoglycaemia in 15
subjects with Type 1 diabetes191. In particular, there was relative preservation in
performance of tasks assessing attention and pattern recognition, but not in measures
of delayed verbal memory and information processing191.
By contrast, the induction of hypoglycaemia (arterialised plasma glucose 2.6 mmol/1)
in 16 non-diabetic subjects for a two hour period in the afternoon prior to a stepped
hypoglycaemic clamp the following morning, was associated with no overall change
in cognitive performance when compared with results from a stepped hypoglycaemic
i*i *192
clamp with antecedent euglycaemia . However, when performance of individual
tasks at specified blood glucose concentrations was considered, there did appear to
be reduced deterioration in tasks of attention and pattern recognition when glucose
192concentrations were reduced from 2.8 mmol/1 to 2.5 mmol/1 . Dagogo-Jack et al
also found no evidence that antecedent afternoon hypoglycaemia limited the degree
of cognitive impairment during hypoglycaemia induced on the following day in 15
subjects with Type 1 diabetes (indeed there was evidence that attention scores were
worse following antecedent hypoglycaemia)67. Finally, George et al, demonstrated
in eight subjects with Type 1 diabetes that hypoglycaemia (arterialised blood glucose
2.8 mmol/1 for two hours) induced two days prior to a subsequent episode of
hypoglycaemia had no effect on the threshold for impairment of four-choice reaction
time, despite the fact that the noradrenaline response to hypoglycaemia was blunted
by antecedent hypoglycaemia19"1.
Ovalle et al investigated, in six patients with Type 1 diabetes, the impact of the
induction of twice weekly periods of hypoglycaemia (plasma glucose 2.8 mmol/1 for
two hours), for a period of one month, on subsequent cognitive performance during a
stepped hypoglycaemic clamp194. Recurrent antecedent hypoglycaemia blunted the
subsequent symptomatic and hormonal responses to hypoglycaemia and reduced
overall cognitive dysfunction194.
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Impaired Awareness of Hypoqlycaemia
Scientific assessment of the impact of IAH on cognitive function during acute
hypoglycaemia is hampered by the fact that there is not a validated, non-subjective
means of defining the phenomenon. Moreover, as has been suggested already, it is
also difficult to separate out the confounding impacts of recent antecedent
hypoglycaemia and strict glycaemic control, all of which are inter-related. Heller et
a! studied 15 people with Type 1 diabetes - 11 with IAH and four with normal
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awareness of hypoglycaemia . Awareness was defined according to symptomatic
responses during acute hypoglycaemia. Subjects with IAH had a longer duration of
diabetes and lower glycated haemoglobin concentrations than subjects with normal
awareness, and demonstrated comparable cognitive performance (as assessed by
four-choice reaction time) during acute hypoglycaemia IK7. Subjects were not
matched for IQ. By contrast, Gold et al demonstrated statistical trends that Type 1
patients with IAH (defined on the basis of a self-rating scale, in which subjects
scored how often they had symptoms during spontaneous episodes of
hypoglycaemia) exhibited more profound cognitive dysfunction during acute
hypoglycaemia, and that cognitive dysfunction persisted for longer following blood
glucose recovery195. This result is clearly at odds with many of the foregoing
studies, but there is no doubt that the aware and unaware subjects in the study by
Gold et al were matched for pre-morbid IQ, duration of diabetes, HbAlc, and
exposure to previous episodes of severe hypoglycaemia. There was, however, a 0.5
standard deviation difference in current IQ between the groups (which was not
statistically significant), with the unaware subjects having lower mean scores on the
Alice Heim 4 task than the aware subjects, and it is conceivable that this may have
confounded the study results.
The impact of the restoration of hypoglycaemia awareness, by the avoidance of
hypoglycaemia, on the thresholds for cognitive dysfunction during acute
hypoglycaemia has also engendered considerable controversy. Cranston et al studied
12 patients with Type 1 diabetes and IAH (six with good glycaemic control and six
with poor control) before and after a period of three weeks of complete avoidance of
hypoglycaemia (which took a mean of four months to achieve)"5. After avoidance
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of hypoglycaemia, hormonal and symptomatic responses during a stepped
hypoglycaemic clamp were increased, but the threshold for cognitive dysfunction (as
assessed by four-choice reaction time) remained unaltered at an arterialised plasma
glucose concentration of 2.8 mmol/1 "'\ By contrast, Fanelli et al found, in 16
subjects with Type 1 diabetes of moderate duration and with IAH, that the
meticulous prevention of hypoglycaemia for two weeks lowered the threshold for
cognitive dysfunction during hypoglycaemia (i.e. occurred at a higher glucose
concentration) and decreased the degree of cognitive dysfunction at a given glucose
concentration196. These changes were maintained following a year of hypoglycaemia
avoidance196 and were also observed in subjects with IAH who had short-term Type
1 diabetes"4.
Duration of Hypoglycaemia (Short-Term Cerebral Adaptation)
The impact of the duration of hypoglycaemia on cognitive function, in effect a
measure of the ability of the brain to adapt to hypoglycaemia, has been investigated
in several studies. Kerr et al studied changes in reaction times in seven non-diabetic
subjects whose arterialised blood glucose concentrations were clamped at 3.5 mmol/1
for one hour and then reduced to 3.0 mmol/1 for a further hour197. Simple reaction
times deteriorated initially when the glucose concentration was 3.0mmol/l, but then
improved towards baseline after 60 minutes of sustained hypoglycaemia, suggesting
that cerebral adaptation had occurred. However, graphic data from the separate
euglycaemic clamp studies did suggest that there was a learning effect for the
reaction time task, and no statistical comparison of the results from the
hypoglycaemia and euglycaemia clamps was reported197. In a further study of six
subjects with Type 1 diabetes, arterialised blood glucose levels were clamped at 2.8
198mmol/1 for 90 minutes . Reaction time scores deteriorated initially, but there was
evidence of relative improvement in reaction time as the duration of hypoglycaemia
increased. Changes in reaction times were not observed in the euglycaemia arm,
198
although again no direct statistical comparisons were made .
By contrast Gold et al found no evidence of cerebral adaptation following 40-60
minutes of hypoglycaemia (arterialised blood glucose 2.5 mmol/1) in 24 non-diabetic
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subjects199. This study had several considerable strengths in that an extensive
cognitive test battery was utilised with statistical adjustment for potential practice
effects by comparing the hypoglycaemia clamp results with those obtained during a
separate euglycaemic clamp199. The duration of hypoglycaemia was relatively short
and it is of course possible that cerebral adaptation could occur after more prolonged
durations of hypoglycaemia.
Some evidence in support of this came from a remarkable study by Boyle et al of 12
non-diabetic subjects in whom chronic hypoglycaemia (arterialised blood glucose 2.9
mmol/1) was maintained for 56 hours94. Before and after the period of chronic
hypoglycaemia, subjects underwent a stepped hypoglycaemic clamp procedure
during which cognitive function was repeatedly assessed using a four test battery.
Prior to the period of chronic hypoglycaemia, performance in the Stroop and finger
tapping tasks deteriorated at an arterialised plasma glucose concentration of 3.05
mmol/1. At the end of the period of chronic hypoglycaemia, performance in these
tests did not deteriorate until arterialised plasma glucose had fallen to 2.5 mmol/1.
The mechanism behind this putative cerebral adaptation appeared to be a
preservation of brain glucose uptake during hypoglycaemia, rather than the
utilisation of non-glucose fuels by the brain. However, the results of this study
should be viewed with caution since the practice effects on the cognitive tasks were
not controlled for and the statistical analysis compared performance at each glucose
level within a clamp with its own baseline, interaction analyses between the clamps
were not performed, thereby increasing the risk of a spurious effect in line with the
experimental hypothesis.
2.1.4 Clinical Importance of Cognitive Dysfunction during Acute
Hypoglycaemia
If the psychometric test performance impairments observed during experimental
studies of acute hypoglycaemia are clinically relevant, then these experimental
findings have enormous potential implications for patients with diabetes whose
performance at work or when driving may become impaired if hypoglycaemia
supervenes. However, it is difficult to evaluate the relevance of most experimental
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cognitive tasks to everyday life. Because driving is an important daily task involving
many cognitive processes, several hypoglycaemia studies have been performed using
driving simulators. Hoffman et al found no effect of hypoglycaemia (venous blood
glucose 2.7 mmol/1) on driving, although only 10 of 18 subjects with Type 1 diabetes
in the study were tested in a driving simulator that was relatively unsophisticated 169.
Utilising a stepped hypoglycaemic clamp. Cox et al demonstrated that driving
performance in 25 adults with Type 1 diabetes was significantly disrupted at venous
plasma glucose concentration of 2.6 mmol/1, but not 3.6 mmol/1143. Hypoglycaemia
caused more swerving, spinning, time off the midline of the road and time off the
road, as well as more compensatory slow driving 14\ The individual differences in
driving performance during hypoglycaemia were stable at re-testing three months
later200. The driving simulator was, however, relatively basic with non-demanding
driving scenarios that lasted only five minutes. In a more recent study, Cox et al
evaluated driving performance in 37 adults with Type 1 diabetes during progressive
hypoglycaemia, utilising a more sophisticated simulator201. The simulator had a
wrap-around screen, providing a 160 degree visual field, and a programmed 16 mile
course that took approximately 30 minutes to complete. In this study, even relatively
minor levels of hypoglycaemia (arterialised blood glucose concentrations 3.4-4.0
901
mmol/1) were associated with significant driving impairments . Subjects were
generally aware of their impaired driving, but the mean glucose level at which
subjects took corrective actions (either stopping driving or ingesting carbohydrate)
was 2.7 mmol/1. Of the 14 subjects who exhibited severely impaired driving, only
901
eight took corrective actions .
These driving simulator studies have been criticised for not reliably reproducing real
driving experiences. Heller and Macdonald suggested that subjects may regard
driving simulators as a novelty and the resulting increased arousal could reduce the
sensitivity of the task during hypoglycaemia0. They also suggested that
experimentally-induced hypoglycaemia in a driving simulator would be unlikely to
reproduce the effect of mild hypoglycaemia upon a driver after hours of driving
along a motorway, where boredom and fatigue are other important factors to
influence driving performance0. The fact remains, though, that the studies by Cox
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and colleagues provide compelling evidence of the deleterious effects of
hypoglycaemia on driving ability and highlight the importance of educating people
with diabetes about the potential dangers of hypoglycaemia.
2.1.5 Effects of Acute Hypoglycaemia on Mood
The impact of acute hypoglycaemia on mood states has attracted considerably less
attention than its effects on cognitive function. Hepburn et al administered the
Mackay and Cox Mood Adjective Checklist to 12 non-diabetic men and 15 men with
Type 1 diabetes during an insulin infusion technique in which venous blood glucose
fell to a mean nadir of approximately 1.5 mmol/1202. Levels of tense arousal rose in
both groups while energetic arousal decreased significantly. Hypoglycaemia
therefore resulted in the development of a state of 'tense tiredness'202. In a further
study of two adrenalectomised patients (who had no endogenous adrenaline secretion
in response to hypoglycaemia) and 25 healthy non-diabetic subjects, the UWIST
Mood Adjective Checklist (MACT) was administered during a similar insulin
• r* • 203infusion protocol . The UWIST MACL measures levels of hedonic tone
(happiness), tense arousal and energetic arousal. During hypoglycaemia in the
healthy subjects, levels of hedonic tone and energetic arousal fell, while levels of
tense arousal rose. By contrast, in the two adrenalectomised subjects, there was no
change in levels of tense arousal and hedonic tone, following induction of
hypoglycaemia, although energetic arousal decreased significantly. These data were
interpreted as suggesting that adrenaline secretion during hypoglycaemia may
mediate changes in tense arousal and hedonic tone, while alterations in energetic
90T
arousal be a direct effect of neuroglycopenia . The major drawback of the above
studies was the absence of a euglycaemia control arm, but this was included in a
study of 24 non-diabetic subjects by Gold et al who utilised a clamp technique to
induce hypoglycaemia (arterialised blood glucose 2.5 mmol/1)204. Similar results
were obtained, with hypoglycaemia resulting in reduced levels of hedonic tone and
energetic arousal, and increased levels of tense arousal204.
The effects of acute hypoglycaemia on anger have been investigated in at least two
studies. Merbis et al assessed mood, using the Profile of Mood States, in 10 subjects
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with Type 1 diabetes (nine of whom were male), during a stepped hyperinsulinaemic
glucose clamp203. Hypoglycaemia (venous blood glucose 2.0 mmol/1) was associated
overall with increased levels of anger, but there was large inter-individual variability.
Those subjects who had high pre-test levels of hostility tended to demonstrate higher
levels of anger during hypoglycaemia.203. McCrimmon et al also reported that
hypoglycaemia (arterialised blood glucose 2.6 mmol/1), induced using a
hyperinsulinaemic glucose clamp technique, caused a significant increase in feelings
of anger in 18 non-diabetic subjects and 30 subjects with Type 1 diabetes206. In this
study, anger was measured using the State-Trait Anger Expression Inventory and, in
contrast to the study by Merbis et al203, there was no clear association between an
individual's change in reported anger during hypoglycaemia and measures of anger
trait and anger expression.
2.1.6 Summary of Effects of Acute Hypoglycaemia on Cognitive
Function
Although individual studies have demonstrated cognitive decrements at glucose
concentrations between 3.0-3.4 mmol/1, all domains of cognitive function appear to
be consistently impaired at blood glucose concentrations of 2.9 mmol/1 and below.
Acute hypoglycaemia increases levels of anger and results in the development of a
mood state that can be described as 'tense tiredness'. Studies with driving simulators
strongly suggest that the cognitive decrements that occur during experimental
hypoglycaemia are clinically relevant. Individual differences in susceptibility to the
cognitive effects of acute hypoglycaemia are likely to be mediated by a large number
of interacting factors. There is some evidence to suggest that older people and men
are more susceptible to hypoglycaemia and less convincing evidence that the
presence of diabetes per se and high intelligence also confer a greater predilection for
cognitive impairment as glucose concentrations fall. With regard to individuals with
Type 1 diabetes, duration of disease, age of onset and counterregulatory responses do
not appear to be important determinants of cognitive decrements during
hypoglycaemia, but there is evidence that prolonged exposure to hypoglycaemia
results in cerebral adaptation and subsequent better cognitive performance.
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The greatest controversy surrounds the impact of IAH, antecedent strict glycaemic
control and antecedent hypoglycaemia. Some studies have supported the premise
that glycaemic thresholds for cognitive dysfunction are shifted to lower glucose
concentrations in people with IAH (and/or strict glycaemic control and/or exposure
to recent antecedent hypoglycaemia), in a manner analogous to the well-recognised
downward shift in glycaemic thresholds for counterregulatory responses and
symptoms. However, other studies have not demonstrated any shift in glycaemic
thresholds for cognitive dysfunction in these patient groups. It is probable that
methodological differences between the studies, particularly small sample sizes, are
responsible for these discrepant results. It has been noted that, after discounting
investigations with methodological limitations, those studies that have demonstrated
a shift in cognitive thresholds have utilised a battery of cognitive tests or the P300
evoked potential. By contrast, those studies that have not demonstrated any change
9 207
in thresholds have often utilised only one or two cognitive tasks ' . This finding is
open to two contrasting explanations. It is possible that not all cognitive tasks are
affected to the same degree by IAH/strict glycaemic control/antecedent
907
hypoglycaemia, thereby making small test batteries inadequate . Alternatively, the
sympatho-adrenal response to hypoglycaemia may itself interfere with certain
cognitive tasks, notably psychomotor tests, by its propensity to induce tremor and
sweating9, making large cognitive test batteries, in effect, over-sensitive.
Further studies are clearly required to address this important issue. If glycaemic
thresholds for cognitive function are not altered in patients with impaired
hypoglycaemia awareness, then this would imply that the upregulation of GLUT 1
glucose transporters, one of the mechanisms which may underpin the development of
this phenomenon, is centred around only the glucose-sensing areas of the brain. By
contrast, if glycaemic thresholds for cognitive dysfunction do shift to lower glucose
concentrations, then this would imply that the upregulation of GLUT 1 occurs
throughout widespread areas of the brain.
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2.2 EFFECTS OF RECURRENT SEVERE HYPOGLYCAEMIA ON
COGNITIVE FUNCTION
Concerns about the long term effects of hypoglycaemia on the brain first surfaced in
the 1930's and 40's following a series of case reports describing the development of
permanent decrements of cognitive performance and personality in patients with
insulin-treated diabetes who had experienced episodes of severe hypoglycaemia43'208"
211
. The impact of these reports was further heightened by the recognition that
insulin-shock treatment for psychotic illnesses (in which severe hypoglycaemia was
induced for prolonged periods) could also result in permanent neurological and
212 215
cognitive dysfunction " . More recently, Gold et al described significant changes
in cognitive and social function in a self-selected group of five patients with Type 1
diabetes of long duration (24-47 years), all of whom had experienced multiple
episodes of severe hypoglycaemia216.
As a consequence of these observations, considerable research interest has focused
on the impact of recurrent episodes of severe hypoglycaemia on cognitive function in
both adults and children with Type 1 diabetes. This has considerable potential
clinical significance. If a link between severe hypoglycaemia and cognitive
decrements could be proven, then glycaemic targets for people at increased risk of
severe hypoglycaemia would need re-evaluation in order to protect cerebral function.
This research has, however, engendered considerable controversy as controlled
217studies have reached strikingly different conclusions ; this has served to further
highlight the difficulties of assessing cognitive function in diabetes9'146. The
following sections will provide a detailed description of the evidence for and against
the hypothesis that recurrent severe hypoglycaemia causes cognitive decrements.
2.2.1 Methodological Considerations
Many of the methodological considerations that were raised in Section 2.1.1
regarding investigations of the effects of acute hypoglycaemia on cognitive function,
particularly those concerning the limitations of cognitive testing, are relevant to the
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literature examining the longer-term effects of hypoglycaemia. There are some
additional methodological issues, however, that are pertinent to this area.
The literature examining the relationship between hypoglycaemia and cognitive
performance in adults with Type 1 diabetes can be grouped into three main
categories:
1. Case-control studies comparing cognitive function in diabetic and non-diabetic
subjects, with subsequent attempts to correlate cognitive performance in the
diabetic cohort with previous exposure to severe hypoglycaemia.
2. Case-control studies comparing diabetic subjects with and without previous
exposure to recurrent episodes of severe hypoglycaemia.
3. Prospective studies.
Case-control studies are subject to a variety of different problems, none the least that
the cross-sectional design does not allow direction of causality to be assumed.
Moreover, cognitive function is subject to the influence of a large range of differing
factors including age, gender, concurrent medical disorders (e.g. dementia,
hypothyroidism and chronic obstructive airways disease), drugs with effects on the
central nervous system (e.g. beta-adrenoreceptor blocking agents and
antidepressants), alcohol consumption, smoking, and impaired sensory or motor
••218function (e.g. poor eyesight, hearing or hand co-ordination) . In small case-control
studies, these factors may potentially confound any potential association between
cognitive function and recurrent severe hypoglycaemia, unless attempts are made to
control for these in the matching of the subjects in the two groups. Foremost among
potential confounding factors is pre-morbid intellectual ability, that is the highest
219 •level of ability attained prior to any cognitive decrements taking place . A variety
of retrospective methods may be used to assess, and match, subjects' pre-morbid
cognitive function. These include educational histories, academic achievement in
standard examinations and occupational histories. These variables, however, are
limited in that they may be influenced in individuals by factors such as lack of
opportunity rather than lack of ability220. An alternative is to use the National Adult
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Reading Test (NART) as a more useful measure of pre-morbid IQ220. In this task,
subjects are asked to read aloud 50 standard English words using the correct
pronunciation. The number of errors made correlates well with pre-morbid
intellectual function, as word reading ability tends to be preserved even in
generalised cognitive decline220.
Another major potential problem with utilising a case-control design in an attempt to
determine the impact of recurrent severe hypoglycaemia on cognitive function is that
the assessment of previous severe hypoglycaemia history is likely to be retrospective.
This may introduce a large element of error into the subsequent interpretation of
results. The best way of overcoming this is to employ a prospective study design,
which additionally allows causality to be determined. However, a potential difficulty
with prospective studies is that the period of follow-up may be limited and not of
sufficient duration to allow any cognitive decrements to develop.
2.2.2 Recurrent Hypoglycaemia in Adults with Type 1 Diabetes
Early Case-Control Studies
In one of the earliest reports, Bale administered the Walton-Black New Word
Learning Test to 100 adults with Type 1 diabetes of relatively long duration (average
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23.5 years) . Overall 17% of the diabetic subjects had scores which were
classified in the 'brain damaged' range of the test, while no subjects in an age-
matched, non-diabetic control group exhibited such scores. There appeared to be a
correlation between cognitive performance and hypoglycaemia in that 30% of
subjects who had been admitted to hospital in the past with an episode of
hypoglycaemia had scores in the 'brain-damaged' range compared with 20% of
subjects who had experienced severe hypoglycaemia, but had never required hospital
221
admission, and 4% of subjects who had never experienced severe hypoglycaemia .
Skenazy and Bigler also purported to demonstrate an association between severe
hypoglycaemia and neuropsychological performance in 39 subjects with diabetes, 20
222
of whom were visually impaired secondary to diabetic retinopathy . However, the
results of this study are open to question as, in contrast to most other studies, the
authors found that those patients with the most severe diabetic complications actually
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performed better on some measures of cognitive performance222. In neither study
were subjects matched for pre-morbid cognitive ability and little attention was paid
to the impact of other potential confounding factors.
Later Case-Control Studies
Using a more sophisticated cognitive test battery, Wredling et al compared the
neuropsychological function of 17 patients with Type 1 diabetes who had a self-
reported history of repeated episodes of severe hypoglycaemia and 17 patients with
Type 1 diabetes who had never experienced severe hypoglycaemia22j. Subjects were
matched for age, sex, duration of diabetes, educational achievement, employment
status and presence of microvascular complications; cognitive function was assessed
using an extensive cognitive battery. Subjects with a previous history of severe
hypoglycaemia scored lower on measures of motor ability, memory and visuospatial
• ... 223tasks assessing problem-solving ability . In another study, patients with Type 1
diabetes and a history of severe hypoglycaemia performed more poorly than diabetic
control subjects, without previous severe hypoglycaemia, on only one test (word-list
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recall) from a seven-test battery . Subjects were not matched for pre-morbid
224
intelligence and there were no controls for multiple statistical testing .
If the above studies are accepted at face value, then it is possible for their results to
be interpreted in two ways: either recurrent severe hypoglycaemia causes cognitive
impairment or that subjects with pre-existing cognitive impairment are prone to
experiencing recurrent episodes of severe hypoglycaemia. Langan and colleagues
attempted to refute this latter interpretation by including a measure of pre-morbid
cognitive function (the NART) in an extensive cognitive test battery which was
applied to 100 subjects with Type 1 diabetes22\ Only patients who had developed
diabetes after adolescence were studied, to remove the potential deleterious impact of
childhood diabetes on peak intellectual attainment, and rigorous entry criteria
excluded patients with a history of severe alcoholism, cerebrovascular disease, head
injury, epilepsy, psychiatric disorder or use of psychotropic medication. The authors
also went to considerable lengths to corroborate the subjects' retrospective
assessment of their experience of severe hypoglycaemia by checking case records
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from hospitals and general practitioners and by interviewing family members of the
subjects.
Frequency of severe hypoglycaemia correlated with current performance IQ level (r
= -0.32) and IQ decrement (i.e. the difference between pre-morbid IQ and current
performance IQ; r = 0.33), but not with pre-morbid IQ (r = -0.09). Severe
hypoglycaemia was also associated with slower and more variable reaction times.
To estimate the extent of intellectual impairment, two sub-groups were compared: 24
subjects with no previous hypoglycaemia and 23 diabetic subjects with five or more
episodes of hypoglycaemia. The authors concluded that a history of five or more
episodes of severe hypoglycaemia was associated with a modest IQ decrement of 5-6
225 •
points . The cognitive performance of the whole group of 100 diabetic subjects
was subsequently compared with 100 health control subjects, individually matched
226for age, sex, education and social class . After adjustment for pre-morbid IQ, the
diabetic group had lower verbal and performance IQs, as assessed by the Wechsler
Adult Intelligence Scale, than the control group. The difference in performance IQ
between the groups was eliminated after adjustment for previous hypoglycaemia
history. The difference in verbal IQ, however, persisted and it was postulated that
this may be the result of the social impact of diabetes226. A different research group,
employing similar methodology, also demonstrated a significant correlation between
decline in performance IQ and frequency of previous episodes of severe
227
hypoglycaemia (r = -0.22) .
More recently, Kramer et al failed to find any effect of severe hypoglycaemia on
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cognitive function employing a case-control study design . However, subjects
were not matched for pre-morbid intelligence and the neuropsychological test battery
was very limited, comprising only the Mini-Mental State Examination (MMSE) and
Trail-Making Test, Part A (TMA). The scores from the MMSE exhibited a striking
'ceiling effect' in that the mean score (± standard deviation) for patients with no
history of hypoglycaemic coma was 29.5 (±0.9), and for those with a history of
hypoglycaemic coma 29.6 (±0.7). However, the maximum score for this test is 30
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and so it may not have been difficult enough to allow detection of differences in
performance between the study groups.
Prospective Studies
The results of the majority of these cross-sectional, case-control studies have not,
however, been replicated in two large studies in which exposure to severe
hypoglycaemia was evaluated prospectively5"5"229. In the Stockholm Diabetes
Intervention Study, there was no difference in cognitive function over 7.5 years
between 102 diabetic subjects managed with either conventional or intensive
treatment, despite the fact that the latter group experienced significantly more
episodes of severe hypoglycemia53. On its own, the study could be criticised for
insufficient separation of the groups based on patients' experience of hypoglycaemia,
the small sample size and resultant low statistical power, a brief neuropsychological
917
test battery and a relatively short period of follow-up . However, similar results
were obtained in the 1441 participants of the DCCT over 6.5 years of follow up229.
In this study, neuropsychological function was assessed with a large test battery at
three time points (two, five and seven years) and attrition was minimal, with 98% of
the expected test sessions completed. As has already been discussed though, the
period of follow-up may have been insufficient, while the subjects were relatively
young and had little or no exposure to hypoglycaemia before the study. In fact, only
23 subjects experienced more than five episodes of hypoglycaemic coma or seizure
during the trial. Moreover, the data from the neuropsychological test battery was
grouped arbitrarily into eight cognitive domains, none of which were directly
comparable to performance or general IQ. This latter drawback was overcome by a
re-analysis of the DCCT data using a factor analysis approach, in which the cognitive
data was grouped into statistically robust cognitive domains; as in the initial analysis,
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no effect of hypoglycaemia on cognitive performance was demonstrated .
2.2.3 Recurrent Hypoglycaemia in Children with Type 1 Diabetes
The majority of investigations on cognitive function in children with diabetes have
been case-control studies. These studies have consistently demonstrated cognitive
decrements in children and adolescents with diabetes, compared with non-diabetic
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children, and have implied that one of the strongest predictors of impaired cognitive
performance is early onset of diabetes (i.e. less than six years of age) 2jl~2-16. As a
group, such children with early onset diabetes tend to have a higher prevalence of
• • 9T9
clinically significant impairment" and are more likely to have repeated a year in
234 237school ' . Children or adults who develop diabetes after 5 or 6 years of age show
a much less consistent level of cognitive impairment147. Several studies have
demonstrated no evidence of cognitive deficits in this late onset group2"'4'236,238, while
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others have demonstrated the presence of cognitive decrements ' J ' .
Case-Control Studies
It has been postulated that recurrent exposure to severe hypoglycaemia may account
for the cognitive decrements seen in children with early-onset diabetes241. Young
children have higher energy requirements to sustain optimal growth and brain
development, and their immature brains appear to be particularly prone to any type
of traumatic or neurotoxic insult242"244. Indeed, the occurrence of hypoglycaemia in
non-diabetic neonates is associated with subsequent retarded development and lower
IQ24\ Moreover, very young children with diabetes are far more likely to experience
232 234
severe hypoglycaemia than older children " . This is presumably because
episodes of hypoglycaemia may go unrecognised in non-verbal children (who lack
the capacity to perceive and communicate early episodes) and because food intake
and activity levels are unpredictable in young children, making it difficult for parents
and physicians to prescribe appropriate insulin doses241.
Fallstrom demonstrated that diabetic children had elevated levels of behavioural
disturbance, anxiety and perceptual difficulties, relative to non-diabetic children, and
that the severity of these abnormalities correlated with the frequency of previous
hypoglycaemic convulsions246. Impairment of psychomotor efficiency and attention
was also demonstrated in a small cohort of children with early-onset diabetes who
had experienced episodes of severe hypoglycaemia early in childhood, but not in
238children who had experienced severe hypoglycaemia only in late childhood"" .
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Moreover, several studies have demonstrated electrophysiological abnormalities in
children with diabetes and have linked these changes with previous exposure to
severe hypoglycaemia247"2'0. For example, in a large series of 300 diabetic children,
those with a previous history of severe hypoglycaemia were nearly twice as likely to
show abnormalities on electroencephalograms (typically a non-specific
247
abnormality)
Flowever, the major problem with all of the above studies is that it is difficult to see
how accurate estimates of previous hypoglycaemia history could have been obtained
retrospectively.
Prospective Studies
There have been several studies on cognitive function in children with diabetes in
which hypoglycaemia history has been prospectively ascertained. However, most
are too small to allow robust conclusions to be drawn. Golden et al followed 23
diabetic children (mean age 6) over a 6 to 72 month period and found that number of
episodes of asymptomatic hypoglycaemia correlated with impaired performance on
the abstraction and visual reasoning subtests of the Stanford-Binet task21,1. The size
of the cognitive decrements was, however, small and there were no instances of
clinically significant impairment. Rovet and Ehrlich evaluated 16 children over a
seven year period from diagnosis. A significant decline in verbal, but not in
visuospatial, ability was apparent particularly in those children who had experienced
seizures during hypoglycaemia. At the seven year assessment, those children with
hypoglycaemic seizures exhibited deficits on perceptual, motor, memory and
• 252
attention tasks . In another study, 25 older diabetic children (average age 12 years)
were followed from diagnosis over approximately 2.5 years2?J. Thirteen children
were randomly allocated to intensive insulin therapy and 12 to conventional
treatment. Those children receiving intensive insulin therapy had a threefold
increased risk of hypoglycaemia and performed less well on a spatial declarative
memory task. However, this test was part of a very large cognitive battery, which
included several other tests of memory function. The other memory tests showed no
statistically significant between-group differences, although there was a tendency for
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intensively-treated children actually to perform better on several measures.
Therefore, given that no adjustment was made for multiple statistical testing, it is
likely that the significant result in the spatial declarative memory task was a type 1
error.
Interim data from a large prospective study of cognitive performance in children with
diabetes has recently been reported2'10'240. Neuropsychological testing was performed
on 123 children with new-onset Type 1 diabetes, aged between 3 and 14 years, three
months after diagnosis and again at two years. At comparable time points, 129 non-
diabetic children, matched for age and sex, were also evaluated. There was no
difference in the cognitive performance of the groups at the first testing session;
however, at two years there was a non-significant trend for IQ to have fallen in the
diabetic children overall. There was a significant main effect of age on change in
performance IQ, with younger children (i.e. children who diabetes when aged five or
9TQ
less) exhibiting larger drops in IQ . Such children with early-onset diabetes
experienced significantly more episodes of severe hypoglycaemia (defined in this
study as a blood glucose concentration of less than 2.0 mmol/1). In older children,
who were able to undergo more detailed cognitive testing, recurrent severe
hypoglycaemia was associated with impaired performance of several short- and long-
term memory tasks240.
2.2.4 Summary of Effects of Recurrent Hypoglycaemia on Cognitive
Function
In adults with Type 1 diabetes, data from case-control studies has suggested that
exposure to recurrent episodes of hypoglycaemia in adulthood may be associated
with the development of modest cognitive impairment. However, two prospective
studies have failed to demonstrate any association. Even in the cross-sectional
studies, the cognitive decrements reported were relatively mild and so it may be
possible to offer a degree of reassurance, both to people with diabetes and to their
medical attendants, that recurrent severe hypoglycaemia in most adults probably
causes at worst only mild cerebral damage. However, in some of the studies there
were large inter-individual differences in the effects of recurrent hypoglycaemia on
cognitive performance. The cases reported by Gold et al should also act as a
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reminder that in some adults recurrent exposure to severe hypoglycaemia may have
devastating effects on cognitive function216. The future challenge is to identify the
factors that make individuals vulnerable to hypoglycaemia-induced cognitive
impairment.
Children with early-onset diabetes perform less well on subtle measures of cognitive
performance. There are good theoretical reasons to suspect that repeated exposure to
hypoglycaemia may contribute to the development of these cognitive decrements and
this has been supported by cross-sectional, case-control studies. However,
ascertainment of hypoglycaemia histories retrospectively in children is a strategy of
questionable accuracy. Prospective studies reported to date have mainly been small
with very short follow-up periods, but have suggested that hypoglycaemia is
associated with cognitive dysfunction in children with early-onset diabetes.
However, the cognitive decrements that have been described are small, with diabetic





The following chapters describe four studies that were performed to expand clinical
knowledge of the impact and aetiology of hypoglycaemia in patients with Type 1
diabetes.
3.1 ACUTE HYPOGLYCAEMIA, THE PERIPHERAL NERVOUS SYSTEM
AND INFORMATION PROCESSING
The primary aim of Study 1 was to investigate further the basic neuronal processes
affected by acute hypoglycaemia, by attempting to determine if acute hypoglycaemia
has any effects on the function of the peripheral nervous system, in comparison to its
well established deleterious impact on the functions of the central nervous system.
Few studies have considered the effects of acute hypoglycaemia on peripheral neural
function, although a peripheral motor neuropathy has been described following
profound hypoglycaemia of prolonged duration2^4. By studying the effects of
hypoglycaemia on peripheral neural function, insights may be afforded into the basic
metabolic processes within peripheral neurones and may help determine if there is
any evidence of a differential reliance on glucose as a metabolic fuel between the
central and peripheral nervous systems.
A secondary issue that this study aimed to address was the validity of utilising
peripheral nerve conduction velocities as a marker of speed of neuronal function
within the central nervous system. This potential association was investigated on the
basis of the premise that speed of neural function within the central nervous system
may be one of the physiological determinants of speed of information processing and
ultimately of intelligence2^. Some studies have suggested that peripheral nerve
conduction velocities may be a surrogate marker of speed of information processing
and intelligence2^6'2^7. However, such a hypothesis would imply that any external
factor (such as hypoglycaemia) that diminished intelligence should also have a
similar impact on peripheral neural function. Therefore, by comparing multiple
levels of information processing during hypoglycaemia in the same group of
subjects, the lower level processes that may contribute to the decrements in higher-
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level mental performance (which putatively include peripheral nerve conduction) can
be investigated.
3.2 RECOVERY FROM SEVERE HYPOGLYCAEMIA
Severe hypoglycaemia, as has been described in Chapters 1 and 2, is one of the most
feared consequences of insulin therapy for diabetes. The effects of milder levels of
acute hypoglycaemia on cognitive function have been well documented, as these
may readily be studied under experimental conditions. However, studies of the
immediate (as opposed to long-term) cognitive and mood sequelae following severe
hypoglycaemia have attracted little attention, presumably because of the difficulty of
studying such phenomena under controlled conditions. The aim of Study 2 was to
attempt to determine how long cognitive function and mood states took to recover
following an episode of spontaneous severe hypoglycaemia in people with insulin-
treated diabetes. There are unpublished anecdotal reports of cognitive function
taking several days to weeks to recover following an episode of severe
hypoglycaemia in which complete neurological recovery was apparent, but no
previous studies have investigated this issue formally. The results of this study were
anticipated to provide practical information for professionals who care for people
with diabetes. For example, the results could potentially be useful in educating
patients about the appropriate time to return to activities such as work or driving
following an episode of severe hypoglycaemia.
3.3 DETERMINING PROGNOSIS AFTER SEVERE HYPOGLYCAEMIA
The availability of a simple blood test that could help predict clinical outcome in
patients who are comatose following an episode of severe hypoglycaemia, in a
manner analogous to the measurement of serum concentrations of creatine kinase and
troponin following myocardial infarction, would be of considerable value to
clinicians. Following acute stroke, the serum concentrations of two proteins,
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Neurone-Specific Enolase (NSE) and Protein S-100 (S-100), have been shown to be
elevated, and the levels correlate with clinical outcome258'259. The purpose of Study
3 was to investigate whether these markers of neuronal damage could have any
relevance in determining prognosis following severe hypoglycaemia. Therefore, it
was planned to measure changes in serum concentrations of NSE and S-100
following episodes of severe hypoglycaemia in which either complete neurological
recovery occurred, or in which the patient subsequently died.
3.4 INSULIN LISPRO AND POST-PRANDIAL HYPOGLYCAEMIA
Insulin lispro has been advocated as a therapy to reduce the risk of occurrence of
hypoglycaemia, particularly episodes at night1,2. Insulin lispro has a very rapid onset
125of action, so it is recommended that it is injected immediately before food .
However, in theory, if the normal post-prandial rise in blood glucose concentrations
after a meal was reduced or delayed in magnitude, the pre-prandial injection of
insulin lispro could cause early post-prandial hypoglycaemia. Such a situation could
occur following the ingestion of a meal rich in fat (as is often the case in Scotland),
since fat exerts a retardant effect upon gastric emptying260. Therefore, in Study 4, the
differential effects of pre- and post-prandial insulin lispro therapy were compared
following four test meals in which the relative proportions of fat and carbohydrate,
and the relative proportion of solid and liquid phase components, were varied.
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CHAPTER 4
METHODS: COGNITIVE FUNCTION TESTS AND NERVE
CONDUCTION STUDIES
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During the course of Studies 1 and 2, detailed cognitive and mood testing was
performed. All of the cognitive and mood tests utilised were standard and well
validated tasks in common usage in psychological research and clinical practice. To
limit repetition, the theoretical basis and format of each cognitive and mood test are
described in full in this chapter. Nerve conduction studies were also performed in
Study 1. The theoretical basis and the potential sources of error of the nerve
conduction measurements made in Study 1, along with the methods employed, are
also described in this chapter.
4.1 COGNITIVE FUNCTION TESTS
4.1.1 National Adult Reading Test (NART)
The NART provides a measure of 'best' global cognitive function ever attained,
220
irrespective of time . Subjects are asked to read out aloud a list of 50 irregular
English words (such as chord, prelate and campanile) and are marked on their ability
to pronounce the words correctly, according to a standardised scoring system. The
number of errors made is recorded. The NART has been validated against the
Wechsler Adult Intelligence Scale - Revised220 and so, using the error score obtained
and standard tables, it is possible to estimate figures for 'best ever' full-scale, verbal
and performance IQ.
4.1.2 Alice Heim 4 Test (AH4)
The AH4 test is a measure of current intellectual function and is divided into two
parts261. Each part is preceded by practice items and the subject is then allowed 10
minutes to complete as many questions as possible. A choice of potential answers is
provided for each question. The first part of the test measures verbal and numerical
skills, while the second part assesses visuospatial skills. The maximum score for
each part is 65 and the total score provides a measure of global cognitive ability. The
test does not provide an actual IQ score.
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4.1.3 Wechsler Adult Intelligence Scale - Revised (WAIS-R)
The 'performance' subtests of the WAIS-R provide a measure of current intellectual
level144. The performance sub-tests of the WAIS-R are: Picture Completion, Picture
Arrangement, Block Design, Object Assembly and Digit Symbol.
Picture Completion
Subjects are shown a set of 20 picture cards of everyday objects or situations. In
each picture something is missing e.g. the door handles from a car, or the tuning peg
of a violin. Subjects are given 20 seconds to identify the missing part of each card,
and the total number of correct responses is recorded.
Picture Arrangement
Subjects are presented with a series of pictures in a random order and are asked to
arrange them in an order (from left to right) that tells a logical story. There are 10
sets of cards of increasing difficulty and there is a time limit for arranging each card
set. The number of correct arrangements is recorded.
Block Design Task (BD)
Subjects are asked to reproduce, in as short a time as possible, a series of two-
dimensional patterns using a set of nine identical cubes. Marks are awarded on a
structured scoring system dependent on the time taken to complete each pattern.
Object Assembly
Subjects are presented, in random order, with a series of pieces of card that can be
assembled to create a recognisable object, such as a manikin. For each set of cards,
subjects are asked to assemble the object within a time limit and are scored on the
number of pieces that are correctly joined together.
Digit Symbol (DS)
Nine digits are represented by nine different symbols, and subjects are required to
write down the appropriate symbol for each in a given array of numbers over 90
seconds. The number of correct responses is recorded.
87
4.1.4 Digit Span
Digit Span is one of the verbal 1Q sub-tests of the Wechsler Adult Intelligence Scale
- Revised'44. Subjects are asked to repeat strings of numbers in either the precise
order in which they are read out (Forward Digit span, FDS), or in the reverse order
(.Backward Digit Span, BDS). For each test, the number of correct responses is
recorded.
4.1.5 Trail-Making Test B (TMB)
TMB is a test of mental flexibility from the Halsted Reitan Neuropsychological
Battery14"'. The subject has to connect correctly an alternating series of numbers (1-
13) and letters (A-L) - which are dispersed on a standard A4 page - in their
respective orders, as quickly as possible. The time taken (in seconds) to complete
the task correctly is recorded. To limit the effects of practice, nine different versions
of this task are available and have been validated for equal degrees of difficulty. In
the present studies, two versions of the test were administered to subjects at each
testing interval; the mean scores for the two tests are reported. The individual test
versions were administered in random order such that no subject performed the same
trail more than once and all the tests were utilised equally and in different orders.
4.1.6 Logical Memory (LM)
LM, a subtest of the Wechsler Memory Scale, assesses verbal memory function262.
A paragraph of text is read at a standard rate to subjects who are asked to repeat the
text verbatim, both immediately afterwards (immediate recall) and after a period of
30 minutes (delayed recall). Marks are awarded on the basis of a structured scoring
system. To limit the effects of practice, three different versions of the test are
available and have been validated for equal degrees of difficulty. In the present
studies, a different version of the test was administered at each testing session; the
order in which the different versions were utilised remained constant.
4.1.7 Figural Memory (FM)
FM, a subtest of the Wechsler Memory Scale, assesses non-verbal memory
function262. Subjects are asked to attempt to memorise a series of diagrams within a
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set time period. Subjects are then shown another numerically larger set of diagrams
and are instructed to select from these the diagrams that had been seen previously.
The total number of correct responses is recorded.
4.1.8 Borkowski Verbal Fluency Task
Verbal fluency assesses executive functions, which are assumed to involve frontal
lobe activity26"1. Patients are given 60 seconds to state as many words as possible,
beginning with a letter of the alphabet specified by the tester. In the present studies,
each subject gave responses to four letters - 'J', 'S', 'U' and 'M'. The total number of
words obtained, excluding repetitions, was noted.
4.1.9 Stroop Task
The Stroop distraction task provides a very sensitive measure of cognitive
decrement264. However, the precise mental abilities examined are unclear, but are
thought to include attention and speed of information processing. The subject is
provided with a series of eight cards each containing 10 rows of five words (or in
two instances, blocks of asterisks). Each word is printed in one of four colours of
ink. Subjects are asked to read out, as quickly as possible and from left to right and
top to bottom, the colour of ink that the individual words are printed in, rather than
the words themselves. There are four pairs of cards: 1) asterisks; 2) common-words
(e.g. dog); 3) colour-associated words (e.g. grass, sky, blood) in incongruent colours;
4) incongruent colour names (e.g. RED written in yellow ink). A 'practice' card is
also administered in which colour names are printed in black ink and the subject
simply reads the colour names out aloud. The time taken to read the practice card is
subtracted from the average time for each of the four pairs of test cards.
4.1.10 Paced Auditory Serial Addition Task (PASAT)
The PASAT assesses attention, concentration, and general intellectual ability 65.
Subjects listen to a series of numbers that are added together according to the rule:
'add each number that you hear, to the number that preceded it'. After practice, two
trials of 61 digits are performed, with four and two second intervals between
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successive digits, respectively. The total number of correct responses for each test is
recorded (the maximum is 60).
4.1.11 Speed of Information Processing Task (SIP)
The SIP task is a subtest of the British Ability Scales266. Subjects are presented with
a card on which 25 rows of five numbers are printed. The complexity of the numbers
increases from the top to the bottom of the page. Subjects are asked to circle the
highest number on each row as quickly as possible. Two cards are presented to each
subject: one containing 'easy' numbers which are 1 to 4 digits in length, and the other
containing 'difficult' numbers which are 3 to 6 digits in length. For each card, 'easy'
and 'difficult', the time taken to complete the task is recorded, as is the number of
errors made.
4.1.12 Inspection Time (IT)
IT is a two-alternative, forced-choice, discrimination task which assesses the
efficiency of the early stages of visual information processing using psychophysical
procedures148 267. Subjects are instructed to view a screen composed of multiple
light-emitting diodes on which numerous stimuli consisting of two parallel vertical
lines, of markedly different lengths, are presented sequentially. Subjects have to
indicate which of the two vertical lines is the longer. During the test, the
experimenter varies the stimulus duration, with briefer durations being more
difficult. Only correctness of response is recorded; response speed is not measured,
and the subject is instructed to respond at leisure to achieve maximum accuracy. The
IT test's adaptive staircase algorithm measures the stimulus presentation time (in
milliseconds) required by each subject to achieve 85% accuracy in responding (50%
representing chance responding).
4.1.13 Visual Change Detection (VCD)
1 A O
VCD, like IT, assesses speed of early visual processing . The stimulus display
consists of 49 small, non-adjacent rectangles scattered on a computer monitor screen
to which, after a variable interval, a single (target) rectangle is added. The subject's
task is to identify the additional rectangle. The time interval between the onset of the
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49-rectangle array and the target is manipulated by the experimenter; tests with
shorter intervals are more difficult. As with IT, response time is not measured. Each
subject is tested on a random block of 50 presentations; 10 trials of each of five
different stimulus durations are presented at random. A total score of accuracy of
responding is obtained.
4.1.14 Reaction Time (RT)
Reaction time provides a measure of information processing at the cognitive-
experimental level" . In the present studies a Hick-type reaction time device was
utilised. The device, by employing a 'home' button, eight equidistant response
buttons (which may be individually covered to provide the desired level of choice)
and two timers, allows the separation of the decision and movement components of
reaction times. The subject is asked to press the home button with the dominant
hand; when one of the response buttons is lit, the first timer (which records the
decision time) begins and is stopped when the subject's hand leaves the home button.
The second timer (which records the movement time) is started when the subject's
hand leaves the home button and is stopped when the correct response button is hit
by the same hand. In the present studies, measures were made of 1-, 2-, 4- and 8-
choice reaction time. Forty trials were attempted at each level and the median
Decision Time (DT) and median Movement Time (MT) were recorded in
milliseconds. Median values of the two reaction time components were recorded
because of the skewed distribution that repeat reaction time trials consistently
demonstrate.
Decision times (and to a lesser extent movement times) increase with increasing
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complexity of the choice reaction task . This effect is known as the Hick Paradigm
(Figure 4.1). Negative correlations exist between intelligence and mean decision
time (r=—0.32), the y-axis intercept of the regression line of decision times against
number of lights in the Hick Paradigm (r=—0.25) and mean movement time (r=—
0.30)268. Some investigators have also postulated that there is a weak correlation
between intelligence and the slope of the Hick Paradigm regression line (r=—
0.28) . That is, more intelligent people demonstrate a lower rate of increase in
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reaction time with increasing levels of choice than less intelligent people. However,
• • • • 9 S S
the validity of this relationship has been disputed '".
4.1.15 UWIST Mood Adjective Checklist
The UWIST Mood Adjective Checklist is a self-rating assessment of current
270mood . Subjects are provided with a list of 24 mood adjectives (e.g. cheerful,
anxious, jittery) and are instructed to rate the applicability of each adjective to their
present mood as 'definitely', 'slightly', 'slightly not' or 'definitely not'. Responses are
scored 4 for 'definitely' to 1 for 'definitely not'. The scores for three groups of eight
adjectives assessing 'Tense arousal', 'Energetic arousal' and 'Hedonic tone' (or
pleasure-displeasure) are summated to give a maximum score of 32 (and a minimum
score of 4). Higher scores represent greater levels of the particular mood state.
4.1.16 Hospital Anxiety and Depression Scale (HAD)
The HAD is self-rating mood scale which provides a measure of mood state in the
week prior to testing271. Subjects are provided with 14 statements relating to mood
(e.g. 'I feel tense or wound up') and are instructed to complete the statements, on the
basis of their mood state in the preceding week, from a selection of four possible
alternatives. Seven statements assess anxiety levels, and seven assess depression
levels. Individual responses are scored 0-3, and maximum summated anxiety and
depression scores of 21 are obtainable (the minimum score is 0). Higher scores are
indicative of greater levels of anxiety or depression.
4.1.17 Cognitive Function Self-Appraisal Scale (CFSA)
The CFSA provides a subjective measure of everyday cognitive function, with
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particular emphasis on memory . The questionnaire has 35 items and participants
are asked to indicate, for each item, the frequency of lapses in memory or
concentration from 'never' to 'very often' on a five-point scale (0-4). The minimum
score is 0 and the maximum was 140. Subjects are also asked to rate on a three-point
scale whether the overall responses they have given are as 'good as they had ever
been', 'a bit worse' or 'a lot worse'; this is known as the 'cognitive function change
score'.
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FIGURE 4.1: The Hick Reaction Time Paradigm
0 12 3
Log2(Number of Lights)
The number of lights in the choice task (i.e. 1, 2, 4 and 8) is expressed as the
logarithm to the base 2 (i.e. 0, 1,2, and 3). There is a linear relationship between the
Log2 of the number of lights in the choice reaction time task (on the x-axis) and
decision times (on the y-axis), i.e. the more complex the task, the greater the decision
time. It is believed by some psychologists that the gradient of this regression line is a
marker of intelligence, with less intelligent people having steeper slopes.
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4.2 METHODOLOGICAL ISSUES IN THE MEASUREMENT OF
PERIPHERAL MOTOR NERVE FUNCTION
In clinical practice, nerve conduction studies help to delineate the extent and
distribution of peripheral neural lesions and distinguish two main categories of
disease: demyelination and axonal degeneration271. Nerves are stimulated
electrically and the resultant impulse travels along motor, sensory or mixed nerves.
The assessment of conduction characteristics depends on the analysis of compound
evoked potentials recorded from muscle in the study of motor fibres, and from the
nerve itself in the case of sensory fibres. Nerve conduction studies can be performed
on a large number of peripheral nerves, including the median, radial, ulnar, common
peroneal and sural nerves.
4.2.1 Principles and Practice
The study of motor conduction requires stimulation of the nerve at two or more
points along its course. Bipolar nerve stimulators are most commonly used: both
electrodes are placed over the nerve trunk, with the cathode (negative pole) closer to
the recording site to avoid anodal conduction block of the propagated impulse. A
pulse of moderate intensity is initially utilised to adjust the position of the nerve
stimulator to the best stimulating site. At maximal intensity, increasing the
magnitude of the electrical stimulus should result in no further change in the size of
the muscle action potential. Supra-maximal stimuli (20-30 per cent above
maximum) are generally employed to guarantee activation of all the nerve actions.
To record action potentials, two skin surface electrodes are used: an active lead
placed on the belly of the muscle and an indifferent lead sited on the tendon.
The usual measurements made in motor nerve conduction studies are of the
amplitude of the motor action potential (which in clinical practice provides a
measure of axonal density) and the onset latency of the action potential (which is a
measure of the fastest conducting nerve fibres). The onset latency is a function of
nerve conduction time, neuromuscular transmission time and propagation time along
the muscle membrane. Stimulation of the motor nerve at two separate points elicits
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two responses with different latencies, but the last two components are common to
both. Thus the latency difference between the two represents the time necessary for
the nerve impulse to travel from one stimulus point to the other. The nerve
conduction velocity is therefore derived as the ratio of the distance from one point of
stimulation to the next (D) and the difference between the proximal (Lp) and distal
(Ld) latencies:
D (mm)
Conduction velocity (m/s) =
Lp - Ld (ms)
The impulses of slow-conducting fibres lag increasingly behind those of fast-
conducting fibres over a long conduction path. Therefore, a proximal stimulus may
give rise to evoked potentials that are of slightly longer duration and lower amplitude
than are observed following a distal stimulation. Larger discrepancies between the
amplitudes of action potentials after distal and proximal stimulation are indicative of
conduction block.
Lower limb nerves (such as the common peroneal) have substantially slower
conduction velocities than upper limb nerves (such as the median). The factors
possibly responsible for the difference include more abrupt axonal tapering, a more
progressive reduction in axonal diameter, shorter internodal distances and lower
distal temperatures in lower limb nerves.
4.2.2 Common Sources of Error
Although the method of nerve conduction studies is simple in theory, pitfalls abound
in practice:
Problems with the Surface Electrodes
A major technical challenge is often posed by stimulus artefact. This can be
improved by reducing skin impedance; techniques to facilitate this include removing
skin moisture and grease with an alcohol wipe, gently abrading the skin with fine
95
sandpaper and, thereafter, applying high conductance jelly to the skin. A ground
electrode (earth) placed between the stimulating and recording electrodes will also
reduce stimulus artefact.
Unexpectedly small or absent action potentials may be due to a stimulus that is
inappropriately low in intensity (i.e. the stimulus electrodes are in a sub-optimal
position or are mis-directed) or the skin surface electrodes are mis-placed.
Considerable time, therefore, needs to be spent at the outset of nerve conduction
studies to ensure that the muscle action potentials are being optimally detected with
the minimum of stimulus artefact.
Supra-Maximal Stimulation
As was intimated above, it is important to ensure that nerve conduction studies are
performed with supra-maximal electrical stimuli. Sub-maximal stimuli will not
activate all of the axons contained in a nerve and will result in onset latencies that
fluctuate from one trial to another. The use of supra-maximal stimuli, which activate
all axons, circumvents this uncertainty.
Effects of Limb Temperature
Nerve impulses propagate faster at higher body temperatures, with velocities
increasing by approximately 2.4 m/s per degree from 29 to 38°C. Therefore, in
experimental studies it is crucial to control for limb temperature, ideally by using a
thermostatically-regulated limb warmer. If skin temperature falls below 34°C,
indicating a muscle temperature of less than 37°C, it is necessary to warm the limb.
If such facilities are not available, it is theoretically possible to mathematically adjust
for limb temperature by adding 5% of the measured conduction velocity for each
degree below 34°C.
4.2.3 Methods for Nerve Conduction Studies Performed in Study 1
Motor nerve conduction studies were performed by the same investigator, according
to the principles described in Section 4.2.1, on the dominant-side median and
common peroneal nerves using a Medelec Sapphire" 2ME electromyograph
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(Medelec Limited, Old Woking, Surrey, UK). In the case of the median nerve
studies, the nerve was stimulated with a bipolar electrode proximally in the
antecubital fossa and distally on the volar aspect of the wrist; the skin surface
electrodes were placed, after adequate skin preparation, over the muscles of the
thenar eminence. For the common peroneal nerve studies, the nerve was stimulated
proximally behind the head of the fibula and distally over the anterior aspect of the
shin, just above the ankle joint; surface electrodes were placed over the extensor
digitorum brevis muscle in the foot. Skin surface electrodes were sited after
appropriate skin preparation and remained in position during the course of each
experimental study. Ground (earth) electrodes were utilised to reduce stimulus
artefact. Nerves were stimulated orthodromically with supra-maximal electrical
signals; the sites for nerve stimulation were marked at the outset of each study
session and remained constant thereafter. Limb temperature was kept constant at
34°C using a DISA thermostatically-regulated heater (DISA, Bristol, UK).
Recordings were made of the median and common peroneal nerve motor conduction
velocities (m/s) and of the amplitudes of the motor action potentials (mV). The ratio
of the amplitudes of the motor action potentials after distal and proximal stimulations
was also calculated as an index of acute conduction block. If acute conduction block
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5.1.1 Effects of Hypoglycaemia on the Peripheral Nervous System
The ability of acute hypoglycaemia to impair higher functions of the central nervous
system has been described in detail in Chapter 2. Considerably less attention has
focused on the effects of hypoglycaemia on the peripheral nervous system, but
limited experimental evidence in animals and anecdotal evidence in humans supports
the existence of a putative 'hypoglycaemic neuropathy'2"4.
Several studies in diabetic and non-diabetic rats have demonstrated that profound
hypoglycaemia (venous blood glucose below 2.5 mmol/1) of prolonged duration (at
least 12 hours) resulted in axonal degeneration of peripheral nerves with consequent
T"7/1
reduction of nerve conduction velocities and evoked muscle action potentials " .
In the spontaneously diabetic BB rat, prolonged hypoglycaemia (venous blood
glucose less than 3.0 mmol/1 for six days) was associated with the development of a
motor peripheral neuropathy characterised by loss of anterior horn motor neurones,
loss of large myelinated fibres and Wallerian degeneration277.
In humans, peripheral neuropathy is a rare, but recognised, complication of
278 280 ... pinsulinoma " , where the characteristic findings are those of a predominantly
motor peripheral neuropathy which is distal and symmetrical. Upper limb
involvement is generally more frequent and severe, and neurophysiological studies
278
suggest that the axon is the primary site of damage . Following resection of the
278
insulinoma, weakness improves and sensory symptoms may resolve completely
Earlier observations of psychiatric patients undergoing insulin-coma therapy also
suggested that peripheral sensory disturbances and, in some instances, sensory loss
281 283followed prolonged insulin-induced hypoglycaemia " . In addition, anecdotal
reports exist of peripheral neuropathy being precipitated by the onset of strict
glycaemic control in diabetic patients284, in whom recurrent episodes of moderate
hypoglycaemia are common.
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Few data are available on the effects of more moderate degrees and durations of
hypoglycaemia on peripheral nerve function in humans. Tamburrano and colleagues
could not identify any change in median nerve sensory conduction velocity in six
non-diabetic human subjects in whom mean arterialised blood glucose was
maintained at 2.4 mmol/1 for 60 minutes using a hyperinsulinaemic glucose clamp
28b
technique" . However, nerve conduction studies were not performed on nerves in
the lower limb, and motor nerve conduction velocities were not measured. In a
different study, acute hypoglycaemia (venous plasma glucose nadir 2.4 mmol/1
induced by stopping dextrose infusions in fasting subjects) had no effect on sensory
conduction velocities of the median nerve in seven patients with insulinoma286.
However, no information was provided on how, or if, hypoglycaemia was avoided in
the period leading up to the experimental studies, the order of the study sessions
(euglycaemia versus hypoglycaemia) was not randomised and, in the hypoglycaemia
studies, the neurophysiological readings were performed immediately after the blood
glucose nadir was reached, so that insufficient time may have elapsed for significant
alterations in peripheral nerve function to have occurred.
5.1.2 Peripheral Neural Function and Intelligence
287 289
Speed of information processing correlates strongly with overall mental ability " ,
and so there is a widely held view, within the field of contemporary intelligence
9RQ
research, that speed of information processing is a key component of'intelligence'
That is, an intelligent person is one who can quickly and effectively process
incoming stimuli, with this efficient system additionally allowing increased
information handling ability. In a reductionist scheme, from the most complex to the
simplest level, efficiency of information processing in humans can be assessed using
psychometric tests (e.g. the processing speed test of the British Ability Scales),
cognitive-experimental tasks (e.g. choice reaction time procedures) and
psychophysical tests (e.g. backward masking procedures such as visual inspection
time267). However, little is known about factors that might act as the neural substrate
for speed of information processing, but an obvious and simplistic explanation is that
the speed of nerve conduction may be responsible290.
100
In an attempt to examine this hypothesis, several studies have examined the
relationship between peripheral nerve conduction velocity, speed of information
0^*7 OQft OQO
processing and intelligence ' ' " . Peripheral nerve conduction velocities have
been studied because their function involves no cognitive component and so they
represent a purely physiological assessment of speed of neuronal function. It has
been asserted that the accurate assessment of pure nerve conduction velocities cannot
be undertaken using brain evoked potentials (even though this would appear a more
logical choice) since their generation also involves a degree of cognitive
290
processing
Vernon and Mori found correlations of moderate size (r=~0.45) between median
nerve sensory nerve conduction velocities and general IQ in two separate groups of
undergraduate students (~85 students in each group)2?<1. There were smaller
correlations between nerve conduction velocities and reaction times (r=~-0.23), and
adjustments for age and sex had no impact apon the size of the correlation
coefficients. Rijsdijk and Boomsma found a smaller, but statistically significant,
correlation (r=0.15) between median nerve conduction velocities and intelligence in
9 S7
159 Dutch twin pairs aged 18 years . Twin analyses suggested that the relationship
between nerve conduction and intelligence was entirely mediated by common
genetic factors. However, these results were not replicated in three other studies290"
292. Barrett et al studied 44 men and women and did not find a significant correlation
between peripheral nerve conduction velocities and intelligence as assessed by the
Advanced Raven Matrices task290. Similarly Reed and Jensen found no link between
intelligence (measured by Standard and Advanced Raven Matrices) and peripheral
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nerve conduction velocities in 200 male university and college students . However,
there were methodological differences between the latter two studies and that of
Vernon and Mori that could have accounted for the discrepant findings. The study
by Barrett et al was small, with the attendant risk of a type 2 statistical error290.
Moreover, the nerve conduction studies employed .vw^-maximal stimulation of the
sensory component of the median nerve which, as was described in Chapter 4.2,
could have resulted in an atypical nerve conduction velocities. Moreover, in the
study by Reed and Jensen, the effect of limb temperature on nerve conduction
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velocities was controlled statistically rather than directly using a heater291. However,
in a later study, Wickett and Veron employed comparable methodology to that of
Vernon and Mori and did not demonstrate a correlation between peripheral nerve
conduction velocities and intelligence in 38 females292. Clearly, there was again a
risk of a type 2 statistical error in this study but, on the basis of the results, the
authors re-analysed the original data presented by Vernon and Mori2:i6 to determine
whether differences in sex distribution could have accounted for the discordant
results. The repeat analysis was not entirely convincing in this regard, but did raise
the prospect that the correlations between nerve conduction velocities, reaction times
and intelligence were stronger for men than women292.
5.1.3 Aims of the Study
Since moderate hypoglycaemia is known to have significant impact on functions of
the central nervous system, any differential effect of hypoglycaemia on the
peripheral nervous system may offer insights into the metabolic requirements of
central and peripheral neurones. The primary aim of the present study was,
therefore, to consider the impact of one hour of hypoglycaemia (arterialised blood
glucose 2.6 mmol/l) on the motor function of the median and common peroneal
nerves in non-diabetic humans.
A secondary aim of the investigation was, within a single study, to examine
comprehensively the effects of controlled hypoglycaemia on different levels of
human information processing. Since speed of processing, at all levels of
description, is related in normal humans to mental ability, by testing all such levels
during hypoglycaemia in the same group of subjects, the lower level processes that
may contribute to the decrements in higher-level mental performance (which




Sixteen non-diabetic human subjects (eight male) were recruited from staff at the
Royal Infirmary of Edinburgh. None had any relevant previous medical history or a
family history of diabetes, and none were taking regular medication (other than the
oral contraceptive pill). All subjects had a corrected visual acuity of 6/6 or better, as
measured with a Snellen chart. The mean age (± SD) was 31.1 (+ 8.3) years and the
mean body mass index (± SD) was 23.1 (± 2.2) kg/m2. Written informed consent
was obtained from all subjects and the study was approved by the local medical
ethics advisory committee.
5.2.2 Experimental Procedure
Subjects attended for three study sessions, each separated by at least two weeks. The
purpose of the initial visit was primarily to familiarise subjects with the tests that
would be used in the experimental sessions, so as to reduce the effects of practice on
test results. During this initial visit, intellectual ability was assessed by the National
Adult Reading Test (NART) and the Alice Heirn 4 Test (AH4). In the following two
study sessions, the participants underwent the experimental procedures during
conditions of either hypoglycaemia or euglycaemia (Figure 5.1). The subjects were
not informed which condition was being studied at each visit. The subjects
completed both experimental conditions in a counterbalanced fashion, i.e. half of the
subjects underwent the euglycaemia study first followed by the hypoglycaemia study
and the other half underwent the studies in the reverse order.
During the two experimental visits, subjects underwent a glucose clamp procedure.
Following a light breakfast at 07.00 hours, subjects were asked to attend the
department at midday. A teflon cannula was inserted into an ante-cubital vein in the
subject's non-dominant arm under local anaesthetic (1% lignocaine). This cannula
was used to infuse human soluble insulin (Actrapid, Novo Nordisk Pharmaceuticals,
Crawley, UK) and 10% dextrose. A second cannula was inserted in a retrograde
direction into a vein on the dorsum of the same hand, which was then placed in a
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heated box (Plexiglass) at 60°C to arterialise the venous blood. Arterialised blood
samples were obtained throughout the study for the measurement of whole blood
glucose at the bedside using a glucose oxidase method (Yellow Springs Instrument
2300 Stat, Yellow Springs, OH, USA). To maintain patency, both cannulae were
flushed frequently with heparinised saline.
A modified hyperinsulinaemic glucose clamp technique was used to maintain the
blood glucose at predetermined levels149. After a brief priming regimen, insulin was
infused at a steady rate (based on whole-body surface area) of 60mU/m /min using
an IMED Gemini PCI pump; 10% dextrose was infused, using an IVAC Site Saver
pump, at a variable rate according to the blood glucose value. Arterialised blood
glucose was initially measured every three minutes, until a stable level had been
achieved, and then at five minute intervals. Counterregulatory hormone
concentrations were not estimated.
At each laboratory session, the arterialised blood glucose concentration was initially
stabilised at 5.0 mmol/1 for a period of one hour during which baseline peripheral
nerve conduction studies were performed and the subject completed the mental test
battery (baseline; Figure 5.1). Following this, the blood glucose concentration was
either maintained at 5.0 mmol/1 (euglycaemia; Figure 5.1) or lowered to 2.6 mmol/1
(hypoglycaemia; Figure 5.1) and maintained at this level for one hour, during which
peripheral nerve conduction studies were performed every 30 minutes and the
neuropsychological test battery was repeated. The subjects were not informed about
their blood glucose concentration during any phase of the study. A period of 20
minutes was allowed to elapse between the baseline and the attainment of
euglycaemia or hypoglycaemia to allow the blood glucose concentration to stabilise.
The target glucose concentration was maintained for a further ten minutes before the
tests were administered.
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5.2.3 Nerve Conduction Studies
Motor nerve conduction studies were performed by the same investigator, according
to the principles described in Chapter 4.2, on the dominant-side median and common
peroneal nerves. Recordings were made of the motor nerve conduction velocities
(m/s) and of the amplitudes of the motor action potentials (mV). The ratio of the
amplitudes of the motor action potentials after distal and proximal stimulations was
also calculated as an index of acute conduction block. If acute conduction block
occurred, then a ratio significantly greater than 1.00 would have been expected.
Measurements were made once during the baseline, at the beginning (TO) of the
experimental session (hypoglycaemia or euglycaemia) and after 30 (T30) and 60
(T60) minutes.
5.2.4 Cognitive Test Battery
A combined psychometric, cognitive-experimental and psychophysical test battery
was applied during the baseline and experimental phases of the euglycaemia and
hypoglycaemia conditions. The order of the tests (as listed below) remained the
same during each phase of the visit, and the battery was interrupted only to allow
measurement of peripheral nerve conduction velocities at pre-requisite time points.
The cognitive tests were described in detail in Chapter 4.1.
Tests of General Cognitive Ability
Two complex psychometric tests were used to assess general cognitive function:
■ Digit Symbol (DS)
■ Trail-Making Test B (TMB):
Tests of Information Processing
Three tasks were employed to assess the efficiency of information processing at the
psychometric, psychophysical and cognitive-experimental levels:
■ Speed ofInformation Processing (SIP)
■ Inspection Time (IT)
9 1-, 2-, 4-, and 8-Choice Reaction Time (RT)
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5.2.5 Edinburgh Hypoglycaemia Scale (EHS)
This is a subjective self-rating scale in which subjects are presented with a list of
symptoms of hypoglycaemia and are asked to score the severity of each symptom
from 1 (not present) to 7 (very intense)27. The scale was administered during the
baseline and experimental stages of the clamp studies. Symptoms scores were
summated and classified into three groups: autonomic (e.g. sweating, tremor,
hunger), neuroglycopenic (e.g. confusion, drowsiness, inability to concentrate) and
non-specific (nausea and headache).
5.2.6 Statistical Analyses
All data are presented as mean ± standard deviation (SD). Each measure of cognitive
and peripheral nerve function was analysed independently.
The effects of acute hypoglycaemia on symptom scores and cognitive performance
were assessed using a mixed-model Analysis of Variance (ANOVA). 'Order of
session' was used as a between-subjects factor with two levels (euglycaemia-
hypoglycaemia or hypoglycaemia-euglycaemia). There were two within-subjects
factors, each with two levels: 'experimental condition' (euglycaemia versus
hypoglycaemia) and 'time' (baseline versus experimental). The principal outcome
statistic was any ['experimental condition' by 'time'] interaction as this indicated the
effects of hypoglycaemia on cognitive and symptom parameters and controlled for
day-to-day variation by including baseline scores. It was anticipated that the
principal outcome statistic would show a significant effect of hypoglycaemia on the
individual parameters and so significant main effects for 'experimental condition' are
not reported, as subjects were euglycaemic at baseline during both the euglycaemia
and hypoglycaemia condition days, making this effect non-meaningful. Significant
main effects of'time' are also not relevant in this context and are not reported.
The effects of hypoglycaemia on the movement and decision time components of the
individual 1 -, 2-, 4- and 8-choice reaction time tasks were compared using the above
mixed-model ANOVA. In addition the effects of hypoglycaemia on the Hick
Paradigm (i.e. the linear relation between decision time [and movement time] and the
108
logarithm of the number of lights in the choice task) were compared using the data
from the euglycaemia and hypoglycaemia experimental conditions in a mixed model
ANOVA. 'Order of session' was used as a between-subjects factor with two levels
(euglycaemia-hypoglycaemia or hypoglycaemia-euglycaemia). There were two
within-subjects factors: factor one, 'experimental condition', had two levels
(euglycaemia versus hypoglycaemia) and factor two, 'number of lights', had four
levels (1-choice reaction time versus 2-choice, versus 4-choice, versus 8-choice).
The main effects of 'number of lights' and 'experimental condition' indicated the
effects of increasing complexity of the reaction time task and of hypoglycaemia
respectively on the decision and movement time parameters. The interaction of
['experimental condition' by 'number of lights'] indicated whether hypoglycaemia had
a differential effect on decision and movement times depending on the complexity of
the reaction time task.
A mixed-model ANOVA was used to assess the effects of acute hypoglycaemia on
the median and common peroneal nerve conduction parameters. 'Order of session'
was used as a between-subjects factor with two levels (euglycaemia-hypoglycaemia
or hypoglycaemia-euglycaemia). There were two within-subjects factors: factor one,
'experimental condition', had two levels (euglycaemia versus hypoglycaemia) and
factor two, 'time', had four levels (baseline versus TO, versus T30, versus T60). In
addition to the principal outcome statistic of any ['experimental condition' by 'time']
interaction, the main effects of 'time' and 'experimental condition' are also reported.
Direct comparisons between the median and common peroneal nerve conduction
parameters during euglycaemia were also made using a mixed-model ANOVA.
'Order of session' was used as a between-subjects factor with two levels
(euglycaemia-hypoglycaemia or hypoglycaemia-euglycaemia). There were two
within-subjects factors: factor one, 'nerve', had two levels (median versus common
peroneal) and factor two, 'time', had four levels (baseline versus TO, versus T30,
versus T60).
109
A p-value of <0.05 was considered to be significant. All analyses were performed
using SPSS version 7.5.1 for Windows 95. Reported p-values were rounded to two
decimal places; thus p=0.00 signifies that the p-value was <0.005.
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5.3 RESULTS
5.3.1 Intellectual Ability of the Study Participants
All but one of the subjects had above average intellectual ability. The mean (± SD)
AH4 score for all 16 subjects was 98.8 (± 17.0). The mean (± SD) NART error score
for 15 of the 16 subjects was 15.7 (± 5.6), which predicted a mean (± SD)
intelligence quotient (IQ) of 111.2 (± 6.9). The NART was not administered to one
of the subjects who, although fluent in English, did not learn English as his first
language. However, this subject scored highly on the AH4 task. The subject with
below average IQ made 28 errors on the NART, which predicted a full-scale IQ of
96.
5.3.2 Blood Glucose Profiles for the Clamp Studies
Stable glycaemic plateaux were achieved for every subject in each condition of the
study (Figure 5.2). The whole blood glucose (mean ± SD) during the baseline
euglycaemic clamps was 4.95 ±0.15 mmol/1. During the experimental conditions of
euglycaemia and hypoglycaemia, blood glucose values were 5.03 ± 0.07 mmol/1 and
2.63 ± 0.08 mmol/1 respectively.
There were no statistically significant effects of order on any of the outcome
variables (p>0.05).
5.3.3 Symptoms
During the hypoglycaemic condition of the study, significant increments occurred
both in autonomic (p=0.00) and neuroglycopenic symptom scores (p=0.01), but no
significant change was observed in the non-specific symptoms of malaise (p=1.00;
Table 5.1).
5.3.4 General Cognitive Function Tests
Moderate hypoglycaemia resulted in a marked deterioration in performance of the
Digit Symbol (p=0.01) and Trail Making B tasks (p=0.04; Table 5.1).
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5.3.5 Tests of Information Processing
SIP and Inspection Time
The time taken to complete the 'difficult' subset of the SIP test was prolonged by
acute hypoglycaemia (p=0.00; Table 5.1), but the time taken to complete the 'easy'
task failed to reach statistical significance (p=0.09). There was no change in the
number of errors made, which was low in each subtest. Moderate hypoglycaemia
also resulted in a deterioration in performance of the Inspection Time task (p=0.00;
Table 5.1).
Reaction Time
Acute hypoglycaemia caused significant deterioration in the decision time and
movement time components of the 1-, 2-, 4- and 8-choice reaction time tasks (all
p<0.05; Table 5.2), with the exception of the movement time component of 2-choice
reaction time which just failed to reach statistical significance (p=0.05).
With regard to the Hick Paradigm (Figures 5.3 and 5.4), decision times increased
with increasing complexity of the reaction time task, i.e. the main effect of 'number
of lights' was significant (p=0.00). Movement times also increased (p=0.00), but the
proportional increment was smaller. In keeping with the results for the individual
reaction time tasks, the main effect of 'experimental condition' revealed a
significantly deleterious effect of hypoglycaemia on decision (p=0.00) and
movement times (p=0.00). The interaction between ['number of lights' and
'experimental condition'] on decision (p=0.88) and movement times (p=0.67) was
non-significant indicating that there was no differential effect of acute
hypoglycaemia on any of the individual choice reaction time tasks.
5.3.6 Nerve Conduction Studies
Common Peroneal versus Median Nerve Conduction Parameters
Mean nerve conduction velocities (during euglycaemia) were significantly faster in
the median than the common peroneal nerve (p=0.00) and similarly the mean
amplitudes of the proximal (p=0.00) and distal (p=0.00) evoked potentials were
greater in the median nerve. The mean ratio of distal to proximal amplitudes for the
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median nerve were slightly greater than 1.0 at most time points, but approached 1.0
for most time points of common peroneal nerve stimulation. The inter-subject
variability in amplitude measurements (as indicated by the standard deviation values)
was considerably greater than that observed with the nerve conduction velocities for
both nerves.
Effects of Interaction of Experimental Condition' and 'Time' on Nerve
Conduction Parameters
Acute hypoglycaemia had no significant effect on the motor nerve conduction
velocities of the median and common peroneal nerves (p>0.05; Table 5.3).
Similarly, acute hypoglycaemia did not alter the amplitudes of the evoked action
potentials of either nerve after proximal or distal stimulation, nor did it affect the
ratio of the distal to proximal amplitudes (p>0.05; Table 5.3).
Main Effects of 'Experimental Condition' on Nerve Conduction Parameters
The amplitudes of median nerve evoked potentials after proximal stimulation were
smaller during the hypoglycaemia study day than the euglycaemia study day
(p=0.02) and there was also a non-significant trend for the amplitudes after distal
stimulation to be smaller during the hypoglycaemia study day (p=0.11). There were
no significant main effects of 'experimental condition' on median nerve conduction
velocities or on any of the common peroneal nerve conduction parameters (p>0.05).
Main Effects of 'Time' on Nerve Conduction Parameters
There was a significant main effect of 'time' on common peroneal nerve conduction
velocities (p=0.00), i.e. nerve conduction velocities in both experimental conditions
declined with time. No main effect of 'time' was observed on the common peroneal
amplitude data, or on any of the median nerve neurophysiological parameters
(p>0.05).
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Mean blood glucose concentrations (±SD) during the baseline and experimental
conditions of both the euglycaemic (Eug) and hypoglycaemic (Hypo) glucose
clamps. There was no difference in blood glucose concentrations during the baseline
conditions. Blood glucose concentration was approximately 5.0 mmol/1 during the
euglycaemia experimental condition and 2.6 mmol/1 during the hypoglycaemia
experimental condition.
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FIGURE 5.3: Effects of Acute Hypoglycaemia on the Decision Time






Mean of median decision time components (±SD) of choice reaction time during the
experimental conditions of both the euglycaemic (Eug) and hypoglycaemic (Hypo)
glucose clamps. The number of lights in the choice task (i.e. 1, 2, 4 and 8) is
expressed as the logarithm to the base 2 (i.e. 0, 1,2, and 3). There were significant
main effects of 'number of lights' and 'experimental condition' (both p=0.00), but the
interaction of the main effects was not significant (p=0.88). Thus, hypoglycaemia
had a deleterious effect on decision times, but the proportional size of the effect was
not influenced by the complexity of the choice task.
FIGURE 5.4: Effects of Acute Hypoglycaemia on the Movement Time
Component of Choice Reaction Times
Log2(Number of Lights)
J Eug -0— Hypo
Mean of median movement time components (±SD) of choice reaction time during
the experimental conditions of both the euglycaemic (Eug) and hypoglycaemic
(Hypo) glucose clamps. The number of lights in the choice task (i.e. 1, 2, 4 and 8) is
expressed as the logarithm to the base 2 (i.e. 0, 1,2, and 3). There were significant
main effects of 'number of lights' and 'experimental condition' (both p=0.00), but the
interaction of the main effects was not significant (p=0.67). Thus, hypoglycaemia
had a deleterious effect on movement times, but the proportional size of the effect
was not influenced by the complexity of the choice task.
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5.4 DISCUSSION
5.4.1 Differences Between the Median and Common Peroneal Nerve
Conduction Study Data
The differences observed in the present study between the median and common
peroneal nerve conduction velocities and in the amplitudes of the evoked action
potentials were entirely predictable on the basis of normative data from nerve
conduction studies in healthy people27'1. Factors that may be responsible for
differences between upper and lower limb nerves include more abrupt distal axonal
tapering, a more progressive reduction in axonal diameter, shorter inter-nodal
distances and lower distal temperatures in lower limb nerves. The tendency for the
ratio of median nerve distal to proximal amplitudes to be greater than 1.00 was again
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predictable" since proximal stimulation may give rise to evoked potentials that are
of slightly longer duration and lower amplitude than those observed following distal
stimulation. This is because the impulses of slow-conducting fibres lag behind those
of fast-conducting fibres over a long conduction path. It is also recognised that the
variability of amplitude data may be substantially greater than that of nerve
293conduction velocity data , because of the technical vagaries involved in achieving
optimum evoked potential amplitudes (see section 4.2).
5.4.2 Effects of Acute Hypoglycaemia on Peripheral Neural Function
Neurones of the central nervous system are exquisitely sensitive to the prevailing
blood glucose concentration, with even moderate hypoglycaemia resulting in
significant impairment of neuronal function, as demonstrated by the development of
* • *161 * ••• 274 277
cognitive dysfunction . Experimental studies in animals " and anecdotal
778 787
reports in humans " have also suggested that profound and protracted
hypoglycaemia adversely affects peripheral nerve function, and may precipitate the
development of a peripheral neuropathy. The effects of more moderate degrees and
durations of hypoglycaemia on peripheral nerve function have not been definitively
ascertained.
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Previous studies demonstrated that acute moderate hypoglycaemia had no impact on
• • ... 98<S
median nerve sensory function in both non-diabetic subjects and in patients with
285insulinoma . However, these studies had significant methodological limitations,
which were described in section 5.1, and which included very small sample sizes.
The present study has supported and extended these earlier observations by
demonstrating that acute hypoglycaemia had no effect on the motor conduction
velocities of the dominant-side median and common peroneal nerves. The
amplitudes of the action potentials were similarly unaffected and there was no
evidence of acute conduction block. The differences observed between the median
nerve evoked potential amplitudes measured on the euglycaemia and hypoglycaemia
study days (which included the baseline euglycaemic measurements during both
days) do not have an obvious physiological basis and presumably represent a chance
occurrence (i.e. a type 1 statistical error) because of the high variability of the
9QT
amplitude measurements .
It is reasonable to speculate whether any methodological issues such as sample size,
the depth of hypoglycaemia attained, the nature of the nerves chosen for
neurophysiological study or the nerve conduction studies themselves could have
accounted for this null result.
■ The present study had ample power to detect differences in cognitive function
during acute hypoglycaemia. Moreover, because subjects acted as their own
controls the sample size provided approximately 80% power to detect a 0.75
standard deviation change in median nerve conduction velocities with a p-value
set at 0.05. Median and common peroneal nerve conduction velocities did appear
to be consistently 1.0 - 1.5m/s slower during hypoglycaemia compared with
euglycaemia, but these differences were non-significant. It is just conceivable
that these differences could have become statistically significant in a larger study,
but the magnitude of such a difference would be of minimal clinical relevance.
■ An arterialised blood glucose concentration of 2.6 mmol/1 was chosen for the
hypoglycaemia phase of the investigations as numerous previous studies (see
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Chapter 2.1) have demonstrated that this blood glucose level is associated with
significant impairment of cognitive functions. Therefore, if peripheral nerves had
a similar reliance on glucose as a metabolic fuel as central nervous system
neurones, then this level of hypoglycaemia should have been sufficient to
demonstrate a decrement in function. Lower blood glucose concentrations are
associated with increased physical discomfort for subjects and it was not ethically
justifiable to induce more profound hypoglycaemia.
■ The common peroneal and median nerves were chosen for several reasons. Both
nerves are readily accessible for performing neurophysiological studies, and their
stimulation causes minimal discomfort to subjects. Peripheral neuropathies tend
to affect longer nerves rather than shorter nerves, therefore the common peroneal
nerve was chosen on the theoretical basis that its long length may have made it
more susceptible to the effects of moderate hypoglycaemia. The median nerve
was chosen since animal and human studies suggested that 'hypoglycaemic
neuropathy' affects predominantly upper limb nerves. Sensory neural function
was not assessed in this study on the basis that 'hypoglycaemic neuropathy'
primarily affects motor nerves and two previous studies, albeit of limited
methodological quality, had previously shown no susceptibility of peripheral
28^ 286 • • c
sensory nerves to acute hypoglycaemia ' . In addition, the measurement of
sensory nerve function causes considerably more discomfort to subjects and is
open to greater technical errors because the amplitudes of the evoked potentials
• • ... 97T
are considerably smaller (leading to a reduced signal-to-noise ratio) . There
was a limited amount of time available in the context of each clamp study to
perform nerve conduction studies and it was felt that this would best be utilised
measuring motor nerve function. During the clamp studies, the intravenous
cannulae were sited in the non-dominant hand so that the dominant hand was free
for performance of the psychometric tests. Therefore, nerve conduction studies
were performed on the dominant side because it would not have been possible to
guarantee optimum placement of the electrodes for the nerve conduction studies
on the non-dominant hand.
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■ In current clinical practice, nerve conduction studies, and in particular the
measurement of nerve conduction velocities and the amplitudes of the evoked
potentials, represent the most effective methodology for assessing the functions
9 7"2
of peripheral nerves . It is possible to measure other electrophysiological
parameters, such as F-waves (which measure conduction time from the peripheral
nerve to the spinal cord and back) and nerve refractory period (i.e. the shortest
time interval between two sequential nerve stimuli that generate two sequential
evoked potentials). It was not felt that the measurement of these parameters
would have added considerably to the assessment of peripheral neural function.
In particular, the measurement of refractory period is a time-consuming process
and in a previous pilot study of four male Sprague-Dawley rats, acute
hypoglycaemia (arterial blood glucose nadir of 1.66 mmol/1 induced by insulin
infusion) had no effect on the refractory period of the right femoral nerve294.
The foregoing paragraphs, therefore, suggest that methodological issues do not
account for the results of the present study and that the inability to detect any
significant change in the neurophysiological parameters of peripheral nerves during
hypoglycaemia indicates resistance of peripheral neural function to neuroglycopenia.
The significant change in common peroneal nerve conduction velocities that
occurred with time during the hypoglycaemia and euglycaemia studies was
unexpected and was not observed in any of the other peripheral nerve
neurophysiological measurements. Tamburrano et al did not report any impact of
hyperinsulinaemic euglycaemia on median sensory nerve conduction velocities in
five non-diabetic subjects283, and in the later study on nerve conduction parameters in
286 • •
patients with insulinoma no time course data was provided . While this
observation could have resulted by chance, it should be noted that nerve conduction
velocities are generally regarded as being highly reproducible within individual
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subjects (in contrast to amplitude measurements) . It is, therefore, tempting to
speculate that hyperinsulinaemia per se affected the common peroneal nerve
conduction velocities, although the reason for a lack of effect on median nerve
conduction velocities would require explanation. The institution of intensive insulin
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therapy in diabetic patients with poor glycaemic control can promote the
development of a peripheral neuropathy284 but, of course, in observational studies
such as this, and others that have looked at 'hypoglycaemic neuropathy', it is not
possible to separate a potential direct toxic effect of insulin itself from its
hypoglycaemic actions. Greene and Winegrad, however, reported no direct toxic
effects of insulin on isolated endoneurial preparations of rat peripheral nerve29'.
Therefore, the observation that common peroneal motor nerve conduction velocities
changed with time, and the speculation that this may be related to hyperinsulinaemia,
must be re-assessed in future studies that are appropriately controlled.
5.4.3 Effects of Acute Hypoglycaemia on Symptoms of Hypoglycaemia
and Cognitive Function
Acute hypoglycaemia predictably caused an increase in autonomic and
neuroglycopenic symptoms of hypoglycaemia, but did not affect the 'non-specific'
symptoms of nausea and malaise. The insensitivity of the 'non-specific' symptoms to
148 178
hypoglycaemia has been identified in other studies ' . The three-factor model of
hypoglycaemic symptoms, that is utilised in the EHS, is based on a multi-factor
confirmatory factor analysis of symptoms of hypoglycaemia that were
27
retrospectively recalled by two large groups of diabetic subjects . Therefore, the
relative insensitivity of the 'non-specific' symptoms, in the present and previous
studies, suggests that this model may not be appropriate for symptoms of
hypoglycaemia induced during hyperinsulinaemic clamp studies. Further
investigation of this possibility is clearly merited and would simply involve
performing factor analysis on hypoglycaemia symptom data from a large number of
clamp studies.
In contrast to its effects on the peripheral nervous system, acute hypoglycaemia
caused significant disruption of central neural function as evidenced by impaired
performance in the majority of tasks in the cognitive test battery. The deleterious
effects of acute hypoglycaemia on general cognitive ability, as assessed by the Digit
Symbol and Trail Making B tasks, and early stages of visual information processing,
as assessed by the inspection time task, have been documented in other
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studies9'148'161'178 and the results of the present study were entirely consistent with
these.
No previous studies have assessed the effects of acute hypoglycaemia on
performance of the SIP task from the British Ability Scales. Hypoglycaemia
significantly reduced the time taken to complete the 'difficult' subtest, but the
decreased time taken to complete the 'easy' subtest during hypoglycaemia just failed
to reach statistical significance. Moderate hypoglycaemia had no significant effect
on the number of errors made in either the 'easy' or the 'difficult' subtests of this task.
These findings are consistent with previous studies that have suggested that
hypoglycaemia causes greater impairment of complex cognitive tasks than simple
tasks9'148'161'178, but that accuracy of performance tends to be preserved at the expense
of speed162'163.
The present study was also the first to assess the impact of hypoglycaemia on 1-, 2-,
4-, and 8-choice reaction time within one experimental investigation. It is well
established that increasing complexity of the choice task increases the decision time
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component of reaction time more markedly than the movement time component .
The results of the present study support these observations. Acute hypoglycaemia
caused significant impairment in performance of all the choice reaction time
components, with the exception of the movement time component of 2-choice
reaction time which just failed to reach statistical significance (p=0.05).
Correlations exist between intelligence and a variety of parameters that can be
measured using the choice reaction time task (Chapter 4.1.14). Intelligence
correlates with mean decision time (r =—0.32), the y-axis intercept of the regression
line of decision times against number of lights in the Hick Paradigm (r =—0.25) and
mean movement time (r=—0.30)268. Some investigators have also postulated that
there is a weak correlation between intelligence and the slope of the Hick Paradigm
regression line (r=—0.28) ' . That is, more intelligent people demonstrate a lower
rate of increase in reaction time, with increasing levels of choice, than less intelligent
people. If such a relationship were valid, then an intervention that makes people less
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intelligent (such as acute hypoglycaemia) would be expected to alter the gradient of
the slope, such that the intervention would cause proportionately greater disruption in
performance of the 8-choice reaction task, than the 1-choice task. However, acute
hypoglycaemia did not alter the slope of the regression line of the Hick Paradigm and
so the present study supports the observations of others who have failed to
demonstrate a valid relationship between intelligence and the slope of the regression
line255. The present study, however, does support the validity of the correlations
between intelligence and mean decision times, the y-axis intercept of the Hick
Paradigm regression line, and mean movement times, since all were adversely
affected by acute hypoglycaemia.
5.4.4 Implications for the Putative Relationship between Nerve
Conduction Velocities and Intelligence
The hypothesis that differences in peripheral nerve conduction velocity form a partial
basis for the association between psychometric intelligence and measures of
information processing efficiency256'257 is based on the premise that central and
peripheral nervous system neurones behave similarly in terms of neurophysiological
function (i.e. rapid nerve conduction velocities peripherally reflect rapid nerve
conduction velocities centrally). The present study was too small to allow
meaningful correlations between intelligence, measures of speed of information
processing and peripheral nerve conduction velocities to be made. However, if such
a premise were correct then it would be reasonable to assume that central and
peripheral neurones should also respond to external factors such as acute
hypoglycaemia in similar ways. The present study, by demonstrating that multiple
levels of higher information processing were altered in the central nervous system
while peripheral nerve conduction velocities remained intact, therefore, supports
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others that have refuted this hypothesis " . Of course, it remains perfectly feasible
that speed of neuronal conduction within the central nervous system could still relate
to speed of information processing and intelligence, but further studies are clearly
required to investigate this in more detail.
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5.4.5 Reasons for the Disparity in Central and Peripheral Neuronal
Susceptibility to Acute Hypoglycaemia
The marked disparity in the effects of acute hypoglycaemia on peripheral and central
neural system function implies that peripheral nerves do not have the same reliance
on prevailing blood glucose concentrations as is demonstrated by neurones of the
central nervous system. Neural components of peripheral nerves are separated from
plasma and general extracellular fluid by endoneurial capillaries and the perineurial
membrane, which form a 'blood-nerve' barrier that has similar properties to the
blood-brain barrier in preventing the passive transfer of large molecules ' . As
with neurones in the central nervous system, glucose is the major substrate for
energy production in peripheral neural tissue, when plasma concentrations of ketone
• 9QS
bodies are not elevated . Incubation of isolated nerve fascicles in a glucose-
deficient medium produces a profound fall in glucose in nerve tissue, with reduced
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oxygen uptake and decrements in neural oxygen and ATP levels . Glucose
... 295utilisation in peripheral nerves does not appear to be regulated directly by insulin ,
which is also the case with neurones in the central nervous system. Peripheral
neurones can, however, adapt to prolonged exposure to a low blood glucose. This
was demonstrated by an elegant study of non-diabetic rats in which the anterograde
fast component of axonal transport in peripheral neural tissue was reduced by 36%
following the induction of acute hypoglycaemia (blood glucose ~1.5 nimol/1 for two
hours)298. The reduction in axonal transport was prevented, however, by pre-
treatment of the animals for three days with insulin to induce prolonged moderate
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hypoglycaemia" . The mechanisms behind this adaptive response to hypoglycaemia
are not clear, but may be similar to that observed in the rat central nervous system.
Here, chronic hypoglycaemia over a period of days causes upregulation of the GLUT
1 blood-brain barrier glucose transport protein92, which acts to increase extraction of
glucose from the circulation during periods of subsequent hypoglycaemia299.
There are, therefore, several possible explanations whereby peripheral neural tissue
may be unaffected by moderate hypoglycaemia. Peripheral neurones have stores of
glycogen, and these may provide sufficient energy to sustain neural metabolism
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during periods of short-lived, moderate hypoglycaemia . In addition, peripheral
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neurones may be able to utilise other energy substrates, such as ketone bodies,
fructose, lactate, amino acids and free fatty acids97'2 '" more efficiently than neurones
within the brain. It is also possible that the 'blood-nerve' barrier may have a
constitutively greater ability at extracting glucose from the circulation, or that
peripheral neurones have a lower overall glucose requirement.
5.4.6 Summary and Conclusions
Acute hypoglycaemia caused predictable disruption of cognitive functions as
assessed by tasks of general cognitive ability and multiple levels of speed of
information processing. Hypoglycaemia did not have any differential effects on
choice reaction time, as difficulty of the task increased, suggesting that the slope of
the Hick Paradigm regression line may not be a valid marker of general intelligence.
Moreover, acute hypoglycaemia had no demonstrable effect on the function of
peripheral nerves in healthy adult volunteers. This implies that neurones of the
peripheral nervous system do not have the same obligate requirement for glucose as a
metabolic fuel as neurones of the central nervous system. The data also partially
refute the hypothesis that speed of conduction within the peripheral nervous system
may be used as a marker of speed of nerve conduction within the central nervous
system, and thus be a measure of speed of information processing and intelligence.
The effect of time on common peroneal conduction velocities may represent an
effect of hyperinsulinaemia on peripheral neural function, but appropriately




RECOVERY OF COGNITIVE FUNCTION AND MOOD AFTER A
SINGLE EPISODE OF SEVERE HYPOGLYCAEMIA
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6.1 INTRODUCTION
The cognitive decrements that occur during acute hypoglycaemia and the factors that
moderate individual susceptibility to hypoglycaemia were discussed in detail in
Chapter 2. Several investigators have also examined the time taken for cognitive
function to recover to baseline levels following experimentally-induced, mild
hypoglycaemia (blood glucose concentrations 2.5-3.0 mmol/1). Herold et al
demonstrated that the recovery of simple reaction times was delayed for up to 40
minutes after the restoration of normoglycaemia and that there was considerable
inter-individual variability in the recovery time, with the reaction times of some
individuals returning to baseline within 10 minutes179. These findings were
supported by Blackman et al in studies of non-diabetic subjects171, and people with
Type 1 diabetes174, in whom simple reaction times and latencies of the P300 event-
related potential took between 45-75 minutes to return to baseline levels following
correction of hypoglycaemia. Similarly, Lindgren et al reported that P300
amplitudes, which were reduced during hypoglycaemia, were restored approximately
40 minutes after the restitution of normoglycaemia17'\
The slight differences in recovery time between the above studies may be explicable
by the fact that the duration and depth of hypoglycaemia was not consistent between
the studies. Indeed, a recent preliminary report suggested that the recovery of
cognitive function was dependent on the duration of antecedent hypoglycaemiaj()0.
P300 latencies in 17 healthy volunteers took an average of 22 minutes to return to
baseline following 60 minutes of hypoglycaemia (plasma glucose 2.8 mmol/1), but
did not return to baseline values until 49 minutes after more prolonged
hypoglycaemia (plasma glucose 2.8 mmol/1 for 180 minutes)300.
A delayed recovery in reaction times following acute hypoglycaemia was also
observed in children with Type 1 diabetes by Ryan et al. who also noted that other
cognitive tasks (Trail-Making B and the Stroop task) appeared to recover more
quickly following the restitution of normoglycaemia301. This latter observation was
supported by a study of eight non-diabetic men, in whom the decrements in
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performance of the Stroop task, induced by hypoglycaemia, returned to baseline
within 20 minutes of restoration of normoglycaemia'02. However, 4-choice reaction
times were still prolonged at this time'02.
By contrast, in non-diabetic subjects, Gold et al found no delay in recovery of
cognitive function following restoration of normoglycaemia199. The reason for the
discrepancy between this and the above studies that have examined the recovery of
cognitive function after mild hypoglycaemia remains unclear, since a comprehensive
battery of cognitive tasks was utilised and definite decrements in cognitive function
were observed during the hypoglycaemic condition199.
Two studies have considered the impact of nocturnal hypoglycaemia on cognitive
function and well-being the following day. Bendtson et al reported that nocturnal
hypoglycaemia induced by insulin infusion (venous blood glucose nadir 1.5 mmol/1;
blood glucose less than 3.0 mmol/1 for 100 minutes) reduced the amount of deep
sleep but had no impact on cognitive function, as assessed by a battery of tests, the
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following morning . These findings were replicated by King et al, who utilised a
glucose clamp technique to maintain venous blood glucose at 2.3-2.7 mmol/1 for one
hour during the night304. However, while cognitive function was not impaired the
following morning, the subjects had a reduced sense of well-being and experienced
greater fatigue during exercise"'04.
The potential long-term effects of acute hypoglycaemia on mood have received less
attention. Hepburn et ah in two separate studies of the effects of hypoglycaemia
(induced by insulin infusion) on mood state, found that mood parameters,
particularly tense arousal and hedonic tone, recovered in parallel with glucose
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concentrations ' . By contrast. Gold et al demonstrated that the state of tense
tiredness which developed in the context of more prolonged hypoglycaemia, induced
using a glucose clamp technique, persisted for at least 30 minutes after restoration of
normoglycaemia204. Further assessment of mood status was not performed after this
time period, so it is not known at what time the altered mood would have returned to
baseline levels.
No previous studies have examined the timing of recovery of cognitive function and
mood following a single episode of severe hypoglycaemia. It is quite conceivable
that the more prolonged and profound neuroglycopenia that occurs in the context of
an episode of severe hypoglycaemia, as opposed to an episode of experimentally-
induced hypoglycaemia, could result in alterations in mood and cognitive function
that persist for days or weeks. After all, the symptomatic and neuroendocrine
responses to acute hypoglycaemia are diminished following antecedent (episodic)
hypoglycaemia that has occurred within the previous 72 hours82,86'87'190'194 and the
catecholamine response to hypoglycaemia, in particular, may take between six days
and four weeks to return to a normal magnitude30'. Delayed recovery of cognitive
function following severe hypoglycaemia could have potentially important effects on
performance of activities such as work or driving. The purpose of the present study
was, therefore, to examine the temporal changes in mood states and cognitive
functions following a single, spontaneous episode of severe hypoglycaemia
occurring in people with insulin-treated diabetes.
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6.2 METHODS
The study was approved by the local medical ethics advisory committee and all
subjects gave written informed consent after the nature of the study was explained.
Forty subjects with insulin-treated diabetes mellitus were studied, most of whom
were attending the diabetes out-patient department at the Royal Infirmary of
Edinburgh for regular review. Twenty subjects had experienced a recent episode of
severe hypoglycaemia (the 'hypo' group) and twenty subjects had not experienced
severe hypoglycaemia within the preceding year (the 'control' group).
6.2.1 Severe Hypoglycaemia
Severe hypoglycaemia was defined according to the criteria used in the DCCT, as an
episode that required external assistance to aid recovery"06. In addition, the blood
glucose concentration had to be documented at 2.8 mmol/1 or lower and/or the
clinical manifestations had to have been reversed with oral carbohydrate,
intramuscular glucagon, or intravenous glucose306.
Eighteen of the 'hypo' subjects were recruited following their presentation to the
Accident and Emergency Departement of the Royal Infirmary of Edinburgh
following an episode of severe hypoglycaemia. Only two of the subjects required
overnight admission to hospital for observation, the remainder were discharged after
treatment. The remaining two 'hypo' subjects were recruited following an
advertising campaign about the study to both local general practitioners and patients
attending the diabetes out-patient clinic at the Royal Infirmary of Edinburgh.
Therefore, 'hypo' subjects received treatment for the severe hypoglycaemia either in
the community or in the hospital emergency department; none had experienced
persistent neurological dysfunction following restoration of normoglycaemia. Nine
of the subjects were treated with intramuscular glucagon alone, two with intravenous
dextrose alone, two with a combination of intravenous dextrose and intramuscular
glucagon, and seven with oral carbohydrate alone. All subjects who required
parenteral glucagon or dextrose reported a transient loss of consciousness at the time
of hypoglycaemia. Where possible, the history of hypoglycaemia was verified by
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scrutiny of contemporaneous notes made by the patient's general practitioner or the
hospital case records, and by obtaining a direct account from a witness. The latter
involved completion of a short questionnaire documenting the clinical features
demonstrated by the affected patient, the nature of the treatment administered and
their subsequent response. The history of previous severe hypoglycaemia in the
'control' group was confirmed by interview with the individual patients, by scrutiny
of hospital case records and, where possible, by asking a relative or friend to
complete a short questionnaire on when previous episodes of severe hypoglycaemia
had been experienced by each patient. Hypoglycaemia history was graded on a four-
point scale:
1 = no previous episodes of severe hypoglycaemia
2 = one to two previous episodes
3 = three to five previous episodes
4 = more than five previous episodes.
6.2.2 Patient Characteristics
One subject in each group had insulin-treated Type 2 diabetes, and all other subjects
had Type 1 diabetes. All patients had received routine annual assessment in a
diabetes out-patient clinic within the previous year and none had evidence of
macrovascular disease. Few patients in either group had evidence of diabetic
microangiopathy. Subjects were excluded if they had a history of cerebrovascular
disease, previous head injury, epilepsy, serious systemic disease, major psychiatric
illness, or if they were taking medication which could alter cognitive function, such
as psychotropic agents or steroids. The corrected visual acuity of all subjects was 6/9
or better. Hypoglycaemia awareness was assessed using a visual analogue scale of 1
to 7 (1 = always aware of the onset of hypoglycaemia; 7 = never aware of the onset
of hypoglycaemia). A score of 4 or greater has been shown to be associated with
impairment of hypoglycaemia awareness70. Glycated haemoglobin (HbAlc) was
measured at T1 using high-speed liquid chromatography based on an ion-exchange
reverse-phase partition method (Hi Auto Ale HA 8121). The local non-diabetic
range for HbAlc was 5.0-6.5%.
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6.2.3 Neuropsychological Testing
Subjects underwent comprehensive neuropsychological testing at three time points
(Tl, T2 and T3) over a period of one month. To minimise any potential effect of
sleep deprivation on the results of the cognitive tasks, all subjects had at least one
night of undisturbed sleep prior to testing. For the 'hypo' subjects, this meant
ensuring that they had obtained a complete night of sleep after the episode of severe
hypoglycaemia. None of the 'hypo' subjects suffered further exposure to severe
hypoglycaemia during the follow-up epoch of the study. Blood glucose was
measured on three occasions during the cognitive testing sessions (beginning, middle
and end); subjects were allowed to consume a snack, if necessary, to ensure that
blood glucose concentrations did not fall below 4.0 mmol/1 during testing.
The neuropsychological test battery provided a comprehensive assessment of the
main cognitive domains, including fluid intelligence, memory, attention and
concentration, frontal lobe function, information processing and mood state.
Performance of many of the tests had been shown previously to be impaired during
acute hypoglycemia in diabetic and non-diabetic subjects l48'161. The order of the
tests (as listed below) remained constant for each session. Where appropriate,
subjects underwent a brief practice session with each test prior to the recorded
performance. The neuropsychological test battery included the following tests:
■ Cognitive Function Self-Appraisal Scale (CFSA)
■ UWIST Mood Adjective Checklist
■ Hospital Anxiety and Depression Scale (HAD)
■ National Adult Reading Test (NART) - administered at Tl only
■ Wechsler Adult Intelligence Scale - Revised (WAIS-R) - Performance IQ subtests
■ Trail-Making Test B (TMB)
■ Forward Digit Span (FDS)
■ Backward Digit Span (BDS)
■ Logical Memory (LM) - Immediate Recall
■ Figural Memory (FM)
■ Borkowski Verbal Fluency Task
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■ Stroop Task
■ Inspection Time (IT)
■ Visual Change Detection (VCD)
■ Logical Memory (LM) - Delayed Recall
■ l-,2-,4- and 8-Choice Reaction Time (RT)
■ Paced Auditory Serial Addition Task (PASAT)
The cognitive tasks were described in detail in Chapter 4.1. Many of the
Performance IQ subtests of the WAIS-R were subject to a practice effect, i.e.
performance improved significantly following repeated administrations of the task
Therefore, Performance IQ was measured solely at Tl; at the subsequent sessions,
only the DS and BD tasks were administered, as these were subject to the least
practice effect. An IQ Decrement Index was also calculated by subtracting the
present IQ (as measured by the WAIS-R Performance IQ subtests) from the 'pre¬
morbid' IQ (as estimated by the NART).
6.2.4 Statistical Analyses
All data are presented as mean ± standard deviation (SD). Baseline characteristics of
subjects were compared using Student's t tests for unpaired samples, and the Chi-
squared test was used for categorical data. A test of sphericity revealed that there
was insufficient correlation between the scores of individual cognitive tasks to allow
employment of an omnibus, mixed-design, multivariate analysis of variance. Zero
order correlation tables displaying the associations between the individual cognitive
tasks at each time point are included in the Appendix. Therefore, differences in
individual cognitive test scores between the 'hypo' and 'control' groups, at the three
time points, were compared using multiple, mixed-model univariate analyses of
variance (ANOVA) with 'group' ('hypo' or 'control') as a between-subjects factor and
'time' (Tl, T2, or T3) as a repeated measure. Simple effects (unpaired t tests, two-
tailed) at particular time points were examined only when there were significant
group and/or interaction effects.
136
The principal outcome statistic was any ['group' by 'time'] interaction in the ANOVA
analysis. This statistic had the potential to indicate evidence of 'catch-up' on behalf
of the 'hypo' group who were hypothesised to demonstrate under-performance on the
first and perhaps the second time points (Figure 6.1). Significant main effects for
group indicated overall superiority of the 'hypo' or 'control' groups on the test.
Significant effects of 'time' were expected and would indicate practice effects on the
tasks.
Where significant simple effects were evident, cognitive and mood outcome scores
were adjusted for individual differences in severe hypoglycaemia history (using the
4-point hypoglycaemia scoring system) using univariate linear regression. A
multiple regression model was not utilised because of the repeated measures design.
The group effect on the standardised residuals (Z-scores - with a mean value of 0 and
a standard deviation of 1.0 for data across the three time points) was subsequently
examined using Student's t-tests, at the appropriate time points. This was an attempt
to test the hypothesis that any cognitive impairment was secondary to exposure to
previous episodes of severe hypoglycaemia.
A p-value of less than 0.05 was considered to be significant, given the exploratory
nature of this study. Two-tailed tests were used throughout to limit the occurrence of
type 1 statistical errors. All analyses were performed using SPSS version 7.5.1 for
Windows 95. Reported p-values were rounded to two decimal places; thus p=0.00
signifies that the p-value was <0.005.
137
FIGURE 6.1: Graphic Representation of the Hypothesised 'Hangover'




Scores of 'control' and 'hypo' subjects from a theoretical cognitive task administered
at three time points following an episode of severe hypoglycaemia (which occurred
just before session 1 for the 'hypo' subjects). The scores of the 'control' subjects
improved with time, indicating a slight practice effect. The scores of the 'hypo'
subjects were lower than the 'controls' during sessions 1 and 2, but demonstrated




6.3.1 Baseline Clinical Characteristics
The 'hypo' subjects had a history of a significantly greater number of previous
episodes of severe hypoglycaemia than the 'control' subjects (Table 6.1; p=0.00). The
subjects in the two groups were well matched for age, sex, body mass index (BMI)
and duration of diagnosis of diabetes. The 'hypo' subjects had a lower mean HbAlc
at the outset of the study and a tendency towards a higher total insulin dose than the
'control' subjects (Table 6.2). The mean Hypoglycaemia Awareness Scores were
also higher in the 'hypo' group than in the 'control' group, i.e. overall the 'hypo'
subjects were less aware of hypoglycaemia (Table 6.2). Nine subjects in the 'hypo'
group had a score of 4 or greater on the visual analogue scale, compared to only one
patient in the 'control' group (p=0.00).
6.3.2 Timing of Cognitive Test Sessions
All subjects had a complete night of sleep prior to cognitive testing. For the 'hypo'
subjects, as a consequence, T1 took place at a mean (SD) of 1.5 (0.6) days after the
episode of severe hypoglycaemia. T2 took place a mean of 8.9 (2.0) days, and T3
30.2 (2.9) days after severe hypoglycaemia. The 'control' subjects were tested at
comparable time intervals - the mean (SD) interval between T1 and T2 was 7.3 (0.7)
days, and that between T2 and T3 was 29.0 (2.3) days (the comparable intervals for
the 'hypo' subjects were 7.4 and 28.7 days respectively; p>0.05).
6.3.3 Baseline Cognitive Function and IQ Decrement Index
No significant difference in mean NART error scores was observed between the
'hypo' subjects (20.9+9.1) and the 'control' subjects (19.9+5.0; p=0.65), indicating
that the two groups were well matched for pre-morbid IQ. The actual performance
IQ of the 'hypo' subjects, measured at Tl, was on average 6.8+10.8 points lower than
would have been predicted by the NART score (the IQ Decrement Index). By
contrast, the actual performance IQ of the 'control' subjects was 1.7+10.2 points
higher than predicted. The difference in IQ Decrement Indices between the two
groups was statistically significant (p=0.02).
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The means and standard deviations of the scores of the remaining cognitive tests,
mood scales and memory questionnaire are shown in Tables 6.3, 6.4 and 6.5.
6.3.4 Effects of 'Group' by 'Time' Interactions on Cognitive and Mood
Tasks
Significant 'group' by 'time' interactions were found with the BD (p=0.01), PASAT 4
second (p=0.02) and VCD (p=0.03) tasks. In the cases of the BD and PASAT tasks,
the interaction reflected significant differences between the two groups at T1 that
were not present at T2 or T3. The interaction for the VCD task represented an
apparently anomalous difference between the groups at T2, with the 'hypo' subjects
actually attaining better scores, that was not statistically significant (p=0.07), and that
was not present at T1 or T3. The interactions for the Hedonic Tone (p=0.08) and
Energetic Arousal (p=0.05) sub-scales of the UWIST Mood Adjective Checklist
approached statistical significance, although none of the simple effects were
significant. No other cognitive or mood tests demonstrated a statistically significant
'group' by 'time' interaction (p>0.05).
6.3.5 Main Effects of 'Group' on Cognitive Tasks
The 'hypo' group was significantly poorer overall on the DS (p=0.01), PASAT 4
second (p=0.04), FDS (p=0.01), and BDS (p=0.02) tasks relative to 'control' subjects.
In addition, the 'hypo' subjects performed more poorly than controls on the 'colour-
associated words' (p=0.01) and 'incongruent colours' (p=0.01) subtests of the Stroop
task. Post-hoc simple effects analysis demonstrated that performance in the DS and
the 'incongruent colours' Stroop tasks was poorer in the 'hypo' subjects at all three
time points (p<0.05), while that in the 'colour-associated words' Stroop subtest was
significant at T1 and T2 (p<0.05), but did not reach statistical significance at T3
(p=0.06). The FDS and BDS scores were significantly poorer in the 'hypo' subjects
only at T2 and T3 (p<0.05). The main effect of 'group' on the PASAT 2 second
(p=0.07) and BD (p=0.06) tasks just failed to reach conventional levels of statistical
significance. No significant main effects of 'group' were demonstrated on the
information processing (IT, VCD, RT), memory (FM. LM), TMB and verbal fluency
tasks (p>0.05).
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6.3.6 Main Effects of 'Group' on Mood Scales
Significant main effects of 'group' ('hypos' versus 'control') were observed on the
HAD-depression (p=0.01) and HAD-anxiety (p<0.05) scales. The 'hypo' subjects
had significantly higher HAD-depression scores at all three time points (p<0.05) and
significantly higher HAD-anxiety levels at T1 (p=0.02). No significant 'group'
effects were recorded with any of the UWIST mood scores (p>0.05).
6.3.7 Main Effects of 'Group' on Self-Rated Cognitive Ability
A significant main effect of 'group' ('hypos' versus 'control') was noted for the CFSA
'total' score (p=0.00) with the 'hypo' subjects having significantly lower levels of self-
rated cognitive ability at all three time points (p<0.05). At each time point, higher
numbers of 'hypo' subjects indicated that they had noticed either a large or slight
change in cognitive function with time (Table 6.5; p<0.05).
6.3.8 Main Effects of 'Time' on Cognitive and Mood Tasks
All cognitive tasks, with the exception of the FDS (p=0.74) and BDS tests (p=0.23),
showed significant learning effects (as indicated by a statistically significant main
effect of time; p<0.05). The UWIST Energetic Arousal, and the HAD depression
scores did not show a significant effect of 'time' (p>0.05), while a time effect was
seen with the UWIST Hedonic Tone (p=0.01) and Tense Arousal (p=0.01) scores,
and the HAD-anxiety scores (p=0.00). Hedonic Tone increased with time, while
Tense Arousal and HAD-anxiety decreased with time. These results do not affect the
interpretability of the effect of the experimental variable ('hypo' versus 'control')
because they apply to both groups.
6.3.9 Effects of Previous Episodes of Severe Hypoglycaemia on
Cognitive and Mood Tasks
Following adjustment for history of severe hypoglycaemia, differences in DS, BD,
Stroop (colour-associated words and incongruent colours), FDS, BDS, PASAT 4
second, HAD-anxiety, HAD-depression and CFSA scores (at time points where
significant simple effects were obtained) became non-significant (Table 6.6; p>0.05).
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TABLE 6.1: History of Severe Hypoglycaemia
Never 1-2 3-5 >5
'Hypos' 0 4 4 12
'Controls' 13 3 2 2
Data represents the number of subjects who experienced no previous episodes of
severe hypoglycaemia, 1-2 episodes, 3-5 episodes or greater than 5 episodes.
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TABLE 6.2: Clinical Characteristics of Subjects
'Hypos' 'Controls' p-value
Age (yrs) 36.4±14.7 33.7±12.5 0.54
Sex (M/F) 13/7 12/8 0.74
Duration of Diabetes (yrs) 15.5±7.6 13.0±8.2 0.32
BMI (kg/m2) 25.8±4.0 25.4±3.1 0.72
Insulin Dose (U/kg) 0.82±0.31 0.71±0.18 0.17
HbAlc (%) 8.3±1.3 10.0±1.7 0.00
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TABLE6.3:CognitiveestResults(Co tinued)
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TABLE 6.5: Cognitive Function Self-Appraisal Scale - 'Change' Scores
T1 T2 T3
'Hypo'
No Change 9 14 14
Slight Change 8 6 6
Large Change oJ 0 0
'Control'
No Change 18 19 19
Slight Change 2 1 1
Large Change 0 0 0
p-values 0.01 0.04 0.04
('Hypo' v 'Control')
Data are number of subjects
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TABLE6.6:StandardisedResiduals(Z-scorformat)ofSignific ntCognitiveTasknMoo Scalesaft rAdjustmentforeve eHypoglyca miai tory Time1i2Ti e3 Z-scorep-valuerp-valueZ-scorp-value DigitSymbol 'Hypo' -0.27(0.8 )0.50790. 10 38(0. 3)1 'Control' -0.47(0.98)001 13.3( . ) BlockDesign 'Hypo' -0.16(0.92)0.19N/A//A 'Control' -0.53(0.81) StroopTest-Colour-Ass ciatedWords 'Hypo'0.16(0.81)7-0.254.4-0.28(0. 9)97 'Control'0.69(1.40)-0. 30 9-0.28( .80) StroopTest-IncongruousC lo rs 'Hypo'0.34(0.63)17-0.2680.55-0.46(0.67)7 'Control'0.86(1.46)-0.090 8-0.39(0. 7) PASAT4Second 'Hypo' -0.12(0.85)0.25N/A/A 'Control' -0.58(1.52) Standardisedresi ualsaiZ-scorformat(m anof0ndst d rdevi t on1.0acrosstheemp n ), p-valueisthelev lofsignificancef rb twe ngroupcomp risonsZ- co es. N/A-statisticalcomparisonnotapprop atethecognitivekm odc lw stsi ficant,ti tiht lt hocanalyses. 150




ForwardDigitSpan 'Hypo'N/A 'Control' BackwardDigitSpan 'Hypo'N/A 'Control' CognitiveFunction-Self-Appraisal 'Hypo'0.00(0.53)2 'Control'0.40(1.24) HAD-Anxiety 'Hypo'0.06(0.64)2 'Control'0.42(1.28) HAD-Depression 'Hypo'0.00(0.93)71 'Control'0.11(0.84)
Z-score
0.07(0.87) -0.10(1.2 ) -0.03(0.92) -0.00(0.84) -0.16(0.60) 0.09(1.26) N/A
p-value 0.62 0.94 0.43 N/A
-0.05(0.9 )0.68 0.08(0.98)
Z-score
0.00(0.88) -0.10(1.16) 0.25(1.10) 0.02(0.79) -0.22(0.66) -0.11(1.32) N/A -0.14(0.88) -0.00(1.4 )
p-value 0.75 0.44 0.75 N/A 0.73
Standardisedresi ualsa eiZ-scorformat(m anof0ndst nd rdevi t on1.0cr ssth ep ), p-valueisthelev lofignificancf rb twe ngroupcomp isonsZ- cores. N/A-statisticalcompar sonnotappr p iatethegnitivkm odc lw sn tsign ficant,ti o titht lt hocanalyses. 151
6.4 DISCUSSION
6.4.1 Interpretation of Results
The present study attempted to evaluate changes in mood and cognitive function
prospectively in patients with insulin-treated diabetes who had experienced a
spontaneous episode of acute, severe hypoglycaemia. It was appreciated during the
initial phases of study design that not all episodes of severe hypoglycaemia are the
same in terms of the depth and duration of neuroglycopenia and, ultimately, in the
magnitude of the 'hypoglycaemic insult' experienced by the brain. The
overwhelming majority of such episodes occur in the community where accurate
measurements of variables such as blood glucose nadir and duration of loss of
consciousness are often not available or are not estimated with accuracy. Therefore,
to have attempted to achieve a greater degree of uniformity in terms of the magnitude
of the 'hypoglycaemic insult' would have been of dubious validity and would have
imposed enormous logistical strain on the study with regard to the recruitment of
subjects. As a consequence, a pragmatic approach was taken to utilise the definition
of severe hypoglycaemia employed in the DCCT".
In the statistical analyses, it was anticipated that a significant interaction between
'group' and 'time' effects might be indicative of a 'hangover' effect of severe
hypoglycaemia on the cognitive parameter measured, with performance improving
with time in the 'hypo' subjects more than in the 'controls' (Figure 6.1). Such an
interaction was statistically significant in only two cognitive tasks - BD and PASAT
4 second. The results for the PASAT 4 second task can be interpreted as showing a
'ceiling effect'. The performance of the 'control' subjects at T1 was very close to
maximum and consequently there was little scope for their scores to improve with
time. By contrast, the scores of the 'hypo' subjects at T1 were significantly lower,
allowing the opportunity for improvement to occur over time. Thus, it may not be
appropriate to attribute the significant result for the PASAT 4 second interaction as
evidence of a prolonged effect of severe hypoglycaemia on cognitive function.
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Therefore, in only one (BD) of the 14 cognitive tasks employed was convincing
evidence obtained of improvement in the 'hypo' subjects relative to 'controls' over
time. This implies that, in the main, any cognitive decrement that resulted as a
consequence of the acute episode of severe hypoglycaemia had recovered by the time
of the initial testing session at 1.5 days. The 'group' by 'time' interactions for UWIST
Hedonic Tone and Energetic Arousal approached statistical significance, with
evidence that 'happiness' and 'energy' increased with time in the 'hypo' subjects, with
respect to 'controls'. There was no evidence of a ceiling effect with regards these
mood parameters, and while such mood alterations in response to severe
hypoglycaemia might be predictable, the 'simple effects' for the statistical
interactions were not significant. Therefore, the interpretation that acute severe
hypoglycaemia had a 'hangover' effect on mood must be made with caution.
The two study groups were well matched for standard demographic characteristics
and pre-morbid IQ, but subjects in the 'hypo' group had a previous history of
significantly more episodes of severe hypoglycaemia. Significant main effects of
'group' ('hypo' versus 'control') were observed with several of the psychometric tests
measuring fluid-type intelligence and attention and concentration skills. In addition,
the 'hypo' subjects had higher levels of HAD-depression and HAD-anxiety, and
exhibited higher self-rated levels of cognitive impairment (CFSA). No significant
'group' effects were observed with the memory or information processing tasks.
Several previous cross-sectional studies have suggested that recurrent exposure to
episodes of severe hypoglycaemia is associated with cumulative cognitive
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impairment ' ' " . In the present study, the differences in cognitive
performance and mood between the two groups was abolished when statistical
adjustment was made for the number of previous episodes of severe hypoglycaemia
experienced by subjects. In addition, the difference in mean IQ decrement index
scores (i.e. the difference in IQ scores as predicted by the NART scale and as
measured by the WAIS-R scale) for the 'hypo' and 'control' subjects was 8.5 points.
This is comparable to the mean difference in IQ decrement scores of 5.8 points
observed by Langan and colleagues22^ when comparing diabetic subjects with a
history of multiple episodes of severe hypoglycaemia with those who had no history
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of previous severe hypoglycaemia. It is possible, therefore, that the difference in
cognitive ability noted in the current study between the 'hypo' subjects and 'controls'
was a consequence of the previous exposure of the former group to many more
episodes of severe hypoglycaemia. However, the study was not powered to
specifically investigate this issue and the statistical adjustment for the effects of
exposure to previous severe hypoglycaemia should be interpreted with caution
because severe hypoglycaemia was itself a significant variable between the study
groups. The small sample size precluded a sufficiently powerful correlational
analysis between cognitive performance and previous severe hypoglycaemia history
in the 'hypo' subjects alone.
The elevated anxiety and depression scores recorded in the 'hypo' subjects have been
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noted previously in diabetic patients exposed to recurrent severe hypoglycaemia '
and could be either a consequence or a cause of the previous severe hypoglycaemia.
Unfortunately, it is not possible to perform a surrogate 'retrospective' assessment of
mood in a similar manner to the use of the NART for intellectual ability. Gonder-
908 • •
Frederick et al prospectively measured symptoms of depression (using the Beck
Depression Inventory) in 20 subjects who experienced two or more episodes of
severe hypoglycaemia over a six month period and in 20 control subjects who
experienced no severe hypoglycaemia during that time. Depression scores were
comparable between the groups at baseline, but at six months were significantly
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higher in the subjects exposed to severe hypoglycaemia .
The other main differences between the 'hypo' and 'control' subjects was that the
former group had a greater frequency of impaired awareness of hypoglycaemia and
had lower mean glycated haemoglobin concentrations. Impaired awareness of
hypoglycaemia70'71 and strict glycaemic control" are associated with an increased
risk of severe hypoglycaemia and so their increased prevalence in the 'hypo' group
was predictable and probably unavoidable. The controversy surrounding the impact
of impaired awareness and strict glycaemic control on cognitive function during
acute hypoglycaemia is discussed in detail in Chapter 2. The majority of studies
have suggested that impaired awareness of hypoglycaemia and strict glycaemic
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control are associated with either no effect on cognitive function or reduced
cognitive decrements during acute hypoglycaemia. The possibility that either factor
per se was associated with the 'group' effects noted in the present study cannot be
excluded, but seems unlikely.
Most of the cognitive tasks showed a significant main effect of 'time', which was
presumably indicative of a practice effect. The practice effect was evident despite
the fact that subjects undertook training in the individual cognitive tasks before the
formal test performance and clearly highlights the importance of a parallel,
longitudinal 'control' group in studies of this type. The UWIST Tense Arousal and
Hedonic Tone, and the HAD-anxiety scores also showed a significant main effect of
'time', with levels of tense arousal and anxiety decreasing with time and levels of
hedonic tone or 'happiness' increasing with time. This may reflect the natural initial
apprehension of subjects participating in a clinical study.
6.4.2 Limitations of the Study
The present study has some limitations. These include the relatively small sample
size, the absence of pre-hypoglycaemia cognitive and mood data, and the need for
multiple statistical testing.
The study had approximately 80% power to detect a 0.9 standard deviation
difference in Digit Symbol scores (a task that is particularly sensitive to the effects of
acute hypoglycaemia) with a p-value set at 0.05. The sample size meant that a small
'hangover' effect of severe hypoglycaemia on cognitive function may not have been
detected and precluded meaningful analysis to determine if there were large
individual differences in the impact of severe hypoglycaemia. The recruitment of
insulin-treated diabetic patients following severe hypoglycaemia proved to be very
difficult, despite the high frequency of this problem in clinical practice. As indicated
previously, the majority of episodes of severe hypoglycaemia are treated effectively
in the community309, and only a small, selected group requires hospitalisation310.
Attempts to improve recruitment by advertising the study in advance to the patients
attending our clinic, and to all local general practitioners, were fruitless. In addition,
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as observed previously in a local survey of acute, severe hypoglycaemia310,
recruitment was hampered by the fact that many of the diabetic patients attending
hospital for emergency treatment were either elderly, had concurrent medical
disorders or were infrequent attendees at the diabetic clinic. Furthermore, many
patients who were eligible for inclusion were unable to participate in the study
because of the short notice or the time constraints necessitated by the study design,
with the requirement for multiple testing sessions.
The comparability of the study groups in terms of NART scores provides a degree of
reassurance about the matching for pre-morbid cognitive ability. The collection of
more detailed cognitive and mood data on the 'hypo' subjects, prior to the index
episode of severe hypoglycaemia, would have necessitated testing a large number of
diabetic subjects and a relatively long period of follow-up to identify subsequent
hypoglycaemic episodes. Future studies could reduce the number of subjects that
would undergo cognitive pre-testing by studying subjects who are at high risk of
severe hypoglycaemia, e.g. patients who have had an episode of severe
hypoglycaemia in the preceding year or who have impaired awareness of
hypoglycaemia.
The large number of statistical tests that were employed in analysing the data
generated by this study, increased the risk of type 1 statistical errors and, indeed, the
significant interaction between the 'group' and 'time' effects for the BD task may
represent such an error. The risk of a type 1 error could have been reduced by
applying the Bonferroni correction, in which a p-value of less than -0.004 would
strictly be accepted as evidence of statistical significance for the 12 main cognitive
parameters measured. However, at the outset of the study, it was unclear which
specific areas of cognitive function and mood might exhibit a 'hangover' effect and
clearly a balance had to be made between testing a wide number of cognitive
functions and risking type 1 errors, and including a limited number of cognitive
measures and potentially missing an effect in area not tested. Given the
exploratory/preliminary nature of the present study the former approach, utilising a
conventional level of statistical significance, was adopted. The pattern of cognitive
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and mood data provided should allow future investigators to select a smaller test
battery, that is more specifically targeted towards potentially sensitive cognitive
domains.
6.4.3 Conclusions
The results of this study imply that a single episode of acute, severe hypoglycaemia,
from which recovery appears complete, does not have a prolonged effect on
cognitive function. People with insulin-treated diabetes may be reassured that
performance of activities such as work or driving are unlikely to be impaired 36
hours after an episode. The evidence of persistent impairment of cognitive
performance and the mood disturbance demonstrated by the 'hypo' subjects may be a





EVALUATION OF SERUM MARKERS OF NEURONAL
DAMAGE FOLLOWING SEVERE HYPOGLYCAEMIA
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7.1 INTRODUCTION
The ability of severe hypoglycaemia to induce both transient and permanent
neurological abnormalities, and rarely death, was described in Chapter 1. Clinicians
often have difficulty in determining the prognosis of comatose patients following
exposure to severe hypoglycaemia, in terms of both survival and risk of permanent
neurological dysfunction. The identification of serum markers that could predict the
degree of neuronal damage and prognosis of patients after severe hypoglycaemia,
analogous to the measurement of creatine kinase or troponin after myocardial
infarction, would therefore have considerable clinical value.
Two proteins, Neuron-Specific Enolase (NSE) and Protein S-100 (S-100), have
shown promising results as prognostic agents in the context of other acute
neurological syndromes. NSE is a 78kD glycolytic enzyme that originates
• #311
predominantly from the cytoplasm of neurones and neuroendocrine cells
Increased NSE concentrations are found in patients with small-cell lung cancer,
neuroblastoma and neuroendocrine tumours3". Furthermore, the concentrations of
NSE, both in cerebrospinal fluid (CSF) and in serum, are elevated in various
neurological disorders"2~,2\ In particular, concentrations of serum NSE, measured
in venous blood within 48-72 hours of an acute stroke, correlate significantly with
clinical outcome2"'326'327.
S-100 is a calcium-binding protein which exists as homo- or heterodimers of two
subunits - a (10.4kD) and p (10.5kD)328'329. The aa-S-100 form is found
exclusively in neurones, a.p-S-100 is present in glial cells, and PP-S-100 is found in
glial cells and in Schwann cells"9. S-100 has also been detected in some non-neural
330 • 331
tissues, such as melanocytes and adipose tissue , and elevated serum
332concentrations of S-100 have been reported in patients with malignant melanoma .
As with NSE, acute neurological injury causes concentrations of S-100 to rise in CSF
and in serum259'314>320'321<324'333-3405 anci concentrations of S-100 measured in serum




At present, no biological markers are available which predict clinical outcome with
accuracy after an episode of severe hypoglycaemia. The effects of severe
hypoglycaemia on serum concentrations of NSE and S-100 have not been evaluated
previously. Serum concentrations of NSE and S-100 were, therefore, estimated
(acutely) in 16 diabetic patients who experienced a single episode of severe
hypoglycaemia without permanent neurological injury, in three diabetic patients who
sustained significant brain damage (and who subsequently died) following an
episode of severe hypoglycaemia, and in ten diabetic patients who had not




The study was performed in conjunction with Study 2, reported in Chapter 6, and
was approved by the local medical ethics advisory committee. Twenty six of the 29
subjects studied participated in Study 2: 16 subjects were in the 'hypo' group (i.e.
were recruited shortly after experiencing an episode of severe hypoglycaemia) and
10 were in the 'control' group (i.e. had not experienced an episode of severe
hypoglycaemia for at least one year). The methods of recruitment of the subjects, the
definition of severe hypoglycaemia employed, the verification of the subjects'
previous history of hypoglycaemia and the method of HbAlc estimation were
described in Chapter 6. With regard to the 'hypo' subjects, nine of the subjects were
treated with intramuscular glucagon, two with intravenous dextrose and five with
oral carbohydrate. None of the subjects had a previous history of any neoplastic or
neurological disorder that is known to elevate serum NSE or S-100 concentrations.
In addition, three diabetic subjects who died after an episode of severe
hypoglycaemia were studied as individual cases and their case histories are described
in Chapter 7.2.5.
7.2.2 Timing of Blood Samples
Venous blood samples were taken for measurement of NSE and S-100
concentrations at two time points designated T1 and T2. In the case of the 'hypo'
group, T1 was approximately 36 hours after the onset of the hypoglycaemic event
(Table 7.1), while in the 'control' group, T1 represented the time of taking the first
blood sample. In both groups, the second blood sample (T2) was taken
approximately 7 days after the first blood sample (i.e. approximately 8.5 days after
the hypoglycaemic event in the case of the 'hypo' group).
7.2.3 Measurements of Serum NSE and S-100 Concentrations
Blood samples were centrifuged within four hours of venepuncture at 1500g for 10
minutes and sera were stored at -20°C. Haemolysed samples were not analysed for
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NSE because this enzyme is present within erythrocytes and platelets. All
biochemical analyses were performed blinded to patient status.
NSE was measured by an enzyme immumological test (Enzyme-Test NSE,
Boehringer Mannheim Immunodiagnostics, Lewes, United Kingdom). The lower
limit of detection of the assay was 0.5pg/l; the intra-assay coefficient of variation
(CV) was 2.2% at 4.9pg/l and 1.5% at 13.6pg/l. The interassay CV was 5.8% at
23.1 ptg/1.
S-100 was measured by immunoradiometric assay (IRMA Sangtec, Bromma,
Sweden). The lower limit of detection was 0.05pg/l; the intra-assay CV's were 2.8%
at 0.18pg/l, 0.7% at 1.5pg/l and 0.8% at 5.3pg/l. The inter-assay CV's were 3.3%,
4.4% and 1.5% respectively.
7.2.4 Statistical Analyses
All demographic data (which was not normally distributed) are presented as median
(interquartile range), while the NSE and S-100 data are presented as mean ± standard
deviation (SD). Baseline characteristics of subjects were compared using the Mann-
Whitney U test, and the Chi-squared test was used for categorical data. Differences
in NSE and S-100 concentrations between the 'hypo' and 'control' groups, at the two
time points, were compared using a mixed model analysis of variance (ANOVA)
with 'group' ('hypo' or 'control') as a between-subjects factor and 'time' (T1 or T2) as
a repeated measure. A p-value of less than 0.05 was considered to be significant.
All analyses were performed using SPSS version 7.5.1 for Windows 95.
7.2.5 Case Histories
Patient 1
A 49 year old Caucasian male with Type 1 diabetes for four years, who had a
previous history of frequent hypoglycaemia and alcohol dependence, was found
unconscious at home. He had been drinking large amounts of alcohol in the previous
two weeks, during which he had recorded frequent biochemical hypoglycaemia on
his routine home blood glucose monitoring. He had last been seen awake 17 hours
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earlier and, when found unconscious, a member of his family had injected a
subcutaneous dose of insulin in the mistaken belief that he was suffering from
hyperglycaemia and ketoacidosis. His general practitioner estimated a blood glucose
that was less than 1.0 mmol/1 and gave emergency treatment in the form of
intramuscular glucagon and intravenous dextrose.
On admission to hospital, the patient was comatose, with a Glasgow Coma Scale
(GCS) of 4. He was haemodynamically stable but had hypotonia and bilateral
extensor plantar responses. A CT brain scan showed no evidence of cerebral oedema
or raised intracranial pressure. The patient was intubated and ventilated and received
infusions of mannitol and phenytoin to control mild epileptiform activity. He was
extubated five days later, but his conscious level remained depressed with a GCS of
5. He subsequently developed bronchopneumonia and died 11 days after admission.
At autopsy the lungs showed extensive bronchopneumonic consolidation. The fresh
brain weighed 1500 grams and showed an old contusion on the inferior surface of the
left temporal lobe. Brain histology showed mild sulcal widening and generalised
vascular congestion consistent with agonal hypoxia. There was a mild degree of
white matter pallor and rarefaction with U-fibre sparing, indicative of mild cerebral
oedema, but no mid-line shift or evidence of herniation was noted. The brunt of
neuronal damage was borne by the hippocampus where there was severe neuronal
depletion with corresponding gliosis, most marked in the CA4 and CA1 zones
(Figure 7.1), with acidophilia of remaining neurones. Neurones of the dentate gyrus
showed conspicuous acidophilia. The neocortex contained scattered acidophilic
neurones, particularly in layers 2 and 3 and at the depths of sulci. These changes
were most severe in the temporal neocortex, where similar changes were also seen in
layer 4. Basal ganglia, hypothalamus, brain stem, cerebellum and spinal cord were
unaffected and, in particular, cerebellar Purkinje cells were intact. There was no
evidence of recent traumatic brain damage, inflammation, haemorrhage, regional
infarction or Wernicke's encephalopathy.
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Blood samples were obtained for estimation of NSE and S-100 concentrations
approximately 24 hours after the onset of hypoglycaemia (Tl) and seven days later
(T2), although the time of onset of the severe hypoglycaemia could only be
estimated.
Patient 2
A 27 year old Caucasian male with a four year history of Type 1 diabetes was found
unconscious (GCS 3) at home, having last been seen awake 13 hours previously
following a row with his girlfriend. Two empty vials of porcine soluble insulin and
three insulin syringes were lying beside him, suggesting that he had self-
administered a large dose of insulin. Blood glucose was estimated at less than 1.0
mmol/1 by paramedical staff who attended the emergency call and intra-muscular
glucagon was administered. On admission, the patient was tachypnoeic with
extensor posturing and a CT brain scan showed evidence of cerebral oedema. He
was intubated and ventilated for 24 hours without clinical improvement. All active
intervention was subsequently withdrawn and the patient died shortly afterwards.
A post mortem revealed acute bronchitis and evidence of right lower lobe
bronchopneumonia. The fresh brain weighed 1500 grams and externally showed a
moderate degree of global swelling. Histological examination of the brain revealed
widespread swelling and breakdown of the blood-brain barrier. There was global
transcortical neuronal shrinkage and acidophilia (Figure 7.2). Acute inflammation
was limited to the temporal neocortex and leptomeninges. Similar neuronal changes
were present in the CA1 to CA4 zones of the hippocampus, proximal subiculum,
dentate gyrus, head of the caudate nucleus, putamen and, to a lesser extent, globus
pallidus. Relative neuronal sparing was observed in the distal subiculum, angle of
the dentate gyrus, caudate tail and claustrum, as well as selected larger neurones in
the basal ganglia. Selective superficial cortical damage was seen in the cingulate
gyri. Thalamic neurones were distorted due to transtentorial herniation, whilst the
mid-brain and pons showed oedema, patchy infarction and Duret haemorrhage due to
terminal brain stem herniation and compression. Other significant features included
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basal ganglia microcalcification and relative Purkinje cell preservation in the
cerebellum.
Samples were obtained for estimation of NSE and S-100 concentrations at only one
time point, approximately 18 hours after the presumed onset of hypoglycaemia (Tl).
Patient 3
A 47 year old man with a 30 year history of poorly-controlled Type 1 diabetes was in
hospital, seven days following an aortic valve replacement operation. He was found
unconscious before breakfast, blood glucose was measured at less than 1.0 mmol/1
and he was treated with intravenous dextrose. During this episode, the patient had a
grand mal seizure that was complicated by aspiration of gastric contents and a
respiratory arrest. He was intubated and ventilated and initial CT scan of the brain
showed no intracerebral abnormality, although a repeat scan two days after the
episode showed gross cerebral oedema. Despite treatment with mannitol and
dexamethasone, his conscious level remained depressed and the patient died 33 days
following the episode of severe hypoglycaemia. Permission was not obtained for an
autopsy.
Blood samples were obtained, for estimation of S-100 concentration only, at serial
time points between 1 and 17 days after the onset of severe hypoglycaemia.
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7.3 RESULTS
7.3.1 Clinical Characteristics of the Subjects and Timing of Blood
Samples
The clinical characteristics of the subjects are shown in Table 7.1. The subjects in
the two groups were matched for age, sex and duration of diabetes. The 'hypo' group
had a significantly lower HbAlc (p=0.02). The differences in the timing of the T2
samples were not statistically significant (p>0.05).
7.3.2 NSE and S-100 Concentrations Following Severe Hypoglycaemia
The NSE and S-100 data for the 'hypo', and 'control' patients are presented in Figures
7.3 and 7.4. There were no significant main effects of 'group' (F=0.09, p=0.77), or
'time' (F=4.09, p=0.05) on mean serum NSE concentrations. The 'group' by 'time'
interaction was also not significant (F=0.75, p=0.39). Similarly, the main effects of
'group' (F=1.09, p=0.31), 'time' (F=2.12, p=0.16) and the interaction of 'group' by
'time' (F=2.37, p=0.14) did not reach statistical significance for mean serum S-100
concentrations.
The NSE and S-100 concentrations of Patient 1 were comparable with the 'control'
patients at both time points (Figures 7.3 and 7.4). In Patient 2, however, NSE and S-
100 concentrations were markedly elevated, at approximately 8 and 130 times,
respectively, the levels noted in the 'control' subjects (Figures 7.3 and 7.4). In Patient
3, there was a large rise in S-100 concentrations that peaked at 24 hours after the
severe hypoglycaemia; S-100 concentrations fell thereafter, but were still above
baseline levels at 17 days (Figure 7.5).
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TABLE 7.1: Clinical Characteristics of Subjects and Timing of Blood
Samples
'Hypo' 'Control' p-value
Age (years) 40.0 (32.3-54.3) 30.0 (26.0-47.3) 0.18
Sex (M/F) 10/6 5/5 0.69
Duration of diabetes (years) 15.0 (10.3-23.5) 12.5 (8.0-27.0) 0.20
HbAlc (%) 8.2 (7.6-9.4) 10.1 (8.5-11.7) 0.02
Tl: Time to 1st Blood Sample (days) 1.5 (1.1-1.9)
T2: Time between 1st and 2nd 7.1 (6.6-7.4) 7.0 (6.9-7.1) 0.96
Blood Samples(days)
All continuous variables are median (inter-quartile range).
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FIGURE 7.1: Section of CA4 Zone of the Hippocampus from Patient 1
There is complete absence of neurones and numerous reactive gemistocytic
astrocytes (arrows). (Haematoxylin and eosin x360)
FIGURE 7.2: Section of the Superficial Cortex (Layer 2) from Patient 2
There is neuronal acidophilia and shrinkage in the cingulate gyrus. (Haematoxylin
and eosin x360)
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FIGURE 7.3: Serum Concentrations of NSE in the 'Hypo' and 'Control'
Subjects, and in Patients 1 and 2
Time Period
'Hypo' ■ 'Control' |§ Patient 1 b Patient 2
Mean (± SD) NSE concentrations at T1 and T2. There were no significant
differences between 'hypo' and 'control' subjects in NSE at either T1 or T2 (p>0.05).
NSE concentrations did not rise appreciably in Patient 1, but were markedly elevated
in Patient 2 at Tl.
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FIGURE 7.4: Serum Concentrations of S-100 in the 'Hypo' and 'Control'
Subjects, and in Patients 1 and 2
Time Period
'Hypo' ■ 'Control' ^ Patient 1 m Patient 2
Mean (+ SD) NSE concentrations at T1 and T2. There were no significant
differences between 'hypo' and 'control' subjects in S-100 at either T1 or T2 (p>0.05).
S-100 concentrations did not rise appreciably in Patient 1, but were markedly
elevated in Patient 2 at T1.
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Day 1 Day 2 Day 3 Day 4 Day 11 Day 12 Day 13 Day 14 Day 15 Day 16 Day 17
Time
Time course of serum concentrations of S-100 in Patient 3 from the day of the
episode of severe hypoglycaemia (Day 1) to 17 days afterwards. The S-100
concentrations peaked 24 hours after the detection of severe hypoglycaemia, but
remained elevated up to Day 17.
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7.4 DISCUSSION
The possible clinical sequelae of an episode of severe hypoglycaemia vary widely,
ranging from complete recovery to permanent neurological disability or, rarely,
death97'98'341. Even when complete neurological recovery is apparent, recurrent
exposure to severe hypoglycaemia may result in cumulative cognitive
997 99S 797 •
decrements ' " , possibly because of chronic, low-level neuronal damage. When
significant neuronal destruction does occur during acute hypoglycaemia, it may be
very difficult in the early stages to predict the likely clinical outcome. The clinical
picture may be affected by intercurrent disease, pharmacologically-induced sedation,
or the need for artificial ventilation. CT scanning of the brain, while providing
valuable information, may show no intracerebral abnormality initially (as in Patient
3), despite significant neuronal damage. Therefore, any biological index that could
assist with prediction of the likely clinical outcome after an episode of severe
hypoglycaemia would be of value in planning the optimal medical management for
such patients. NSE and S-100 offer such a possibility, because serum concentrations
of both proteins are elevated following neuronal damage from other causes and
correlate with clinical outcome after stroke238'239"526'327. However, changes in the
serum concentrations of these markers have not been reported previously in diabetic
patients exposed to severe hypoglycaemia.
In the first part of the present study, serum concentrations of NSE and S-100 were
measured following severe hypoglycaemia that was not associated with permanent
neurological impairment. This part of the investigation was performed concurrently
with Study 2, but did not include all of the subjects who participated in this study.
There were practical reasons for the discrepancy in subject numbers. The decision to
measure NSE and S-100 was not made until after recruitment for Study 2 had
commenced and there was an additional element of delay while an extension to the
ethical permission for that study was obtained to allow blood samples to be taken for
NSE and S-100 concentrations. A sample size of 10 'control' subjects was
considered to be adequate to establish baseline values in people with diabetes and the
subjects were selected at random from those who participated in Study 2. In the
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'control' subjects, the serum NSE concentrations at T1 and T2 and the S-100
concentrations at T2 were comparable with those measured in healthy non-diabetic
• • 259 327
subjects in other studies" ' . However, the 'control' S-100 levels at T1 were
somewhat lower than that previously observed, although the difference between the
S-100 concentrations at T1 and T2 was not statistically different. Given that there
was no reason why the S-100 concentrations should have changed with time in the
'control' subjects, the apparent difference is likely to be spurious.
Severe hypoglycaemia, without subsequent permanent neurological sequelae, was
not associated with any significant alteration in serum NSE and S-100
concentrations, either 36 hours or 8.5 days after the event. It is important, however,
to consider whether the null result of this aspect of the study may have been a
consequence of methodological limitations with regard to sample size, the timing of
the blood samples or the sensitivity of the assays:
■ The present study had somewhat less than 80% power to detect a one standard
deviation difference in NSE and S-100 concentrations with a p-value set at 0.05.
However, despite the lack of power, it is unlikely that a type 2 statistical error
occurred, as perusal of the data presented in Figures 7.3 and 7.4 reveals (with the
exception of the S-100 concentrations at Tl) no evidence of a trend for the 'hypo'
patients to have higher NSE or S-100 levels. The apparent difference in the S-
100 concentrations at Tl was more a reflection of spuriously low S-100
concentrations in the 'control' subjects, rather than high S-100 concentrations in
the 'hypo' subjects.
■ Previous studies in patients with various cerebral disorders, particularly stroke,
have shown consistently that serum concentrations of NSE and S-100 become
elevated within 48 hours of the acute insult and remain so for several days, or
even weeks, afterwards258'259'324'326'327. In fact, such a profile of S-100
concentrations was seen with Patient 3. Therefore, in the present study, it is
unlikely that a transient rise in serum NSE and S-100 occurred in the 'hypo'
subjects outwith the times of the blood sampling.
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■ Following acute stroke, elevations in serum concentrations ofNSE and S-100 are
related to the size of the cerebral infarction258'259. Thus, NSE and S-100
concentrations may not rise following small strokes in which only modest
degrees of acute neuronal injury have occurred, indicating a relative lack of
sensitivity of these markers. Therefore, the results from the patients who made a
complete neurological recovery following severe hypoglycaemia should not be
interpreted as implying that no neuronal damage occurred. Neuronal injury could
have taken place, but of a degree that was below the detection of the NSE and S-
100 assays.
Episodes of severe hypoglycaemia which result in permanent neurological
abnormality are relatively rare in clinical practice, but changes in serum
concentrations ofNSE and S-100 were measured before death in three fatal cases.
The serum concentrations ofNSE and S-100 were low in the diabetic patient who
died nearly two weeks following an episode of severe hypoglycaemia (Patient 1) and
whose neuronal damage was centred primarily on the hippocampus. The significant
CA1 and end-folial hippocampal damage may at least partly have pre-dated the fatal
illness, and would be consistent with damage from previous episodes of
hypoglycaemia37'43'45. However, the acidophilia of the remaining neurones in the
hippocampus implies that acute neuronal damage also occurred at the time of the
episode of severe hypoglycaemia that preceded death. The patient's seizures were
mild and promptly treated and, while they may have contributed to the hippocampal
damage, are unlikely to have been the principal cause.
By contrast, serum NSE and S-100 concentrations were markedly elevated in a
young diabetic patient (Patient 2) who died within 48 hours of the development of
profound neuroglycopenia, after a probable deliberate insulin overdose. This patient
suffered very extensive brain damage. The involvement of the dentate gyrus and the
relative preservation of Purkinje cells and of larger basal ganglia and deep cingulate
cortex neurones are consistent with the effects of hypoglycaemia37'43'43. However, it
must be stressed that there is considerable overlap between the neuropathological
174
features of hypoglycaemia, hypoxia/ischaemia and seizures38'39 and it is quite
possible that hypoxia and seizure activity could have developed in Patient 2 when he
was lying unconscious at home. Serum concentrations of S-100 were also
significantly elevated in a middle-aged patient (Patient 3) who had a prolonged
episode of severe hypoglycaemia, seven days following cardiac surgery. Initial
concentrations of S-l 00 were low and a CT scan of the brain was normal. However,
within 24 hours of the event, S-100 concentrations had risen significantly and a
repeat CT scan of the brain confirmed gross cerebral oedema. Serum S-100
concentrations remained elevated, albeit at lower levels, for several days afterwards.
This patient had a grand rnal seizure and a respiratory arrest which were treated
promptly, but clearly both events may have contributed to the neurological damage
and the subsequent rise in S-100 concentrations. In both the above cases, the serum
concentrations of NSE and S-100 were elevated to levels equivalent to those
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observed after a large ischaemic cerebral infarction"" ' " . Neither patient had a
previous history of any neurological or neoplastic condition that could have caused
elevation of these serum proteins, and no evidence of an alternative cause was found
at the autopsy of Patient 2.
Secondary neurological insults (such as hypoxia and seizure activity) are common in
patients who have experienced profound hypoglycaemia. Therefore, in future studies
of comatose patients, it may not be possible to separate out the impact of severe
hypoglycaemia per se on serum concentrations of NSE and S-100. However, the fact
that the serum concentrations of both neuronal markers rose in two of the three
patients who subsequently died following an episode of severe hypoglycaemia, but
did not rise in patients who made a complete neurological recovery, raises the
prospect that NSE and S-100 could have a future role in predicting both the severity
of neuronal damage and the clinical outcome of patients who remain comatose
following prolonged severe hypoglycaemia. The potential value of using such
markers is that they are easy to measure, relatively inexpensive and show a rapid
response following acute neurological insult that causes neurological damage.
Therefore prognostic information could be available to clinicians at an early stage of
management, and possibly before any abnormality is detectable by neuroimaging
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techniques. However, the results of the present study are preliminary and require
validation in a larger series of patients experiencing hypoglycaemic coma, with or
without cerebral oedema, relating the increments in these serum markers to initial
clinical parameters (such as initial GCS, other neurological abnormalities and the
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The studies presented in Chapters 5, 6 and 7 of this thesis have examined the effects
of hypoglycaemia on the peripheral and central nervous systems. In this Chapter, the
ability of a new therapy for diabetes, insulin lispro, to induce hypoglycaemia
following certain meal types was specifically examined. Insulin lispro is a
genetically engineered analogue of human insulin whose chemical and glucodynamic
properties were described in detail in Chapter 1.8.2124'125. Several studies have
suggested that therapy with insulin lispro is associated with a reduced frequency of
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hypoglycaemia, particularly nocturnal episodes J J . The rapid onset of action of
insulin lispro means that it should be administered shortly before meals to avoid pre-
prandial hypoglycaemia1"'2"'42. However, if for any reason the normal rise in post¬
prandial blood glucose was reduced in magnitude, or was substantially delayed, the
rapid onset of action of insulin lispro could theoretically promote an increased risk of
early post-prandial hypoglycaemia.
Gastric emptying is an important determinant of the timing of the rise in post¬
prandial blood glucose concentrations343. In turn, meal composition has a significant
influence on gastric emptying"'44'345. Liquids pass through the stomach more rapidly
than solids"'46"348, and gastric emptying is slower in the context of a high fat content
meal260'349'350. It is, therefore, possible that the use of pre-prandial insulin lispro
therapy in conjunction with a high fat diet (such as that which predominates in many
Northern European countries, including Scotland) could be associated with an
increased risk of early post-prandial hypoglycaemia. One approach to minimising
this risk would be to inject insulin lispro after the meal, so as to delay its peak
hypoglycaemic action.
The aim of the present study was, therefore, to compare the glucodynamics
associated with pre- and post-prandial administration of insulin lispro following the
consumption of test meals in which the relative proportions of carbohydrate and fat
were varied. In particular, evidence was saught to support the premise that





The study was approved by the local medical ethics advisory committee and all
subjects gave written informed consent before participation. Twenty subjects with
Type 1 diabetes were recruited from the diabetes out-patient clinic of the Royal
Infirmary of Edinburgh. All subjects had diabetes for more than one year and had
moderately good glycaemic control, with a HbAlc level of less than 9.0% (non-
diabetic range 4.5-5.8%). No subjects had significant microvascular complications
of diabetes (other than background retinopathy) or other medical disorders, and none
had a history of dyspepsia or gastric fullness after meals. All subjects administered
human insulin in a multiple injection (basal-bolus) regimen. Autonomic neural
351function was assessed using standard tests of cardiovascular reflexes " .
The subjects were allocated to two groups which were matched for age, body mass
index, duration of diabetes, glycated haemoglobin concentration (HbAlc) and total
daily insulin dose (Table 8.1). Eighteen subjects had normal tests of cardiac
autonomic function; one subject in Group 2 had an abnormal result on the Valsalva
manoeuvre alone. In another subject from Group 2, the full battery of tests of
autonomic function could not be completed for technical reasons. This individual
had no symptoms suggestive of autonomic neuropathy or gastroparesis and did not
have postural hypotension.
8.2.2 Test Meal Protocol
Four isocaloric test meals were used in the study (Table 8.2). Two meals (designated
F) had a high fat content and a relatively low carbohydrate content. Two meals
(designated C) had a high carbohydrate content and a low fat content. One meal of
each type had a pronounced liquid (L) content and one meal of each type had a
prominent solid (S) component. The meals were designated as CL (carbohydrate,
liquid), CS (carbohydrate, solid), FL (fat, liquid) and FS (fat, solid).
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All subjects underwent four separate study sessions. On two occasions a high fat
meal was consumed and on two occasions a high carbohydrate meal was consumed.
Subjects in Group 1 were given the test meals with a pronounced liquid component
(CL and FL), while subjects in Group 2 received the meals with a prominent solid
phase (CS and FS). For each meal type, lispro was administered pre-prandially (10
minutes before the start of the test meal) on one occasion and post-prandially (20
minutes after the start of the test meal) on the other. The order of meal type and the
timing of the lispro injection were randomised. There were four possible sequences
of meal type and timing of the lispro injection:
Sequence 1: pre-prandial lispro/high carbohydrate meal
post-prandial lispro/high carbohydrate meal
post-prandial lispro/high fat meal
pre-prandial lispro/high fat meal
Sequence 2: post-prandial lispro/high carbohydrate meal
pre-prandial lispro/high fat meal
pre-prandial lispro/high carbohydrate meal
post-prandial lispro/high fat meal
Sequence 3: pre-prandial lispro/high fat meal
post-prandial lispro/high fat meal
post-prandial lispro/high carbohydrate meal
pre-prandial lispro/high carbohydrate meal
Sequence 4: post-prandial lispro/high fat meal
pre-prandial lispro/high carbohydrate meal
pre-prandial lispro/high fat meal
post-prandial lispro/high carbohydrate meal
The time taken to consume the different test meals was very similar. The dose of
lispro administered was determined individually, after consultation with each subject,
and was equivalent to the amount of soluble insulin that the individual would
normally have taken before a breakfast of the nature, size and caloric content as used
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in the study. The dose of lispro administered to each subject remained constant
across the four study sessions.
The subjects fasted overnight and omitted their normal morning dose of soluble
insulin before each study. The study session was postponed if fasting blood glucose
was greater than 12.0 mmol/1 or if hypoglycaemia had been experienced during the
preceding night. An intravenous cannula was inserted for frequent blood sampling.
Each dose of insulin lispro was administered subcutaneously into the anterior
abdominal wall. Venous blood samples were collected before the meal and at 15
minute intervals after the start of the meal, for a period of two hours. At each time
point, the blood glucose excursion was calculated as the difference in blood glucose
concentration from that at baseline.
Significant biochemical hypoglycaemia was arbitrarily defined as a venous blood
glucose concentration of less than 3.0 mmol/1. The study was discontinued
immediately if the blood glucose declined below 2.5 mmol/1, or if symptoms of
hypoglycaemia developed with blood glucose below 4.0 mmol/1.
8.2.3 Sample Analyses
Glycated haemoglobin (as HbAlc) was measured using high speed liquid
chromatography based on an ion-exchange reverse-phase partition method (Hi Auto
Ale HA 8121). Whole blood venous glucose was determined using a glucose
oxidase method (Yellow Springs Instrument 2300 Stat).
8.2.4 Statistical Analyses
Data are presented as mean (+SD), with exception of the glucose profde data
presented in Figures 8.1, 8.2, 8.3 and 8.4, which are presented, for purposes of
clarity, as mean (±SEM). Baseline characteristics of subjects were compared using
the Mann-Whitney U test and the Chi-squared test was used for categorical data.
Baseline blood glucose concentrations were compared using Student's t-test for
paired data. Post-prandial blood glucose excursions for each of the four individual
meal types were compared using a repeated-measures analysis of variance
182
(ANOVA). 'Order of session' was a between-subjects factor with four levels
(sequence 1 versus sequence 2, versus sequence 3, versus sequence 4). There were
two within-subjects factors: factor one, 'lispro timing', had two levels (pre-prandial
lispro versus post-prandial lispro) and factor two, 'time' had eight levels
(corresponding to the time points of the blood samples). The principal outcome
statistic was any ['lispro timing' by 'time'] interaction, which indicated whether the
timing of the lispro injection had any impact on the blood glucose profde for the test
meal. Main effects of 'lispro timing' and 'time' are not reported. Post-hoc analyses
were performed using Student's t-test for paired data. A p-value of less than 0.05
was considered significant for the Mann-Whitney U-test, Chi-squared test and
ANOVA analyses. A p-value of less than 0.01 was considered significant for the
paired t-test analyses, to reduce the risk of a type 1 statistical error. All analyses
were performed using SPSS version 6.1.3 for Windows. Reported p-values were
rounded to two decimal places; thus p=0.00 signifies that the p-value was <0.005.
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TABLE 8.1: Clinical Characteristics of Subjects
Group 1 Group 2 p-value
Age (years) 29.3 (9.2) 27.6 (9.9) 0.60
Sex (M/F) 7/3 4/6 0.37
Duration of diabetes (years) 11.5 (8.2) 13.9 (8.4) 0.68
Weight (kg) 77.0 (10.3) 75.7 (8.4) 0.79
BMI (kg/m2) 25.5 (3.2) 26.4 (3.4) 0.54
HbAlc (%) 7.3 (1.1) 7.2 (1.0) 0.71
Total daily insulin dose 0.71 (0.22) 0.78 (0.26) 0.43
(units/kg)
Values shown are mean (SD)
Non-diabetic range for HbAl c was 4.5-5.8%
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TABLE 8.2: Constituents Of Test Meals
Food Weight Energy CHO Fat Protein
(g) (kcals) (g) (g) (g)
High Carbohydrate [ Liquid] Breakfast (CL)
Wholemeal Bread 40 86 16.7 1.0 3.5
Low Fat Spread 14 51 0.0 5.5 0.0
Weetabix 35 119 24.6 1.2 4.0
Skimmed Milk 568 187 28.4 0.5 19.3
Skinned Banana 100 79 19.2 0.5 1.1
Total (g) 88.9 8.5 27.9
Energy (kcals) 522 356 79 112
% Energy 68 15 21
High Carbohydrate [Solid] Breakfast (CS)
Wholemeal Bread 80 173 33.4 2.2 7.0
Low Fat Spread 14 51 0.0 5.7 0.0
Fruit Jam 15 167 10.3 0.0 0.1
Weetabix 35 119 24.6 1.2 4.0
Skimmed Milk 180 59 9.0 0.2 6.1
Skinned Banana 100 81 19.9 0.3 1.0
Total (g) 97.2 9.6 18.2
Energy (kcals) 522 389 86 73
% Energy 74 17 14
High Fat [Liquid] Breakfast (FL)
White Bread 40 87 18.8 0.5 3.0
Butter 14 104 0.0 1 1.5 0.1
Whole Milk 568 369 26.7 21.6 18.7
Total (g) 45.5 33.6 21.8
Energy (kcals) 560 182 302 87
% Energy 33 54 16
High Fat [Solid] Breakfast (FS)
White Bread 40 87 18.8 0.5 3.0
Butter 14 104 0.0 11.5 0.1
Cornflakes 25 92 21.3 0.4 2.2
Cheese 45 183 0.0 15.1 11.7
Whole Milk 180 117 8.5 6.8 5.9
Total (g) 48.6 34.3 22.9
Energy (kcals) 583 194 309 92
% Energy 33 53 16
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8.3 RESULTS
The baseline fasting blood glucose concentrations before each test meal did not differ
whether lispro was administered pre- or post-prandially (Table 8.3). There were no
significant between-subjects effects i.e. the sequence of administration of the meals
and the pre- and post-prandial injections of insulin lispro had no effect on the
resulting glycaemic excursions (all p>0.05). The mean dose of insulin lispro
administered to subjects in Group 1 (12.7 ± 4.0 units) and Group 2 (13.4 ± 4.5 units)
was not statistically different (p=0.72)
8.3.1 High Carbohydrate Liquid Meal (CL)
When insulin lispro was administered before the CL breakfast, the post-prandial
glycaemic excursion was modest, with a mean peak rise in blood glucose of 2.0
mmol/l (Figure 8.1). By contrast, when lispro was administered after the test meal, a
significantly larger blood glucose excursion was observed (p=0.00 for interaction of
'lispro timing' and 'time'), with the maximum mean rise in blood glucose of 5.6
mmol/l occurring at 45 minutes. The blood glucose excursions at the 30, 45, 60 and
75 minute time points were all significantly higher with post-meal administration of
lispro (p<0.01). No subjects developed significant biochemical hypoglycaemia.
8.3.2 High Carbohydrate Solid Meal (CS)
Injection of insulin lispro before the CS meal produced a much smaller blood glucose
excursion, compared with post-prandial administration of lispro (p=0.00 for
interaction of 'lispro timing' and 'time'); Figure 8.2). Following pre-prandial
administration, a small negative excursion of between 0.5 to 1.0 mmol/l was
observed during the initial 30 minutes after the start of the breakfast; thereafter the
blood glucose excursion rose, peaking at 1.0 mmol/l at 90 minutes. Significant
asymptomatic, biochemical hypoglycaemia occurred in one subject whose fasting
glucose concentration was 3.2 mmol/l. Blood glucose concentrations fell to a nadir
of 2.8 mmol/l at 15 minutes, but rose to 4.7 mmol/l at 30 minutes and thereafter
remained above 4.0 mmol/l. No other subject developed significant biochemical
hypoglycaemia.
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In the post-prandial lispro studies, the mean blood glucose excursion peaked at 3.5
mmol/1 at 45 minutes, and was significantly higher than in the pre-prandial lispro
studies at 15, 45 and 60 minutes after the test meal (p<0.01). No subjects developed
significant biochemical hypoglycaemia.
8.3.3 High Fat Liquid Meal (FL)
Administration of insulin lispro before the FL breakfast was associated with a post¬
prandial glycaemic excursion in which the mean blood glucose varied little from
baseline values (Figure 8.3). One subject developed persistent, biochemical
hypoglycemia which provoked symptoms and necessitated termination of the session
after 60 minutes. This subject started the study session with a pre-meal blood
glucose of 5.0 mmol/1 (the lowest value recorded for any subject ingesting the FL
meal) which declined progressively over 60 minutes to 2.7 mmol/1, at which point
the study was terminated. Because a repeated-measures ANOVA can only be
performed on complete data sets, the incomplete time course data from this subject
was not included in the ANOVA and subsequent t-test analysis. The data presented
in Figure 8.3 are derived from the remaining nine subjects, in whom blood glucose
did not fall below 3.0 mmol/1 at any time.
Administration of lispro after the FL breakfast produced a significantly larger blood
glucose excursion (p=0.00 for interaction of 'lispro timing' and 'time'). No subjects
developed significant hypoglycaemia. The blood glucose excursion peaked at 5.2
mmol/1 at 45 minutes, and was significantly greater at the 30, 45, 60 and 75 minute
time points, than that observed following pre-prandial administration of insulin lispro
(p<0.01).
8.3.4 High Fat Solid Meal (FS)
Administration of insulin lispro before the FS meal provoked a continuous decline in
blood glucose, so that by 120 minutes mean blood glucose was 3.4 mmol/1 below
baseline concentrations (Figure 8.4). One subject developed persistent, symptomatic
hypoglycaemia that necessitated termination of the study session after 105 minutes.
The subject's pre-meal blood glucose was 6.4 mmol/1 and this fell progressively to
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2.0 mmol/1 when the session was terminated. Data from this subject was not
included in the ANOVA analysis or in Figure 8.4. Two other subjects developed
significant, asymptomatic biochemical hypoglycaemia. In one individual, pre-meal
blood glucose was 11.7 mmol/1 and at 120 minutes was 2.8 mmol/1; in the other
subject, pre-meal blood glucose was 7.4 mmol/1 and at 120 minutes was 2.6 mmol/1.
In all other subjects, the blood glucose remained above 3.0 mmol/1 throughout the
study.
Post-prandial administration of lispro resulted in significantly greater mean blood
glucose concentrations than pre-prandial administration (p=0.00 for interaction of
'lispro timing' and 'time'), with a peak excursion of 3.6 mmol/1 at 45 minutes. No
subject developed significant hypoglycaemia. When lispro was administered post-
prandially, the blood glucose excursions were significantly greater at all time points
from 15 to 105 minutes inclusive (p<0.01).
The difference in the incidence of significant biochemical hypoglycaemia between
the groups (3 versus 0 instances) was not statistically significant (p=0.06).
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TABLE 8.3: Baseline Blood Glucose Concentrations
Test Meal Blood Glucose (mmol/I) p-value
Pre-Prandial Lispro Post-Prandial Lispro
CL 9.1 (3.0) 8.0 (2.7) 0.42
CS 8.1 (2.6) 8.1 (3.1) 0.97
FL 8.8 (2.8) 9.0 (2.7) 0.90
FS 8.6(2.4) 7.7(3.2) 0.55
Values shown are mean (SD)
CL: liquid high carbohydrate meal
CS: solid high carbohydrate meal
FL: liquid high fat meal
FS: solid high fat meal
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FIGURE 8.1: Glucose Excursions Following the High Carbohydrate
Liquid (CL) Meal
15 30 45 60 75
Time (mins)
90 105 120
LP After LP Before
Mean (±SEM) post-prandial glycaemic excursions for two treatment arms, after
ingestion meal CL. Time '0' represents the start of the test breakfast. * p<0.01 (pre-
prandial vs post-prandial insulin lispro). n=10 for both treatment arms. LP
represents insulin lispro.
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LP After LP Before
Mean (±SEM) post-prandial glycaemic excursions for two treatment arms, after
ingestion meal CS. Time '0' represents the start of the test breakfast. * p<0.01 (pre-
prandial vs post-prandial insulin lispro). n=10 for both treatment arms. LP
represents insulin lispro.
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FIGURE 8.3: Glucose Excursions Following the High Fat Liquid (FL)
Meal
0 15 30 45 60 75 90 105 120
Time (mins)
LP After LP Before
Mean (±SEM) post-prandial glycaemic excursions for two treatment arms, after
ingestion meal FL. Time '0' represents the start of the test breakfast. * p<0.01 (pre-
prandial vs post-prandial insulin lispro). n=9 for both treatment arms. LP represents
insulin lispro.
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FIGURE 8.4: Glucose Excursions Following the High Fat Solid (FS) Meal
45 60 75
Time (mins)
- LP After LP Before
90 105 120
Mean (±SEM) post-prandial glycaemic excursions for two treatment arms, after
ingestion meal FS. Time '0' represents the start of the test breakfast. * p<0.01 (pre-




8.4.1 Meal Composition, Insulin Lispro and Post-Prandial
Hypoglycaemia
In clinical practice, the introduction of insulin lispro has offered potential benefits for
patients with Type 1 diabetes in terms of convenience of time of administration
before meals and a reduced frequency of, particularly nocturnal,
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hypoglycaemia ' ' ' ' . However, if for any reason the rise in blood glucose
after a meal was delayed or of low magnitude, the rapid onset of action of insulin
lispro could potentially increase the risk of early post-prandial hypoglycaemia.
The potential importance of meal composition in determining the post-prandial
glycaemic response was first raised in a study of 12 patients with Type 1 diabetes by
Burge et al " . In this study, subjects attended for three sessions and consumed, on
each occasion, one of three isocaloric test meals - the meals were designated as
'standard' (50% carbohydrate, 20% protein and 30% fat), 'high carbohydrate low fat'
(80% carbohydrate, 10% protein, 10% fat) and 'low carbohydrate high fat' (20%
carbohydrate, 20% protein and 60% fat). The subjects were divided into two groups
of six - one group received injections of insulin lispro immediately before the meals
and the other received injections of soluble insulin 30 minutes before the meals; both
groups received insulin doses of 0.15units/kg. Pre-prandial euglycaemia was
established, if necessary, by a continuous infusion of soluble insulin for 90 minutes
to attain a target glucose concentration of 5.0-7.8 mmol/1. Hypoglycaemia was
defined as a plasma glucose of <2.8 mmol/1 associated with typical symptoms, or a
plasma glucose of <2.2 mmol/1, irrespective of whether symptoms were induced or
not. Subjects injected with insulin lispro demonstrated significantly smaller glucose
excursions over four hours for all three meal types. Overall, insulin lispro therapy
was associated with an increased risk of post-prandial hypoglycaemia (p = 0.04).
Hypoglycaemia was particularly common after the low carbohydrate, high fat meal
in which five subjects receiving insulin lispro were affected compared with two
subjects who received soluble insulin (p=0.09)j:i2. The study did, however, have
many drawbacks. The use of a between-subjects design considerably reduced the
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power of the study and left open the possibility that individual differences between
the subjects may have been responsible for the study results. For example, subjects
receiving insulin lispro had a mean BMI of 22.4 kg/nr, compared with 24.6 kg/m2
for subjects receiving soluble insulin; this was not statistically different given the
small sample size, but in view of the fact that subjects in both groups received the
same dose of insulin, the potentially increased insulin sensitivity of the lispro
subjects may have increased their risk of hypoglycaemia. The risk of hypoglycaemia
may also have been over-estimated by the artificial lowering of plasma glucose
concentrations before to the study. Moreover, the glucose profde data was of
doubtful validity, since complete data was obtained only on a proportion of the
subjects, because of the high dropout rate caused by the development of post-
on
prandial hypoglycaemia " .
8.4.2 Methodological Considerations Regarding the Present Study
In the present study, the effects of pre- and post-prandial administration of insulin
lispro were compared in relation to test meals of differing composition. The
principal aim of the study was to assess the risk of early post-prandial
hypoglycaemia, for which a two hour time course was thought to be adequate. A
strength of the present study was that the effects of pre- and post-prandial lispro were
compared within individual subjects, providing increased statistical power.
A major premise of the study was that meals with a high fat content would exhibit a
delayed glycaemic response by retarding gastric emptying. However, gastric
emptying is not influenced solely by meal composition. 'Gastroparesis diabeticorum'
is a rare, but debilitating complication of diabetes associated with autonomic
neuropathy344. More subtle abnormalities of gastric emptying have been described in
many individuals with diabetes of relatively long duration344'3 8'334-359. Gastric
emptying is also influenced by ambient blood glucose concentration: hyperglycaemia
Iff) T/') T/"I
delays gastric emptying 1 " , while hypoglycaemia promotes gastric emptying J"
363. In the present study, the mean basal blood glucose concentrations did not differ
between the pre- and post-prandial lispro arms. However, the subjects had a mean
duration of diabetes of more than 10 years. None had any symptoms suggestive of
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gastric stasis and the majority had normal cardiac autonomic neural function.
Therefore, although the two subject groups were well matched demographically and
in particular did not differ with respect to glycaemic control, total daily insulin dose
and dose of insulin lispro administered, complete normality of gastric emptying
cannot be asserted in all subjects, in the absence of formal studies of gastric
emptying. Ideally, all test meals would have been administered to the entire cohort
of subjects. However, this would have involved each subject attending for nine
individual sessions which was considered to be an unrealistic demand on the
subjects' time. Unrecognised differences between the groups do not affect the
validity of the within-subjects comparisons (i.e. the effects of pre-prandial versus
post-prandial insulin lispro for each meal type), but for this reason between-subjects
comparisons (i.e. direct comparisons of the excursions for the different meal types)
were not made.
The precise timing of the insulin lispro injections was determined in a pragmatic
manner. It was hypothesised when designing the study that a difference of
approximately 30 minutes between the insulin lispro injections would yield
statistically significant results. It was felt that administration of the post-prandial
injection a full 30 minutes after the test meal might result in unacceptably high post¬
prandial blood glucose concentrations, and as a compromise the 20 minute post¬
prandial time point was chosen. This required the pre-prandial injection to be given
10 minutes before food (to maintain the 30 minute gap). The insulin lispro data sheet
recommends that lispro should be administered between zero and 15 minutes before
food, so the 10 minute time period was well within the recommended schedule.
In contrast to the study by Burge et al , baseline blood glucose concentrations were
not reduced artificially by insulin infusion prior to the administration of the test
meals. There were no differences in baseline blood glucose concentrations for the
pre- and post-prandial lispro study days for each test meal. The blood glucose
concentrations were, inevitably, higher than those studied by Burge et al , but were
perhaps more representative of clinical practice. Moreover, the higher baseline blood
glucose concentrations resulted in fewer subjects failing to complete the protocols
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because of intercurrent hypoglycaemia, thereby providing more accurate profile
data.
It would have been of additional interest to have compared the impact of pre-prandial
injections of soluble insulin on the blood glucose profiles following the test meals.
Subjects were invited to participate in such an extension to the study, but an
insufficient number was willing to continue to allow this proposed extension to be
statistically meaningful.
The definition of biochemical hypoglycaemia employed in the present study was
entirely arbitrary, as it is in any study of this type. The definition chosen was felt to
be clinically relevant and yet did not pose a danger to the subjects participating.
8.4.3 Interpretation of Results and Comparisons with Other Studies
Irrespective of the composition of the test meal, the post-prandial excursions of blood
glucose were lower when insulin lispro was administered before rather than after
food. This resulted in better post-meal glycaemic control with high carbohydrate
(low fat) meals. Administration of lispro before meals with a high fat (and low
carbohydrate) content produced a significant fall in post-prandial blood glucose
when the meal was predominantly in solid phase. When the meal was in a more
liquid form, the blood glucose excursion was flat, presumably because the liquid
traversed the stomach more rapidlyj43'346,j48. Complete data sets were not obtained
for either form of the high fat meal, as one subject developed a level of
hypoglycaemia that necessitated premature termination of the session during each
pre-meal lispro study. If complete data sets had been available for analysis, the mean
decrement in blood glucose might have been greater when lispro was administered
before either type of high fat meal. Therefore, when lispro is injected before meals
with a high fat content, particularly those with a prominent solid phase, the post¬
prandial fall in blood glucose which occurs may induce early post-prandial
hypoglycaemia, especially if the pre-meal blood glucose is relatively 'low' (for
example, less than 8 mrnol/1). Indeed, there was a non-significant trend for pre-
prandial lispro to be associated with an increased risk of significant biochemical
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hypoglycaemia in the context of the meal with a high fat content that was
predominantly in solid phase. However, if the pre-meal blood glucose is high, the
post-prandial fall in blood glucose may be acceptable and indeed desirable. In the
present study, when insulin lispro was administered after a high fat breakfast, post¬
prandial blood glucose rose in most subjects and the risk of post-prandial
hypoglycemia was minimal. The increments in post-prandial blood glucose were,
however, relatively high and might have been restricted by administering the insulin
lispro immediately after the test meal, instead of after an interval of 20 minutes.
The efficacy of the post-prandial administration of insulin analogues has been
examined in two recent studies366'367. Injection of insulin lispro 15 minutes after the
start of a test meal consisting of 350g of beef stroganoff (584.5kcal; 35g protein,
45.5g carbohydrate and 28g fat) produced a glucodynamic pattern over two hours
which was comparable to soluble human insulin given, either 20 minutes before, or
immediately before, the meal. The lowest post-prandial glucose excursion occurred
when insulin lispro was injected 20 minutes before the meal, but this provoked early
post-prandial hypoglycaemia (defined as a blood glucose of <2.78 mmol/1) in some
subjects '66, consistent with the findings of the present study. Post-prandial injection
of the newer insulin analogue, insulin aspart, has also been demonstrated to result in
comparable glucodynamic profiles with human soluble insulin administered 15
minutes pre-prandially, and superior results to soluble insulin injected immediately
before meals'67. Insulin aspart therapy (injected either immediately pre-prandially or
15 minutes after food) was also associated with a non-significant increased trend
towards increasing early post-prandial hypoglycaemia (defined as a plasma glucose
<2.8 mmol/l)j67.
8.4.4 Other Factors which may Influence Post-Prandial Glucose
Excursions
The present study has indicated that the optimal timing for administration of insulin
lispro is determined, in part, by the composition (carbohydrate and fat content) of the
meal being consumed, and also by its relative liquid and solid content. However, the
high carbohydrate test breakfast contained not only larger monosaccharide,
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disaccharide and starch components, relative to the high fat breakfasts, but also a
greater proportion of insoluble (cereal) fibre. Variation in the insoluble fibre content
of test meals generally has little effect on the overall glycaemic response368. By
contrast, meals with a large proportion of soluble fibre, as found in barley and
legumes, generally exhibit blunted glycaemic responses"368. The test meals used in
the present study contained only a small amount of soluble fibre, and an important
area of further study would be to examine the glycaemic responses of meals with a
high soluble fibre content in relation to the timing of administration of insulin lispro.
All test meals used in the present study had a comparable protein content. The
effects of variations in protein content on the glycaemic response to a test meal are
112 368
more varied ' , and may also merit further investigation in relation to the use of
insulin lispro.
The impact of insulin lispro on prevailing blood glucose could be affected by factors
other than the timing of the insulin injection alone. Insulin is absorbed into the
circulation from subcutaneous tissue at different rates depending on the site of
~\f\Q 771 • • •
injection ~ . In the present study, lispro was injected subcutaneously into the
anterior abdominal wall, a site which is associated with a rapid rate of absorption of
insulin369"371. Administration of insulin lispro into an alternative anatomical site,
such as the arm or the thigh, is associated with a slower onset of glucose-lowering
activity369"371. Therefore, when a person with diabetes wishes to consume a high fat
meal, an alternative strategy may be to inject insulin lispro into the thigh instead of
considering a post-prandial time of administration. However, the absorption of
insulin from any injection site is dependent on many variables (such as depth of
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injection, skin temperature and subcutaneous tissue blood flow) " and so the use
of an injection site from which the absorption of insulin is usually slow may be a less
reliable method of avoiding hypoglycaemia than adjusting the time of injection in
relation to meals. A further means of avoiding early post-prandial hypoglycaemia
would be to reduce the dose of insulin lispro, but this may provoke late post-prandial
hyperglycaem ia3 ? 2.
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8.4.5 Conclusions
When a person with Type 1 diabetes consumes a meal with a high carbohydrate
content, the pre-prandial administration of insulin lispro provides better glycaemic
control with little risk of early post-prandial hypoglycaemia. By contrast, when
consuming meals that have a high content of fat, which is mainly in a solid phase, the
risks of early post-prandial hypoglycaemia are markedly increased and so post¬
prandial administration of lispro may be more appropriate. Patients who are
commencing therapy with insulin lispro should therefore be educated that the timing
of insulin injections, in relation to food, may need to be varied according to
prevailing blood glucose concentrations and the content of the meal. Patients should
also be advised of the potential risk of early post-prandial hypoglycaemia.
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CHAPTER 9
CONCLUSIONS AND FUTURE RESEARCH
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The results of the DCCT , and to a more limited extent the United Kingdom
Prospective Diabetes Study (UKPDS)j7x376, have demonstrated the importance of
achieving strict glycaemic control in the prevention of microvascular complications
of diabetes. However, strict glycaemic control comes at the price of an increased
incidence of hypoglycaemia6, and indeed hypoglycaemia represents the major barrier
in preventing the majority of patients with insulin-treated diabetes achieving and
maintaining blood glucose concentrations that are within the non-diabetic range8.
Therefore, research into the epidemiology, pathogenesis, clinical features and
prevention of hypoglycaemia is of considerable importance and relevance. The data
presented in this thesis have extended our understanding of the effects of
hypoglycaemia on the peripheral and central nervous systems and have identified
strategies that may reduce the occurrence of hypoglycaemia in patients treated with
insulin lispro.
9.1 ACUTE HYPOGLYCAEMIA, THE PERIPHERAL NERVOUS SYSTEM
AND INFORMATION PROCESSING
The primary aim of Study 1 was to determine the effects of hypoglycaemia on the
function of the peripheral nervous system. Acute hypoglycaemia had no impact on
the motor nerve conduction velocities, or on the amplitudes of the evoked action
potentials, of either the median or common peroneal nerves. This study has provided
clear evidence that the peripheral nervous system does not have the same reliance on
glucose as a metabolic fuel as the central nervous system. This may be a reflection
of the enhanced ability of peripheral neurones to use non-glucose fuels or to extract
glucose more efficiently from the peripheral circulation. Future studies should,
however, examine the effects of acute hypoglycaemia on peripheral neural function
in people with diabetes, with and without peripheral neuropathy, as it is conceivable
that peripheral nerves that are already dysfunctional may exhibit a greater degree of
sensitivity to glucopenia.
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It has been a widely held belief that insulin does not have any role in regulating the
glucose metabolism or function of neural tissues. However, the discovery of insulin-
sensitive glucose transport proteins within the central nervous system17 and of insulin
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receptors within the brain has forced a re-evaluation of this hypothesis. An
unexpected finding of Study 1 was the potential for common peroneal nerve
conduction velocities to decline throughout the course of both the euglycaemic and
hypoglycaemic hyperinsulinaemic clamps. This raises the prospect that insulin, in
supra-physiological concentrations, may be exerting a direct effect on peripheral
neural function. Further studies, employing a euglycaemic/normoinsulinaemic
control arm, are clearly required to investigate this in more detail. If the effect of
hyperinsulinaemia on peripheral nerve function was confirmed, it would be
important, once more, to study patients with diabetes, with and without peripheral
neuropathy and to examine sensory, as well as motor, peripheral neural function.
As a secondary issue, Study 1 has also provided some fascinating insights into the
field of contemporary intelligence research. Indices of speed of information
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processing correlate strongly with general intelligence . Foremost among these
indices is the choice reaction time task. There is a linear relationship between the
decision time component of reaction time and the logarithm of the number of lights
• 268from which the choice is made (the so-called Hick Paradigm) . It has been
suggested that the slope of this regression line correlates with intelligence, with less
9ro
intelligent people having steeper slopes . However, the failure of the slope of the
Hick Paradigm line to be altered by acute hypoglycaemia in Study 1 provides
compelling evidence that this putative relationship with intelligence is not valid.
Moreover, attempts by psychologists to determine a physiological basis for general
intelligence by proposing a link between peripheral nerve conduction velocities and
intelligence2^6'257 have been partially refuted by the inability of hypoglycaemia to
impair peripheral neural function, despite its obvious deleterious effects on speed of
information processing. The results of Study 1 do not discount the hypothesis that
speed of central nervous system function may form part of the physiological basis of
intelligence, merely that peripheral neural function cannot be used as a surrogate
marker. This is not, however, entirely surprising given the differences in structure
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between peripheral and central neurones. Future investigators in this field may,
therefore, wish to examine the link between auditory, visual and/or somotosensory
evoked potentials (more direct measures of speed of central nervous system
processing) and intelligence.
9.2 RECOVERY FROM SEVERE HYPOGLYCAEMIA
Study 2 has yielded important information in determining the time course of
cognitive and mood alterations following severe hypoglycaemia in patients with
insulin-treated diabetes. The absence of any significant 'hangover' effect of
hypoglycaemia on cognitive function at the time of the first testing session,
approximately 36 hours after the episode, suggests that patients can be reassured that
it is safe to return to work or to drive after this time interval. However, further
studies should examine the potential 'hangover' effect of severe hypoglycaemia on
more relevant everyday tasks such as performance in driving simulators. Future
studies that attempt to determine, more precisely, how quickly cognitive function
recovers following severe hypoglycaemia will require that subjects are tested within
1.5 days following the severe hypoglycaemia. Given that most episodes of severe
hypoglycaemia occur in the community, this will pose considerable ethical and
practical difficulties. However, many cognitive tasks are now available in hand-held
computer format. Thus, one potential study design would be to provide,
prospectively, hand-held computers to subjects at high risk of severe hypoglycaemia,
such as people with impaired hypoglycaemia awareness, and to ask them to perform
the cognitive tasks repeatedly at fixed time intervals following recovery from an
episodes of severe hypoglycaemia. Control subjects would clearly be required to
adjust for practice effects, and the potential confounding influence of sleep
deprivation would also have to be considered.
The impression that mood state took slightly longer to recover following severe
hypoglycaemia was predictable and highlights the psychological impact that severe
hypoglycaemia has on patients with diabetes. Study 2 also provided further evidence
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to support the premise that recurrent episodes of severe hypoglycaemia are
associated with cumulative cognitive decrements226. This area of research has
engendered considerable controversy217 and prolonged follow-up and evaluation of
large cohorts of diabetic subjects, such as those who participated in the DCCT, are
clearly essential.
9.3 DETERMINING PROGNOSIS AFTER SEVERE HYPOGLYCAEMIA
Clinicians often have difficulty in determining the clinical outlook of patients
admitted in a coma following an episode of hypoglycaemia. The results of
neuroimaging may be normal within the first few days following the episode, and the
clinical picture may be altered by the need for sedation and artificial ventilation, and
the presence of concurrent physiological abnormalities. The availability of a simple
blood test that could aid clinicians in evaluating the prognosis of such patients would
have considerable clinical value. Serum concentrations of NSE and S-100 have
258 259demonstrated such ability in the context of acute stroke ' . The preliminary
results of Study 3 suggest that NSE and S-100 may have the potential to fill such a
role following severe hypoglycaemia. Concentrations of the neural markers were
elevated in two of three patients who died following severe hypoglycaemia, but not
in patients who made a complete neurological recovery. Further detailed study is
clearly required in large numbers of patients admitted in a coma with severe
hypoglycaemia, correlating NSE and S-100 concentrations with clinical variables
(such as the presence of neurological abnormalities and the results of neuroimaging)
and final outcome. It must be stressed that elevated concentrations of NSE and S-
100 following severe hypoglycaemia may not be caused solely by hypoglycaemic
brain damage, but other factors may also be responsible, such as seizure activity and
hypoxia, which commonly occur in this situation.
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9.4 INSULIN LISPRO AND POST-PRANDIAL HYPOGLYCAEMIA
Insulin lispro has been advocated as a potential therapy for patients at increased risk
of severe hypoglycaemia, because of trial evidence that suggests its use is associated
with a decreased incidence of nocturnal hypoglycaemia1 j2 and, possibly, severe
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hypoglycaemia "'. However, the rapid onset of action of insulin lispro creates the
theoretical risk that its administration may actually increase the risk of early post¬
prandial hypoglycaemia. Study 4 has confirmed this theoretical risk by
demonstrating marked negative glucose excursions following the ingestion of meals
with a high fat content. The fall in glucose concentrations was prevented by post¬
prandial administration of the insulin lispro. The results of this study imply that
patients who are being commenced on insulin lispro therapy should be educated
about the possibility of early post-prandial hypoglycaemia, particularly if pre-
prandial blood glucose concentrations are low or if high fat meals are to be
consumed. In such circumstances, post-prandial injection of the insulin lispro may
be safer. Further studies are required with insulin lispro to determine the its impact
on glucose concentrations following the ingestion of meals with high soluble fibre or
protein contents. In addition, large-scale studies are required in patients who are at
particular risk of hypoglycaemia, such as those with impaired hypoglycaemia
awareness, to determine whether insulin lispro can be advocated as a therapy in such
patients.
9.5 CONCLUSIONS
Much still remains to be done in the field of hypoglycaemia research to improve our
understanding of its pathogenesis and, ultimately, to prevent its occurrence. The
advent of sophisticated neuroimaging techniques such as functional MRI, positron
emission tomography (PET) and single photon emission tomography (SPET), as well
as the continued advances in molecular genetic techniques, are likely to herald
significant progress in our understanding of the pathogenesis of hypoglycaemia and
associated disorders such as impaired awareness of hypoglycaemia. There is also
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considerable research activity into the use of neuroprotective agents, such as N-
methyl-D-aspartate receptor antagonists, which are currently of particular interest in
the context of acute strokej77, but which could ultimately be utilised to protect
patients from the neurotoxic effects of severe hypoglycaemia. The advent of non¬
invasive blood glucose monitoring may one day allow patients with diabetes to
continually monitor blood glucose concentrations and may provide early warning
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about the onset of hypoglycaemia . The long-term survival of pancreatic and islet
r> • • • • • • T7Q
cell grafts in patients with Type 1 diabetes continues to improve , while the
introduction of new short- and long-acting insulin analogues may provide insulin
therapy that mimics more closely the normal physiological pattern of insulin
secretion180. The Holy Grail of specific treatments that prevent diabetes or return
physiological insulin secretion remains elusive, but continued research effort will
surely see the development, in the foreseeable future, of therapies that abolish the
risk of hypoglycaemia in insulin-treated diabetes.
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APPENDIX 1
STUDY 2: CORRELATIONS BETWEEN THE COGNITIVE
TASKS AT THE INDIVIDUAL TESTING POINTS
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**•Correlationissignifica tathe0.01lev l(2-tailed). * Correlationissignifica tathe0.05lev l(2-tailed).
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The investigation of cognitive function in relation to
diabetes has a long history which stretches back to the
early 1920s.' An extensive literature has accumulated
describing the effects of insulin-dependent and non-
insulin-dependent diabetes on cognitive ability.2-6 Studies
have considered the impact of acute, transient metabolic
derangement (principally hypoglycaemia and hypergly-
caernia) on cognitive function,4-5-7-8 as well as the longer-
term effects of chronic hyperglycaemia2 and recurrent
severe hypoglycaemia9 on the brain. Several review
articles2-6 have demonstrated that there is widespread
inconsistency in the conclusions drawn from the individ¬
ual studies in these areas. This discrepancy may be
attributable to multiple factors, such as the use of non-
comparable patient populations, insufficient sample sizes
and inadequate controls. However, an additional and
important cause of discrepancy has been the use of
different cognitive test batteries.5-6
Although much of the variance in human mental
abilities is attributable to general intelligence, in clinical
practice it is useful to employ tests to examine the
various cognitive domains.10-" These domains include
attention and concentration, memory (both verbal and
non-verbal), abstract thinking, constructional ability, and
speed of information processing. Full assessment of
cognitive function requires, therefore, the administration
of a battery of psychometric tests, to ensure that sufficient
cognitive domains are examined to detect any deficits
or decrements. However, a bewildering range of psycho¬
metric tests is available.10 The format of individual tests
is very variable, ranging from the relative simplicity of
paper and pencil tasks, such as Trail-Making B (from the
Halstead-Reitan battery)12 and Digit Symbol (from the
Wechsler Adult Intelligence Scale),13 to the electronic
complexity of driving simulators. The lack of gold
standards for the validation of psychological tests means
that multiple tests of differing nature and complexity are
available to examine the parameters of any given
cognitive domain. The situation is made more complex
since many tests measure more than one aspect of
cognitive ability, so that the results from two different
tests purporting to examine, for example, verbal memory
may not be directly comparable. Thus, comparisons
between studies which have used different batteries of
cognitive tests must be made with caution, even though
they may have been attempting to examine the same
nominal cognitive domains. This lack of common end--
points precludes the combination of study results by
meta-analysis, thereby greatly diminishing the value of
CCC 0742-3071/97/060421-02$17.50
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Diabetes: the
smaller studies. The practical reality of this situation has
been illustrated by ourselves in a recent review on the
effects of non-insulin-dependent diabetes on cognitive
function; the heterogeneity of the cognitive testing
performed in the 19 studies that were evaluated prevented
a meta-analysis being conducted and allowed only
qualitative comparisons to be made between the studies.6
This reduces the strength of conclusions that can be
drawn from the body of work published on this topic.
Achieving a Consensus on
Neuropsychological Assessment
This problem is not unique to diabetes. Investigators in
other fields have addressed the matter of assessing
cognitive function to facilitate comparisons across differ¬
ent studies. A recent meeting in Fort Lauderdale, USA,
entitled 'CNS Dysfunction After Cardiac Surgery: Defining
the Problem', was attended by leading investigators in
cerebral physiology and in outcomes of cardiac surgery.14
This group agreed a consensus statement which attempted
to standardize the assessment of neuropsychological
function after cardiac surgery. Among a list of 14
recommendations, the statement suggested a core battery
of psychological tests to be employed in such an
assessment. The tests recommended were the Rey Audi¬
tory Verbal Learning Test (assessing learning and immedi¬
ate and delayed memory functions), the Trail-Making A
and B Tests (assessing attention, concentration, and
mental flexibility) and the Grooved Pegboard Test
(assessing psychomotor skills, including dexterity). These
tests are well standardized and validated and are not
dependent on sophisticated computer technology. The
Fort Lauderdale statement14 stressed that mood state
assessment should be performed concurrently with neur¬
opsychological testing, as performance of the latter can
be influenced by mood state and its variation. While
the suggested core test battery does not provide a
comprehensive assessment of cognitive function, investi¬
gators retain the scientific freedom to add supplementary
tests as appropriate. The key point, however, is that
the core battery provides a basis for making rational
comparisons between studies and should allow, if
required, the combination of study results by meta¬
analysis.
A Diversity of Batteries?
We suggest that if significant scientific progress is to be
made, the development and application of core batteries
of neuropsychological tests are vital for future studies of
cognitive function in diabetes. However, the situation in
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diabetes is especially complex because of the diversity
of situations in which cognitive function is measured.
Diabetes affects people of widely differing ages and
cognitive function may be altered either by acute
metabolic perturbation or by the longer-term effects of
diabetes. Clearly it might not be reasonable to have the
same core battery of tests for children, young adults,
and elderly people. Similarly, it may be more appropriate
to use different batteries of tests (and experimental
designs) in studies examining acute metabolic effects as
opposed to longer-term cognitive deficits. For example,
where investigators wish to identify the precise glycaemic
threshold for impairment in specific cognitive domains,5
a small battery of domain-sensitive tests, perhaps in
conjunction with other physiological measurements, may
be more appropriate than the larger battery of cognitive
tests that would be required to identify cognitive impair¬
ment secondary to recurrent, severe hypoglycaemia.9
Thus, in diabetes, it is likely that several different core
batteries of cognitive tests will be required to meet the
requirement of investigators. Such investigators would of
course be at liberty to supplement these batteries with
extra tests where necessary.
We propose that an international forum of investigators
with expertise in this field should be convened to agree
on guidelines for core cognitive testing in diabetes,
thereby advancing the study of this important area.
M.W.j. Strachan
B.M. Frier
Department of Diabetes, Royal Infirmary of Edinburgh
I.J. Deary
Department of Psychology, University of Edinburgh
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Optimal Time of Administration
of Insulin Lispro
Clinical Care/Education/Nutrition
Importance of meal composition
Mark W.J. Strachan, mrcp
Brian M. Frier, md
OBJECTIVE — To compare the glucodynamics of pre- and postprandial administration of
insulin lispro using test meals of differing composition.
RESEARCH DESIGN AND METHODS— Twenty subjects with IDDM were studied
on four separate occasions. Ten subjects ingested high-carbohydrate and high-fat breakfasts
with a large liquid component, and 10 subjects ingested high-carbohydrate and high-fat break¬
fasts in a more solid form. With each meal, insulin lispro was injected 10 min preprandial on
one occasion and 20 min postprandial on another. The magnitude and temporal pattern of
postprandial glucose excursions were observed.
RESULTS— With all meal types studied, postprandial blood glucose excursions were
significantly smaller when insulin lispro was administered preprandially (P < 0.05). With both
high-carbohydrate meals and the liquid high-fat meal, preprandial administration of lispro was
associated with modest postprandial increments of blood glucose. With the solid high-fat meal,
preprandial lispro produced a cumulative decline in postprandial blood glucose, whereas blood
glucose rose when lispro was administered postprandially.
CONCLUSIONS — For meals with a high carbohydrate content, the optimal time of
administration of lispro is preprandial. However, for meals with a high solid fai content, post¬
prandial administration of lispro may be preferable.
Insulin lispro [Lys(B28), Pro(B29) insulin]is a genetically engineered analog ofhuman insulin (1). Compared to co ¬
ventional regular insulins, it is absorbed
more rapidly and its glucose-lowering
activity is both more rapid in onset and of
shorter duration (1). To avoid preprandial
hypoglycemia, it is recommended that
lispro be administered shortly before meals
(2,3). However, if the rise in postprandial
blood glucose is reduced in magnitude or
substantially delayed, the rapid onset of
action of insulin lispro may promote early
postprandial hypoglycemia.
Gastric emptying is an important
determinant of the timing of the rise in
postprandial blood glucose (4), and the
composition of a meal has a significant
influence on gastric emptying (5,6). Liq¬
uids pass through the stomach more
rapidly than solids (7-9), and gastric emp¬
tying is slower when a meal has a high fat
content (10-12). ft is possible, therefore,
that the administration of insulin lispro
before a meal with a high fat content may
promote early postprandial hypoglycemia.
One approach to minimizing this risk
would be to inject lispro after the meal.
The aim of the present study was to
compare the glucodynamics associated
with pre- and postprandial administration
of insulin lispro after the consumption of
test meals in which the relative propor¬
tions of carbohydrate and fat were varied.
The roles of the solid and liquid con¬
stituents of the meals were also evaluated.
RESEARCH DESIGN AND
METHODS — Twenty subjects with
IDDM were recruited from the diabetes out¬
patient clinic of the Royal Infirmary of Edin¬
burgh. All had IDDM, diagnosed according
to WHO criteria, for more than 1 year and
had an HbAlc level of less than 9.0% (non-
diabetic range 4.5-5.8%). No subjects had
significant complications of diabetes (other
than background retinopathy) or other
medical disorders, and none had a history
of dyspepsia or gastnc fullness after meals.
All subjects were administering human
insulin in a multiple injection (basal-bolus)
regimen. Autonomic neural function was
assessed using standard tests of cardiovas¬
cular reflexes (13). The study was approved
by the local medical ethics advisory com¬
mittee, and all subjects gave written
informed consent before participation.
The subjects were allocated to two
groups matched for age, BMI, duration of
diabetes, HbAlc, and total daily insulin dose
(Table 1). Eighteen subjects had normal
tests of cardiac autonomic function; one
subject in Group 2 had an abnormal result
on the Valsalva maneuver alone. In another
subject from Group 2, the full battery of
tests of autonomic function could not be
completed for technical reasons. This per¬
son had no symptoms suggestive of auto¬
nomic neuropathy or gastroparesis and did
not have postural hypotension.
Four isocaloric test meals were used in
the study (Table 2). Two meals (designated
F) had a high fat content and a relatively
low carbohydrate content. Two meals (des¬
ignated C) had a high carbohydrate content
and a low fat content. One meal of each
type had a pronounced liquid (L) content
and one meal of each type had a prominent
solid (S) component. The meals are desig¬
nated as CL (carbohydrate, liquid), CS (car¬
bohydrate, solid), FL (fat, liquid), and FS
(fat, solid).
All subjects underwent four separate
study sessions. On two occasions, a high-fat
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meal was consumed, and on two occasions,
a high-carbohydrate meal was consumed.
Subjects in Group 1 were given the test
meals with a pronounced liquid component
(CL and FL), and subjects in Group 2
received the meals with a prominent solid
phase (CS and FS). For each meal type,
lispro was administered preprandially on
one occasion (10 min before the start of the
test meal) and postprandially on the other
(20 min after the start of the test meal). The
order of meal type and the timing of the
lispro injection were randomized. The time
taken to consume the different test meals
was very similar. The dose of lispro admin¬
istered was determined individually after
consultation with each subject, and the dose
was equivalent to the amount of regular
insulin that each subject would normally
take before breakfasts of the nature, size,
and caloric content used in the study. The
agreed dose of lispro administered to each
subject remained constant across the four
study sessions.
The subjects fasted overnight and
omitted their normal morning dose of reg¬
ular insulin before each study. The study
session was postponed if fasting blood glu¬
cose was >12.0 mmol/1 or if hypoglycemia
had been experienced during the preceding
night. An intravenous cannula was inserted
for frequent blood sampling. Each dose of
insulin lispro was administered subcuta-
neously into the anterior abdominal wall.
Venous blood samples were collected
before the meal and at 15-min intervals
after the start of the meal for a period of 2
h. At each time point, the blood glucose
excursion was calculated as the difference
in blood glucose concentration from that at
baseline. The study was discontinued
immediately if the blood glucose declined
below 2.5 mmol/1 or if symptoms of hypo¬
glycemia developed with blood glucose
below 4.0 mmol/1.
Sample analyses
Glycated hemoglobin (as FlbAic) was meas¬
ured using high-speed liquid chromatogra¬
phy based on an ion-exchange
reverse-phase partition method (Hi Auto
Ale HA 8121). Whole blood venous glu¬
cose was determined using a glucose oxi¬
dase method (Yellow Springs Instrument
2300 Stat).
Statistical analyses
Clinical characteristics of subjects were com¬
pared using the Mann-Whitney U test, and
the x2 test was used for categorical data.
Table 1—Clinical characteristics of subjects with IDDM
Group 1 Group 2 P value
n 10 10
Age (years) 29.3 ± 2.9 27.6 ± 3.1 0.60
Sex (M/F) 7/3 4/6 0.37
Duration of diabetes (years) 11.5 ± 2.6 13.9 ±2.6 0.68
Weight (kg) 77.0 ±3.3 75.7 ±2.6 0.79
BM1 (kg/m2) 25.5 ± 1.0 26.4+ 1.1 0.54
HbAlc (%) 7.3 ±0.4 7.2 ± 0.3 0.71
Total daily insulin dose (U/kg) 0.71 ±0.07 0.78 ± 0.08 0.43
Data are n and means ± SE.
Table 2—Constituents of test meals used in the study
Weight Energy Carbohydrate Fat Protein
Food (g) (kcal) (g) (g) (g)
High-carbohydrate (liquid)
breakfast
Wholemeal bread 40 86 16.7 1.0 3.5
Low-fat spread 14 51 0.0 5.5 0.0
Weetabix 35 119 24.6 1.2 4.0
Skimmed milk 568 187 28.4 0.5 19.3
Skinned banana 100 79 19.2 0.5 1.1
Total(g) — — 88.9 8.5 27.9
Energy (kcal) — 522 356 79 112
% Energy — — 68 15 21
High-carbohydrate (solid)
breakfast
Wholemeal bread 80 173 33.4 2.2 7.0
Low-fat spread 14 51 0.0 5.7 0.0
Fruit jam 15 167 10.3 0.0 0.1
Weetabix 35 119 24.6 1.2 4.0
Skimmed milk 180 59 9.0 0.2 6.1
Skinned banana 100 81 19.9 0.3 1.0
Total (g) — — 97.2 9.6 18.2
Energy (kcal) — 522 389 86 73
% Energy — — 74 17 14
High-fat (liquid)
breakfast
White bread 40 87 18.8 0.5 3.0
Butter 14 104 0.0 11.5 0.1
Whole milk 568 369 26.7 21.6 18.7
Total (g) — — 45.5 33.6 21.8
Energy (kcal) — 560 182 302 87
% Energy — — 33 54 16
High-fat (solid)
breakfast
White bread 40 87 18.8 0.5 3.0
Butter 14 104 0.0 11.5 0.1
Cornflakes 25 92 21.3 0.4 2.2
Cheese 45 183 0.0 15.1 11.7
Whole milk 180 117 8.5 6.8 5.9
Total (g) — — 48.6 34.3 22.9
Energy (kcal) — 583 194 309 92
% Energy — — 33 53 16
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Table 3—Baseline blood glucose concentrations for each test meal with pre- or postprandial
administration of insulin lispro
Blood glucose (mmol/1)
Test meal Preprandial lispro Postprandial lispro P value
n 10 10
CL 9.1 ±0.9 8.0 ±0.9 0.42
CS 8.1 + 0.8 8.1 ±1.0 0.97
FL 8.8 ±0.9 9.0 ±0.9 0.90
FS 8.6 ±0.8 7.7 ± 1.0 0.55
Data are means ± SE.
Baseline blood glucose concentrations were
compared using Student's t test for paired
data. Postprandial blood glucose excursions
were compared using a repeated measures
analysis of variance (ANOVA). Post hoc
analyses were performed using Student's t
test for paired data. A P value of <0.05 was
considered significant for the Mann-Whit¬
ney U test, x2 test, and ANOVA; a P value of
<0.01 was considered significant for the
paired t test analyses, to reduce the risk of a
type 1 statistical error occurring in view of
the multiple analyses earned out. All analy¬
ses were performed using SPSS version 6.1.3
for Windows.
RESULTS — The baseline fasting blood
glucose concentrations before each test meal
did not differ whether lispro was adminis¬
tered pre- or postprandially (Table 3).
Between-subjects ANOVA showed that nei¬
ther the order in which the test meals were
consumed nor the order of the timing of the
injection of lispro had an effect on the result¬
ing glycemic excursions (P > 0.05). No
significant difference existed in the mean
dose of lispro administered to subjects in
Group 1(12.7+1.3 U) compared with sub¬
jects in Group 2 (13.4 ±1.4 U).
High-carbohydrate liquid (CL) meal
When insulin lispro was administered
before the CL breakfast, the postprandial
glycemic excursion was modest, with a
mean peak rise in blood glucose of 2.0
mmol/1 (Fig. 1A). By contrast, when lispro
was administered after the test meal, a
significantly larger blood glucose excursion
was observed (P < 0.05), with the maxi¬
mum mean rise in blood glucose of 5.6
mmol/1 occurring at 45 min. The blood
glucose excursions at 30, 45, 60, and 75
min were all significantly higher with post-
meal administration of lispro (P < 0.01).
No subjects developed significant hypogly¬
cemia.
High-carbohydrate solid (CS) meal
Injection of insulin lispro before the CS
meal produced a much smaller blood glu¬
cose excursion compared with postprandial
administration of lispro (P < 0.05; Fig. IB).
After preprandial administration, a small
negative excursion of between 0.5 and 1.0
mmol/1 was observed during the initial 30
min after the start of the breakfast; there¬
after, the blood glucose excursion rose,
peaking at 1.0 mmol/1 at 90 min. In the
postprandial lispro studies, the mean blood
glucose excursion peaked at 3.5 mmol/1 at
45 min and was significantly higher than in
the preprandial lispro studies at 15,45, and
60 min after the test meal (P < 0.01). No
subjects developed significant hypogly¬
cemia.
High-fat liquid (FI.) meal
Administration of insulin lispro before the
FL breakfast was associated with a post¬
prandial glycemic excursion in which the
mean blood glucose varied little from base¬
line values (Fig. 1C). One subject devel¬
oped persistent, biochemical hypoglycemia
that provoked symptoms and necessitated
termination of the session after 60 min.
This subject started the study session with
a premeal blood glucose of 5.0 mmol/1 (the
lowest value recorded for any subject
ingesting the FL meal), which declined pro¬
gressively over 60 min to 2.7 mmol/1, at
which point the study was terminated.
Because a repeated-measures ANOVA can
only be performed on complete data sets,
the incomplete time course data from this
subject has not been included in the
ANOVA and subsequent t-test analysis. The
data presented in Fig. 1C are derived from
the remaining nine subjects, in whom
blood glucose did not fall below 3.0 mmol/1
at any time.
Administration of lispro after the FL
breakfast produced a significantly larger
blood glucose excursion (P < 0.05). No
subjects developed significant hypogly¬
cemia The blood glucose excursion
peaked at 5.2 mmol/1 at 45 min and was
significantly greater at 30, 45, 60, and 75
min than that observed following prepran¬
dial administration of insulin lispro (P <
0.01).
Higli-fat solid (FS) meal
Administration of insulin lispro before the
FS meal provoked a continuous decline in
blood glucose, so that by 120 min, mean
blood glucose was 3.4 mmol/1 below base¬
line concentrations (Fig. ID). One subject
developed persistent, symptomatic hypo¬
glycemia that necessitated termination of
the study session after 105 min. The sub¬
ject's premeal blood glucose was 6.4
mmol/1, and it fell progressively to 2.0
mmol/1, when the session was terminated.
Data from this subject have not been
included in the ANOVA analysis or in Fig.
ID. In two other subjects, blood glucose
fell below 3.0 mmol/1 by 120 min. In one
individual, premeal blood glucose was 11.7
mmol/1 and at 120 min was 2.8 mmol/1; in
the other subject, premeal blood glucose
was 7.4 mmol/1 and at 120 min was 2.6
mmol/1. In all other subjects, the blood
glucose remained above 3.0 mmol/1
throughout the study.
Postprandial administration of lispro
resulted in a significant rise in mean blood
glucose (P < 0.05), with a peak excursion
of 3.6 mmol/1 at 45 min. No subject devel¬
oped significant hypoglycemia. When
lispro was administered postprandially, the
blood glucose excursions were significantly
greater at all time points from 15 to 105
min inclusive (P < 0.01).
CONCLUSIONS — When the rise in
blood glucose after a meal is delayed or of
low magnitude, the rapid onset of action of
insulin lispro may potentially increase the
risk of early postprandial hypoglycemia.
The importance of meal composition in
determining the postprandial glycemic
response was highlighted in a recent study
of patients with 1DDM in which the injec¬
tion of lispro before the consumption of a
test meal with a low carbohydrate and high
fat content resulted in a higher frequency of
early postprandial hypoglycemia (14).
In the present study, the effects of pre-
and postprandial administration of insulin
lispro were compared in relation to test
meals of differing composition. The princi¬
pal aim of the study was to assess the risk
of early postprandial hypoglycemia, for
28 Diabetes Care, volume 21, number 1, January 1998
Strachan and Frier
15 30 45 60 75 90 105 120
Time (min)

















Figure 1-—Mean ± SE postprandial glycemic excursions for two treatment arms, after ingestion offour isocaloiic test meals: A: liquid high-carbohydrate
meal (CL); B: solid high-carbohydrate meal (CS); C: liquid high-fat meal (FL); D; solid high fat meal (FS). •, postprandial insulin lispro: ■, preprandial
insulin lispro. Time 0 represents the start of the test breakfast. *P < 0.01 for preprandial vs. postprandial insulin lispro. n = 10 for treatment arms of A
and B and n = 9 for treatment arms of C and D.
which a 2-h time course was thought to
suffice. Administration of all test rheals to
the entire cohort of subjects (which would
have required eight separate study sessions)
was considered to be an unrealistic demand
on the subjects' time. The two subject
groups were well matched demographi-
cally; and, in particular, the groups did not
differ with respect to glycemic control, total
daily insulin dose, or dose of lispro admin¬
istered.
Irrespective of the composition of the
test meal, the postprandial excursions of
blood glucose were lower when insulin
lispro was administered before rather than
after food. This resulted in better postmeal
glycemic control with high-carbohydrate
(low-fat) meals. Administration of lispro
before meals with a high fat (and low car¬
bohydrate) content produced a significant
fall in postprandial blood glucose when
the meal was predominantly in solid phase.
When the meal was in a more liquid form,
the blood glucose excursion was flat, pre¬
sumably because the liquid traversed the
stomach more rapidly (4,7,9). Complete
data sets were not obtained for either form
of the high-fat meal, as one subject devel¬
oped hypoglycemia during each premeal
lispro study. If complete data sets had been
available for analysis, a greater mean decre¬
ment in blood glucose might have been
observed when lispro was administered
before either type of high-fat meal. There¬
fore, when lispro is injected before meals
with a high fat content, particularly those
with a prominent solid phase, the resultant
postprandial fall in blood glucose may
induce early postprandial hypoglycemia,
especially if the premeal blood glucose is
relatively low (for example, <8 mmol/l).
However, if the premeal blood glucose is
high, the postprandial fall in blood glucose
may be acceptable and indeed desirable. In
the present study, when insulin Hspro was
administered after a high-fat breakfast,
postprandial blood glucose rose in most
subjects, and the risk of postprandial hypo¬
glycemia was minimal. The increments in
postprandial blood glucose were, however,
relatively high and might have been
restricted by administering the insulin
lispro immediately after the test meal,
instead of after an interval of 20 min.
The efficacy of the postprandial admin¬
istration of insulin lispro has been examined
in a previous study (15). Injection of lispro
15 min after the start of a test meal consist¬
ing of beef stroganoff produced a glucody-
namic pattern over 2 h that was comparable
to the pattern of regular human insulin
given either 20 min before or immediately
before the meal. The lowest postprandial
glucose excursion occurred when insulin
lispro was injected 20 min before the meal,
but this provoked early postprandial hypo¬
glycemia in some subjects (15), consistent
with the findings of the present study
A major premise of the present study
was that a meal with a high fat content may
be associated with a delayed glycemic
response by retarding gastric emptying.
However, gastric emptying is not influenced
solely by meal composition. Gastroparesis
diabeticomm is a rare but debilitating com¬
plication of diabetes (5). More subtle abnor¬
malities of gastric emptying have been
described in many individuals with diabetes
■?
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, of relatively long duration (5,9,16-21). Gas¬
tric emptying is also influenced by ambient
blood glucose concentration; hyperglycemia
( delays gastric emptying (22-24), whereas
if hypoglycemia promotes gastric emptying
£ (25-27). In the present study, the mean
basal blood glucose concentrations did not
| differ between the pre- and postprandial
lispro arms. The subjects had a mean dura¬
tion of IDDM of >10 years. None had any
symptoms suggestive of gastric stasis, and
the majority had normal cardiac autonomic
neural function. However, in the absence of
formal studies of gastric emptying, complete
normality of gastric emptying cannot be
asserted in all subjects, some ofwhom might
have had subclinical abnormalities of gastric
function.
In the present study, lispro was injected
subcutaneously into the anterior abdomi¬
nal wall, a site that is associated with a
rapid rate of absorption of insulin (28-30).
Administration of insulin lispro into an
alternative anatomical site, such as the arm
or the thigh, is associated with a slower
onset of glucose-lowering activity (28-30).
Therefore, when a person with IDDM
wishes to consume a high-fat meal, an
alternative strategy may be to inject insulin
lispro into the thigh instead of choosing a
postprandial time of administration. The
absorption of insulin from any injection site
is dependent on many variables (31-33),
however, and so the use of an injection site
from which the absorption of insulin is
usually slow may be a less reliable method
of avoiding hypoglycemia than adjusting
the time of injection in relation to meals. A
further means of avoiding early postpran¬
dial hypoglycemia would be to reduce the
dose of insulin lispro, but this may provoke
late postprandial hyperglycemia (14).
In conclusion, when a person with
IDDM consumes a meal with a high carbo¬
hydrate content, the preprandial adminis¬
tration of insulin lispro provides better
glycemtc control with little risk of early
postprandial hypoglycemia. By contrast,
when a person consumes a meal that has a
high content of fat mainly in a solid phase,
postprandial administration of lispro may
be more appropriate.
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Abstract
Background Neurone-specific enolase (NSE) and protein S-100 (S-100)
may be used as markers of acute neuronal damage in humans with
neurological disorders.
Method To evaluate their use following a single episode of severe
hypoglycaemia (defined as an episode requiring external assistance to aid
recovery), serum concentrations of NSE and S-100 were measured following
hypoglycaemia which had not caused persistent neurological impairment in
16 patients with insulin-treated diabetes (the 'hypo' subjects), and in three
diabetic patients who died following severe hypoglycaemia. The serum
proteins were also measured in 10 subjects with insulin-treated diabetes
who had not experienced an episode of severe hypoglycaemia within the
preceding year (the 'control' subjects).
Results No differences in serum concentrations of NSE and S-100 were
observed between the 'control' and the hypo' subjects at either 36 hours or
seven days after the episode of severe hypoglycaemia (p>0.05). However,
in two of the three subjects who died following hypoglycaemia, serum
concentrations of the markers were markedly elevated.
Conclusions Any neuronal injury occurring during severe hypoglycaemia
that is not associated with persistent neurological deficit is insufficient to
provoke elevation of these serum markers. However, the measurement
of serum concentrations of NSE and S-100 may have a prognostic role
in evaluating clinical outcome following severe hypoglycaemia which
is associated with neurological damage. Copyright © 1999 John Wiley &
Sons, Ltd.
Key words neurone-specific enolase; protein S-100; hypoglycaemia;
insulin-treated diabetes; neuroglycopenia
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Introduction
People with diabetes mellitus who receive treatment with insulin or oral
hypoglycaemic agents may experience transient or occasionally permanent
neurological abnormalities, such as hemiplegia, coma and convulsions, as a
consequence of severe hypoglycaemia [1-3]. Rarely decerebration and brain
death may supervene [1-3]. In addition, some studies have suggested that
CCC 1520-7S52/99/010005-08$ 17.50
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repeated exposure to severe hypoglycaemia may have
a cumulative effect, resulting in permanent, though
mostly modest, neuropsychological decrements [4—7].
The identification of serum markers that could predict
the degree of neuronal damage and prognosis of patients
after neurological injury, analogous to the measurement
of creatine kinase or troponin after myocardial infarc¬
tion, would have considerable clinical value. Two
proteins, neurone-specific enolase (NSE) and protein
S-100 (S-100), have shown promising results in this role.
NSE is a 78 kD glycolytic enzyme which originates
predominantly from the cytoplasm of neurones and
neuroendocrine cells [8]. Increased serum concentra¬
tions of NSE are found in patients with small-cell lung
cancer, neuroblastoma and neuroendocrine tumours [8].
Furthermore, the concentrations of NSE, both in
cerebrospinal fluid (CSF) and in serum, are elevated in
various neurological disorders [9-22]. In particular,
serum concentrations of NSE, measured in venous blood
within 48-72 hours of an acute stroke, correlate
significantly with clinical outcome [23-25].
S-100 is a calcium-binding protein which exists as
homo- or heterodimers of two subunits - a (10.4 kD)
and [i (10.5 kD) [26,27]. The aa-S-100 form is found
exclusively in neurones, a/)-S-100 is present in glial cells,
and pp-S-100 is found in glial cells and in Schwann cells
[27]. S-100 has also been detected in some non-neural
tissues, such as melanocytes [28] and adipose tissue
[29], and elevated serum concentrations of S-100 have
been reported in patients with malignant melanoma
[30], As with NSE, acute neurological injury causes
concentrations of S-100 to rise in CSF and in serum [11,
17,18,21,31-39] and concentrations of S-100 measured
in serum samples taken within 48 hours of an acute
stroke correlate significantly with clinical outcome [38].
At present, no biological markers are available which
can predict clinical outcome with accuracy after an
episode of severe hypoglycaemia. To our knowledge, the
effects of severe hypoglycaemia on serum levels of NSE
and S-100 have not been evaluated previously. Serum
concentrations of NSE and S-100 were therefore
estimated acutely in 16 diabetic patients experiencing
a single episode of severe hypoglycaemia which was not
associated with persistent neurological abnormality, in
3 diabetic patients who sustained profound brain
damage and subsequently died following an episode of
severe hypoglycaemia, and in 10 diabetic patients who
had not experienced an episode of severe hypoglycaemia
within the preceding year.
Patients and methods
Patients
The study was approved by the local medical ethics
advisory committee. Sixteen subjects were recruited
shortly after experiencing an episode of severe hypogly¬
caemia (the hypo' group), as part of a simultaneous
investigation of cognitive function following hypogly¬
caemia. Severe hypoglycaemia was defined, according to
the criteria used in the Diabetes Control and Complica¬
tions Trial (DCCT), as an episode that required external
assistance to aid recovery [40]. In addition, the blood
glucose concentration had to be documented as
2.8 mmol T1 or less and/or the clinical manifestations
had to have been reversed with oral carbohydrate,
subcutaneous glucagon, or intravenous glucose [40].
The hypo' subjects received treatment for the severe
hypoglycaemia either in the community or in the
hospital emergency department; none had experienced
persistent neurological dysfunction following restoration
of normoglycaemia. Nine of the subjects were treated
with intramuscular glucagon, two with intravenous
dextrose and five with oral carbohydrate. The subjects
treated with glucagon or dextrose all experienced
transient loss of consciousness at the time of hypogly¬
caemia. Where possible the history of hypoglycaemia
was verified by scrutiny of general practitioners' notes or
the hospital records, and by obtaining a contempora¬
neous account from a witness through completion of a
short questionnaire documenting the clinical signs
demonstrated by the affected patient, the nature of the
treatment administered and the subsequent response.
Ten subjects, who had not experienced an episode of
severe hypoglycaemia within the preceding year (the
'control' group), were studied. The subjects in the two
groups were matched for age, sex and duration of
diabetes (Table 1), and none had a previous history of
any neoplastic or neurological disorder that is known to
elevate serum NSE or S-100 concentrations. The mean
glycated haemoglobin (HbAlc) was lower in the 'hypo'
subjects than in the 'controls' (the non-diabetic range for
HbAlc was 5.0-6.5%; Table 1). The history of previous
severe hypoglycaemia in the control group was con¬
firmed by interview with the individual patients, by
scrutiny of hospital records and, where possible, by asking
a relative or friend to complete a short questionnaire
on when previous episodes of severe hypoglycaemia had
been experienced by the patients. Blood glucose con¬
centrations were measured concurrently to ensure that
no subjects were hypoglycaemic at the time of measure¬
ment of serum NSE and S-100.
Table 1. Clinical characteristics of subjects with Type 1 diabetes
and timing of blood samples
'Hypo' 'Control' Rvalue
40.0 (32.3-54.3) 30.0 (26.0-47.3) >0.05
10/6 5/5 >0.05






T1: Time to 1st blood
sample (days)
T2: Time between 1st and 7.1(6.6-7.4) 7.0(6.9-7.1) >0.05
2nd blood samples (days)
All values are median (inter quartile range).
8.2(7.6-9.4) 10.1(8.5-11.7) 0.02
1.5 (1.1-1.9)
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Timing of blood samples
Venous blood samples for measurement of NSE and
S-100 concentrations were taken at two time points
designated T1 and T2. In the case of the 'hypo' group, T1
was approximately 36 hours after the onset of the
hypoglycaemic event (Table 1), while in the 'control'
group, T1 represented the time of taking the first blood
sample. In both groups, the second blood sample (T2)
was taken approximately 7 days after the first blood
sample (i.e. approximately 8.5 days after the hypo¬
glycaemic event in the case of the 'hypo' group).
Measurements of serum NSE and S-100
concentrations
Blood was centrifuged at 1500 g for 10 minutes within 4
hours of venepuncture and sera were stored at -20°C.
Haemolysed samples were not analysed for NSE because
of the presence of this enzyme within erythrocytes and
platelets. All biochemical analyses were performed blind
to each patient's status.
NSE was measured by an enzyme immunological test
(Enzyme-Test NSE, Boehringer Mannheim Immunodiag-
nostics, Lewes, UK). The lower limit of detection of the
assay was 0.5 pgl"1; the intra-assay coefficient of
variation (CV) was 2.2% at 4.9 pgl-1 and 1.5% at
13.6 pg 1_1. The inter-assay CV was 5.8% at 23.1 pg l-1.
S-100 was measured by immunoradiometric assay
(IRMA Sangtec, Bromma, Sweden). The lower limit of
detection was 0.05 pg I-1; the intra-assay CVs were 2.8%
at 0.18 pg F1, 0.7% at 1.5 pg 1"1 and 0.8% at 5.3 pg l"1.
The inter-assay CVs were 3.3%, 4.4% and 1.5%
respectively.
Statistical analyses
All demographic data are presented as median (inter¬
quartile range), while the NSE and S-100 data are
presented as mean ± standard error of the mean.
Baseline characteristics of subjects were compared using
the Mann-Whitney U test, and the Chi-squared test was
used for categorical data. Differences in NSE and S-100
concentrations between the hypo' and 'control' groups,
at the two time points, were compared using a mixed
model analysis of variance (ANOVA) with group ('hypo'
or 'control') as a between subjects factor and time (T1 or
T2) as a repeated measure. A p-value of less than 0.05
was considered to be significant. All analyses were
performed using SPSS version 7.5.1 for Windows 95.
Case histories
Three diabetic subjects who died following severe
hypoglycaemia were also studied and their histories
are described below.
Patient 1
A 49-year-old Caucasian male with Type 1 diabetes for
four years, who had a previous history of frequent
hypoglycaemia and alcohol dependence, was found
unconscious at home. He had been drinking heavily in
the previous two weeks during which frequent biochem¬
ical hypoglycaemia had been recorded with routine home
blood glucose monitoring. When found comatose, his
blood glucose concentration was less than l.Ommol 1_1
and he was given intramuscular glucagon and intravenous
dextrose. On admission to hospital, the patient was
comatose, with a Glasgow Coma Scale (GCS) of 4, was
haemodynamically stable, but had hypotonia and bilateral
extensor plantar responses. A CT brain scan showed no
evidence of cerebral oedema or raised intracranial
pressure. The patient was intubated and ventilated and
received infusions of mannitol and phenytoin to control
mild epileptiform activity. He was extubated five days
later, but his conscious level remained depressed with a
GCS of 5. He subsequently developed bronchopneumonia
and died 11 days after admission. Blood samples for NSE
and S-100 level estimation were obtained approximately
24 hours after the onset of hypoglycaemia (Tl) and seven
days later (T2).
At autopsy, the lungs showed extensive bronchopneu-
monic consolidation. Brain histology showed mild sulcal
widening and generalised vascular congestion consistent
with agonal hypoxia. There was a mild degree of white
matter pallor and rarefaction with U-fibre sparing,
indicative of mild cerebral oedema, but no mid-line
shift or evidence of herniation were noted. The brunt of
neuronal damage was borne by the hippocampus where
there was severe neuronal depletion with corresponding
gliosis, most marked in the CA4 and CA1 zones
(Figure 1), with acidophilia of remaining neurones.
Neurones of the dentate gyrus showed conspicuous
acidophilia. The neocortex contained scattered acido¬
philic neurones, particularly in layers 2 and 3 and at the
depths of sulci. These changes were most severe in
temporal neocortex, where similar changes were also
Figure 1. Section of CA4 zone of the hippocampus from
Patient 1. There are numerous reactive gemistocytic astro¬
cytes (arrows) and neurones are completely absent. (Haema-
toxylin and eosin x 360)
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seen in layer 4. The basal ganglia, hypothalamus, brain
stem, cerebellum and spinal cord were unaffected and,
in particular, cerebellar Purkinje cells were intact. There
was no evidence of recent traumatic brain damage,
inflammation, haemorrhage, regional infarction or Wer¬
nicke's encephalopathy.
Patient 2
A 27-year-old Caucasian male with a 4-year history of
Type 1 diabetes for 4 years was found unconscious (GCS
3) at home, having last been seen awake 13 hours
previously following a row with his girlfriend. Two
empty vials of porcine soluble insulin and three insulin
syringes were lying beside him, suggesting that he had
self-administered a large dose of insulin. Blood glucose
was less than 1 mmol l"1 and intramuscular glucagon
was administered. On admission, the patient was
tachypnoeic with extensor posturing and a CT brain
scan showed evidence of cerebral oedema. He was
intubated and ventilated for 24 hours without clinical
improvement. All active intervention was subsequently
withdrawn and the patient died shortly after. Blood
samples for NSE and S-100 level estimation were
obtained approximately 18 hours after the onset of
hypoglycaemia (Tl).
A post mortem revealed acute bronchitis and right
lower lobe bronchopneumonia. Histological examination
of the brain revealed widespread swelling and breakdown
of the blood-brain barrier. There was global transcortical
neuronal shrinkage and acidophilia (Figure 2). Acute
inflammation was limited to the temporal neocortex
and leptomeninges. Similar neuronal changes were
Figure 2. Section of the superficial cortex (layer 2) front
Patient 2. There is neuronal acidophilia with shrinkage in the
cingulate gyrus. (Haematoxylin and eosin x 360)
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present in the CA1 to CA4 zones of the hippocampus,
proximal subiculum, dentate gyrus, head of the caudate
nucleus, putamen and, to a lesser extent, globus
pallidus. Relative neuronal sparing was observed in the
distal subiculum, angle of the dentate gyrus, caudate tail
and claustrum, as well as selected larger neurones in the
basal ganglia. Selective superficial cortical damage was
seen in the cingulate gyri. Thalamic neurones were
distorted due to transtentorial herniation, while the
mid-brain and pons showed oedema, patchy infarction
and Duret haemorrhage due to terminal brain stem
herniation and compression. Other significant features
included basal ganglia microcalcification and relative
Purkinje cell preservation in the cerebellum.
Patient 3
A 47-year-old man with a 30-year history of poorly
controlled insulin-dependent diabetes was found uncon¬
scious in hospital before breakfast, 7 days following an
aortic valve replacement operation. Blood glucose was
less than 1 mmol 1 1 and he was treated with intrave¬
nous dextrose. During this episode, the patient had a
grand mal seizure which was complicated by aspiration
of gastric contents and a respiratory arrest. He was
intubated and ventilated and initial CT scan of the brain
showed no intracerebral abnormality, although a repeat
scan 2 days after the episode showed gross cerebral
oedema. Despite treatment with mannitol and dexa-
methasone, his conscious level remained depressed and
the patient died 33 days following the episode of severe
hypoglycaemia. Permission was not obtained for an
autopsy. Serial blood samples were obtained for S-100
level estimation only.
Results
The NSE and S-100 data for the 'hypo' and 'control'
patients are presented in Figures 3 and 4. There was no
significant effect of group (F=0.09, p>0.05) or time
(F=4.09, p>0.05) on mean serum NSE concentrations.
The group by time interaction was also not significant
(F=0.75, p>0.05). Similarly, the main effects of group
(F= 1.09, p>0.05), time (F=2.12, p>0.05) and group by
time (F=2.37, p>0.05) did not reach statistical sig¬
nificance for mean serum S-100 concentrations.
The NSE and S-100 concentrations of Patient 1 were
comparable with the 'control' patients at both time
points (Figures 3 and 4). In Patient 2, however, NSE
and S-100 concentrations were markedly elevated, at
approximately 8 and 130 times respectively, the levels
noted in the 'control' subjects (Figures 3 and 4). In
Patient 3 there was also a large rise in S-100 levels,
which peaked at 24 hours after the episode of severe
hypoglycaemia; S-100 concentrations fell thereafter, but
were still above baseline levels at 17 days (Figure 5).
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T1 T2
Time Period
Figure 3. Serum concentrations of NSE at T1 and T2 in the 'hypo' and 'control' subjects, and in Patients 1 and 2. There was
no significant difference between 'hypo' and 'control' subjects in concentrations of NSE at either time point (p>0.05). Serum
NSE concentrations did not rise in Patient 1, but were markedly elevated in Patient 2
T1 T2
Time Period
Figure 4. Serum concentrations of S-100 at T1 and T2 in the 'hypo' and 'control' subjects, and in Patients 1 and 2. There was
no significant difference between 'hypo' and 'control' subjects in concentrations of S-100 at either time point (p>0.05). Serum
S-100 concentrations did not rise in Patient 1, but were markedly elevated in Patient 2
3
Day1 Day 2 Day 3 Day 4 Day 11 Day 12 Day 13 Day 14 Day 15 Day 16 Day 17
Time
Figure 5. Time course of serum concentrations of S-100 in Patient 3 from the day of the episode of severe hypoglycaemia
(Day 1) to 17 days afterwards. The S-100 concentrations peaked 24 hours after the detection of severe hypoglycaemia, but
remained elevated up to Day 17
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Discussion
Acute hypoglycaemia in humans provokes neurological
dysfunction with evidence of cognitive impairment and
neurophysiological and EEG abnormalities. The possible
clinical sequelae of an episode of severe hypoglycaemia
vary widely, ranging from complete recovery to perma¬
nent neurological disability or, rarely, death [1-3]. Even
when neurological recovery is apparently complete,
recurrent exposure to severe hypoglycaemia may result
in cumulative cognitive decrements [4—7], presumably
because of chronic, low-level neuronal damage. When
significant neuronal destruction does occur during acute
hypoglycaemia, it may be very difficult in the early
stages to predict the likely clinical outcome. The patient's
condition may be affected by other intercurrent illness,
pharmacologically induced sedation, or the need for
artificial ventilation. CT scanning of the brain, while
providing valuable information, may show no intracer¬
ebral abnormality initially (as in Patient 3), despite
significant neuronal damage. Therefore, any measurable
biological index that could assist with prediction of the
likely clinical outcome after an episode of severe
hypoglycaemia would be of value in planning the
optimal medical management for affected patients.
NSE and S-100 offer such a possibility, because serum
concentrations of both proteins are elevated following
neuronal damage from other causes and correlate with
clinical outcome after stroke [23-25,38], Acute changes
in the serum levels of these markers have not been
examined previously in diabetic patients exposed to
severe hypoglycaemia.
The present pilot study has demonstrated that serum
concentrations of NSE and S-100 did not alter sig¬
nificantly in diabetic patients who had made a complete
neurological recovery following an episode of severe
hypoglycaemia, either at 36 hours or 8.5 days after the
event. Previous studies in patients with various cerebral
disorders, particularly stroke, have shown consistently
that serum concentrations of NSE and S-100 become
elevated within 48 hours of the acute insult and remain
so for several days, or even weeks, afterwards [21,
23-25,38] and indeed such a pattern of S-100 concen¬
trations was seen in Patient 3. Therefore, in the present
study, it is unlikely that a transient rise in semm NSE
and S-100 had occurred in the hypoglycaemia patients at
the times other than those of the blood sampling.
Fortunately, episodes of severe hypoglycaemia which
result in permanent neurological abnormality are
relatively rare in clinical practice, but we were able to
measure the changes in serum concentrations of NSE
and S-100 before death in three fatal cases. The serum
concentrations of NSE and S-100 were low in the
diabetic patient who died nearly two weeks following an
episode of severe hypoglycaemia and whose neuronal
damage was centred primarily on the hippocampus. The
significant CA1 and end-folial hippocampal damage may
at least partly have pre dated the fatal illness, and would
Copyright © 1999 John Wiley & Sons, Ltd.
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be consistent with damage from previous episodes of
hypoglycaemia [41—43]. However, the acidophilia of the
remaining neurones in the hippocampus implies that
acute neuronal damage had also occurred at the time of
the episode of severe hypoglycaemia that preceded
death. The patient's seizures were mild and were treated
promptly, and while they may have contributed to the
hippocampal damage, they are unlikely to have been the
principal cause.
By contrast, serum concentrations of NSE and S-100
were markedly elevated in a young diabetic patient who
died within 48 hours of the development of profound
neuroglycopenia, after a probable deliberate insulin
overdose. This patient suffered very extensive brain
damage. The involvement of the dentate gyrus and the
relative preservation of Purkinje cells and neurones of
larger basal ganglia and deep cingulate cortex are
consistent with the effects of hypoglycaemia [41-43],
although there is overlap between the neuropathological
effects of hypoglycaemia, hypoxia/ischaemia and sei¬
zures. In addition, serum concentrations of S-100 were
significantly elevated in a middle-aged patient who had a
prolonged episode of severe hypoglycaemia, seven days
following cardiac surgery. Initial serum concentrations
of S-100 were low and CT scan of the brain was normal.
However, within 24 hours of the episode, S-100 levels
had risen significantly and a subsequent CT scan
confirmed gross cerebral oedema. Serum S-100 concen¬
trations remained elevated, albeit at lower levels, for
several days afterwards. This patient had a grand mal
seizure and a respiratory arrest which were treated
promptly, but both events may have contributed to the
subsequent neurological damage and the rise in S-100
concentrations.
In both the above cases, the serum concentrations of
the neurological markers were elevated to levels
equivalent to those observed after a large ischaemic
cerebral infarction [25,381. Following acute stroke,
elevations in serum concentrations of NSE and S-100
are related to the size of the cerebral infarction [25,38].
Thus, NSE and S-100 levels may not rise following small
strokes where only modest degrees of acute neuronal
injury have occurred. Therefore, the results from the
patients who made a complete neurological recovery
following the severe hypoglycaemic episode should not
be interpreted as implying that no neuronal damage has
taken place. It is possible that a degree of neuronal
injury did occur, but at a level that was below the
detection of the NSE and S-100 assays.
The fact that serum concentrations of the neuronal
markers rose in two of the three patients who
subsequently died following an episode of severe
hypoglycaemia raises the prospect that NSE and S-100
may have a role in predicting both the severity of
neuronal damage and the clinical outcome of patients
who remain comatose following prolonged severe
hypoglycaemia. The potential value of using such
markers is that they are easy to measure, are relatively
inexpensive and show a rapid response following acute
Diabetes Metab Res Rev 1999; 15: 5-12.
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neurological insult which causes neuronal damage.
Therefore prognostic information could be available to
clinicians at an early stage of management, and possibly
before any abnormality is detectable by neuroimaging
techniques.
In conclusion, the present study suggests that serum
concentrations of NSE and S-100 do not rise in patients
who have experienced an individual episode of severe
hypoglycaemia without persistent neurological impair¬
ment. However, measurement of the serum concentra¬
tions of these proteins could have prognostic value in
patients who remain comatose following prolonged
severe hypoglycaemia. This requires validation in a
larger series of patients experiencing hypoglycaemic
coma, with or without cerebral oedema, relating the
increments in these serum markers to clinical outcome
and neuropathological findings.
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Recovery of Cognitive Function and
Mood After Severe Hypoglycemia in
Adults With Insulin-Treated Diabetes
Mark W.J. Strachan, mrcp Fiona M.E. Ewing, mrcp
Ian J. Deary, phd Brian M. Frier, frcpe
OBJECTIVE — Acute hypoglycemia in humans impairs cognitive functions and alters
mood states. The time required for cognitive functions and moods to return to normal after an
acute episode of severe hypoglycemia is unknown.
RESEARCH DESIGN AND METHODS — Cognitive functions and moods were stud¬
ied prospectively in 20 subjects with insulin-treated diabetes who had recently experienced a
spontaneous episode of severe hypoglycemia ("hypo" subjects) and 20 matched control sub¬
jects with insulin-treated diabetes who had not experienced severe hypoglycemia during the
preceding year. The hypo subjects had a history of a greater number of episodes of severe hypo¬
glycemia (P = 0.000). Cognitive function tests and mood scales were administered at 1.5,9, and
30 days after the severe hypoglycemia and at similar iniervals for the control subjects.
RESULTS - For most of the cognitive tests, no evidence of a "hangover" effect of the acute
hypoglycemia on cognitive function was observed (P > 0.05). A trend was noted for levels
of hedonic tone (P = 0.082) and energetic arousal (P = 0.053) to improve with time in the hypo
subjects but not in the control subjects. However, the hypo subjects had chronically elevated
levels of depression (P = 0.011) and anxiety (P = 0.049) and persistently performed more
poorly in several cognitive tests, such as the Digit Symbol Test (P = 0.009) and the Stroop Task
(P = 0.007).
CONCLUSIONS — These results suggest that, in general, recovery from any acute cogni¬
tive decrement after severe hypoglycemia was complete by 1.5 days. The cognitive decrements
and altered mood states noted in the hypo subjects may be persistent and may be a consequence
of previous exposure to recurrent episodes of severe hypoglycemia.
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Acute hypoglycemia induces cognitivedysfunction as a consequence of neu-roglyco enia. Cog itive functions
that deteriorate include simple and choice
reaction times, speed of arithmetic calcula¬
tion, verbal fluency, color identification,
trail making and digit, symbol test perfor¬
mance, digit span, and other short-term
memory indices (1). Mood states are also
affected by mild hypoglycemia, which
causes a reduction in levels of energetic
arousal and an increase in tense arousal (2).
Acute hypoglycemia can provoke
longer-term effects, even after normo-
glycemia has been restored. In nondiabetic
and diabetic subjects, the symptomatic and
neuroendocrine responses to acute hypo¬
glycemia are diminished after antecedent
(episodic) hypoglycemia that has occurred
within the previous 72 h (3—7). Indeed, the
catecholamine response to hypoglycemia
may take between 6 days and 4 weeks to
return to a normal magnitude (8). The
effects of acute mild hypoglycemia on cog¬
nitive functions appear to be less prolonged,
in that cognitive function recovers within 1 h
of the restoration of normoglycemia (9—13).
The long-tenn effects of acute hypoglycemia
on other mental states such as mood and
general well-being have received less atten¬
tion. Mood changes during acute hypogly¬
cemia persist for at least 30 min after
restoration of normoglycemia (2), whereas
relatively brief nocturnal hypoglycemia is
not associated with any cognitive impair¬
ment the following morning (14,15) but is
associated with greater levels of fatigue in
response to exercise the next day (15).
Severe hypoglycemia, which is defined
as an episode requiring external assistance
for recovery, causes pronounced neurogly-
copenia that results in a profound degree of
cognitive dysfunction and (rarely) can
cause permanent neurological impairment
(16-18). Fortunately, most patients appear
to make a complete and rapid recovery
after normoglycemia is restored, although
anecdotal observation suggests that some
patients have cognitive impairment for
more protracted periods. Exposure to
repeated episodes of severe hypoglycemia
may possibly result in persistent cognitive
impairment in some patients (19-23),
although this has been disputed (24,25).
No previous studies have examined the
timing of recovery of cognitive function and
mood after a single episode of severe hypo¬
glycemia. Delayed recovery of cognitive
functions after severe hypoglycemia could
have potentially important effects on perfor¬
mance of activities such as work or driving.
The purpose of the present study was to
examine the temporal changes in mood
states and cognitive functions after a single
spontaneous episode of severe hypoglycemia
in people with insulin-treated diabetes.
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Table 1—History of episodes of severe hypo¬
glycemia
Episodes
Subjects Never 1-2 3-5 >5
Hypo 0 4 4 12
Control 13 3 2 2
Data are n.
RESEARCH DESIGN AND
METHODS — The study was approved
by the local medical ethics advisory com¬
mittee, and all subjects gave written
informed consent after the nature of the
study was explained. A total of 40 subjects
with insulin-treated diabetes were studied,
most of whom were attending the Diabetes
Outpatient Department at the Royal Infir¬
mary of Edinburgh for regular review. Of
the subjects, 20 had experienced a recent
episode of severe hypoglycemia (the "hypo"
group) and 20 had not experienced severe
hypoglycemia (the control group) during
the preceding year. Most of the hypo
patients were recruited after they received
treatment in the Accident and Emergency
Department of the hospital or after their
hospital admission.
Severe hypoglycemia
Severe hypoglycemia was defined according
to the criteria used in the Diabetes Control
and Complications Trial as an episode that
required external assistance to aid recovery
(26). In addition, the patient's blood glucose
concentration had to be documented at
£2.8 mmol/1, and/or the clinical manifesta¬
tions had to have been reversed with oral
carbohydrate, intramuscular glucagon, or
intravenous glucose (26).
The hypo subjects received treatment
for the severe hypoglycemia either in the
community or in the hospital emergency
department; none had experienced persis¬
tent neurological dysfunction after the
restoration of normoglycemia. Of the sub¬
jects, 11 were treated with intramuscular
glucagon, 2 were treated with intravenous
dextrose, 2 were treated with a combination
of intravenous dextrose and intramuscular
glucagon, and 7 were treated with oral car¬
bohydrate. All subjects who required par¬
enteral glucagon or dextrose reported a
transient loss of consciousness at the time of
hypoglycemia. Where possible, the patients
history of hypoglycemia was verified by
scrutinizing contemporaneous notes made
by the patient's general practitioner (family
physician) or the hospital case records and
by obtaining a direct account from a witness.
The latter involved completion of a short
questionnaire documenting the clinical fea¬
tures demonstrated by the affected patient,
die nature of the treatment administered,
and the patient's subsequent response. The
history of previous severe hypoglycemia in
the control group was confirmed by inter¬
viewing the individual patients, by scruti¬
nizing hospital case records, and, where
possible, by asking a relative or friend to
complete a short questionnaire regarding
previous episodes of severe hypoglycemia
that the patient had experienced. Hypogly¬
cemia history was graded on a four-point
scale: 1 = no previous episodes of severe
hypoglycemia, 2 = one or two previous
episodes, 3 = three to five previous episodes;
4 = more than five previous episodes. The
hypo subjects had a history of a significantly
greater number of previous episodes of
severe hypoglycemia than the control sub¬
jects (Table 1; P = 0.000). None of the hypo
subjects experienced further exposure to
severe hypoglycemia during the follow-up
period of the study.
Patient characteristics
One subject in each group had insulin-
treated type 2 diabetes, and all other subjects
had type 1 diabetes. All patients had received
routine annual assessment in a diabetes out¬
patient clinic within the previous year, and
none had evidence of macrovascular disease.
Few patients in either group had evidence of
diabetic microangiopathy. Subjects were
excluded if they had a history of cerebrovas¬
cular disease, previous head injury, epilepsy,
serious systemic disease, or major psychiatric
illness or if they were taking medication that
could alter cognitive function, such as psy¬
chotropic agents or steroids. The corrected
visual acuity of all subjects was 20/30 or bet¬
ter. Hypoglycemia awareness was assessed by
using a visual analog scale from 1 to 7 (1 =
always aware of the onset of hypoglycemia, 7 =
never aware of the onset of hypoglycemia).
When using this scale, a score of S4 has
been associated with impairment of hypo¬
glycemia awareness (27). HbAlc was mea¬
sured at two time points (tj and t3) using
high-performance liquid chromatogra¬
phy (A. Menanni Diagnostic, Firenze, Italy)
based on an ion-exchange reverse-phase par¬
tition method (Hi Auto Ale HA 8121). The
nondiabetic range for HbAlc measured in
our laboratory is 5.0-6.5%.
The clinical characteristics of the sub¬
jects are shown in Table 2. The subjects in
the two groups were well matched regard¬
ing age, sex, BMI, and duration of diabetes.
Mean HbA]c concentrations did not change
significantly in either group throughout the
duration of the study (data not shown), but
the hypo subjects had a lower mean HbAlc
level and a tendency toward a higher total
insulin dose than the control subjects (Table 2).
The mean hypoglycemia awareness scores
were higher iri the hypo group than in the
control group (Table 2), and nine subjects in
the hypo group had a score of S4 on the
visual analog scale versus only one patient
in the control group (P = 0.003).
Neuropsychological testing
Subjects underwent comprehensive neu¬
ropsychological testing at three time points
(tj, t2, and t3) during a period of 1 month. To
minimize any potential effect of sleep depn-
vation on the results of the cognitive tasks,
all subjects had at least one night of undis¬
turbed sleep before testing. For the hypo
subjects, this involved ensuring that they
had obtained a full night of sleep after the
episode of severe hypoglycemia, and there¬
fore tj took place a mean of 1.5 days after, t2
took place a mean of 8.9 days after, and t3
took place 30 days after severe hypogly¬
cemia. The control subjects were tested at




































comparable time intervals (P > 0.05). Blood
glucose was measured on three occasions
during the cognitive testing sessions (begin¬
ning, middle, and end). Subjects were
allowed to consume a snack if necessary to
ensure that blood glucose concentrations
did not fall to <4.0 mmol/1 during testing.
The neuropsychological test battery
provided a comprehensive assessment of
the main cognitive domains, including
fluid intelligence, memory, attention and
concentration, frontal lobe function, infor¬
mation processing, and mood state. Perfor¬
mance of many of the tests has been shown
previously to be impaired during acute
hypoglycemia in diabetic and nondiabetic
subjects (1,28). The order of the tests
remained constant for each session. Where
appropriate, subjects underwent a brief
practice session with each test before the
recorded performance. The cognitive test
battery included the following tests:
• Wechsler Adult Intelligence Scale-
Revised (WAIS-R) performance intelli¬
gence quotient (1Q) subtests (29);
• National Adult Reading Test (NART) (30);
• Forward (FDS) and Backward (BDS)
Digit Span (29);
• Trail-Making Test B (TMB) (31);
• Logical Memory (LM) (immediate and
delayed recall) (32);
• Figural Memory (FM) (32);
• Inspection Time (IT) (28);
• Visual Change Detection (VCD) (28);
• Borkowski Verbal Fluency Task (33);
• Paced Auditory Serial Addition Task
(PASAT) (34),
• 1-, 2-, 4-, and 8-Choice Reaction Time
(RT) (35);
• Stroop Task (36);
• University of Wales Institute of Science
and Technology (UW1ST) Mood Adjec¬
tive Checklist (37);
• Hospital Anxiety and Depression Scale
(HAD) (38); and
• Cognitive Function Self-Appraisal Scale
(CFSA) (39).
Many of the performance IQ subtests
of the WAIS-R were subject to a practice
effect (i.e., performance improved signifi¬
cantly after repeated administrations of the
task). Therefore, performance IQ was mea¬
sured solely at t,; at the subsequent ses¬
sions, only the Digit Symbol (DS) and
Block Design (BD) tasks were used because
these were subject to the least practice
effect. The NART is resistant to the effects of
organic brain damage and thus provides a
measure of "best" global cognitive function
ever attained regardless of time (30). The
NART was measured during only. An IQ
decrement index was calculated by sub¬
tracting the present IQ (as measured by the
WAIS-R performance IQ subtests) from the
premorbid IQ (as estimated by the NART).
Statistical analyses
All data are presented as means ± SD. To
allow comparison of the effects of severe
hypoglycemia on the different cognitive
tasks and mood scores, the individual test
scores have been standardized in a Z score
format such that the mean score for each
test is 0 with an SD of 1. Baseline charac¬
teristics of subjects were compared using
Student's t tests for unpaired samples, and
the x2 test was used for categorical data.
Differences in individual cognitive test
scores between the hypo and control
groups at the three time points were com¬
pared before standardization using a mixed
model analysis of variance (ANOVA) with
group (hypo or control) as a between-sub-
jects factor and time (tp t2, or t3) as a
repeated measure. Simple effects (unpaired
two-tailed t tests) at particular time points
were examined only when significant
group and/or interaction effects occurred.
The principal outcome statistic was any
group-by-time interaction in the ANOVA.
This statistic can indicate evidence of
"catch-up" on behalf of the hypo group,
which may be hypothesized to underper-
form at the first and perhaps the second
time points. Significant main effects for
group indicate the overall superiority of
the hypo or control groups on the test. Sig¬
nificant effects of time are expected and
indicate practice effects on the tasks.
Where significant simple effects were
evident, cognitive and mood outcome
scores were adjusted for individual differ¬
ences in severe hypoglycemia histoiy (with
the four-point hypoglycemia scoring sys¬
tem) using univariate linear regression. The
group effect on the standardized adjusted
scores was subsequently examined using
Student's t tests at the appropriate time
points. This was an attempt to test the
hypothesis that any cognitive impairment
was secondary to exposure to previous
episodes of severe hypoglycemia.
P < 0.05 was considered to be signifi¬
cant given the exploratory nature of this
study. The risk of a type 1 statistical error
could be reduced by applying the Bonfer-
roni correction in which P < ~0.004
would be accepted as evidence of statistical
significance for the 12 main cognitive
parameters measured. All analyses were
performed using SPSS Version 7.5.1 for
Windows 95 (Chicago).
RESULTS
Baseline cognitive function and IQ
decrement index
No significant difference in mean NART
error scores was observed between the
hypo subjects (20.9 ± 9.1) and the control
subjects (19.9 ± 5.0) (P = 0 65), which
indicates that the two groups were well
matched regarding premorbid IQ. The
actual performance IQ of the hypo sub¬
jects, which was measured at t,, was on
average 6.8 ± 10.8 points lower than would
have been predicted by the NART score
(the IQ decrement index). By contrast, the
actual performance IQ of the control sub¬
jects was 1.7 ± 10.2 points higher than pre¬
dicted (P = 0.015). Thus, the mean
difference in baseline performance IQ
between the two groups was 8.5 points.
The standard means ± SD of the scores
of the remaining cognitive tests, mood
scales, and memory questionnaire are
shown in Tables 3 and 4.
Group-by-time interactions on
cognitive and mood tasks
Significant group-by-time interactions were
found with the BD (P = 0.008), PASAT 4 sec¬
ond (P = 0.020), and VCD (P = 0.028) tasks.
In the cases of the BD and PASAT tasks, the
interaction reflected significant differences
between the two groups at t} that were not
present at t2 or t^. The interaction for the
VCD task represented an apparently anom¬
alous difference between the groups at (2
(with the hypo subjects actually attaining
better scores) that was not statistically sig¬
nificant (P = 0.065) and that was not present
at t
j or ty The interactions for the Hedonic
Tone (P = 0.082) and Energetic Arousal (P =
0.053) subscales of the UWIST Mood Adjec¬
tive Checklist approached statistical significance,
although none of the simple effects was sig¬
nificant. No other cognitive or mood tests
demonstrated a statistically significant
group-by-time interaction (P > 0.05).
Main effects of group on cognitive tests
The hypo group performed significantly
poorer overall on the DS (P = 0.009), PASAT
4 second (P = 0.043), FDS (P = 0.014), and
BDS (P = 0.021) tasks compared with the
control subjects. In addition, the hypo sub¬
jects performed more poorly than control
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Table 3—Cognitive test results
Time point Hypo vs. Group-by-time Simple effects
£2 <3 control Time interaction 't £2 (3
DS
Hypo -0.75 (0.91) 0.35 (1.06) -0.05 (0.95) 0.009 0000 0 322 0 003 0.017 0.019
Control 0.11 (0.80) 0.41 (0,86) 0.64 (0.82)
BD
Hypo -0.74 (0.84) -0.03(1.12) -0.04(1.07) 0.060 0.000 0.008 0.003 0.453 0.080
Control 0.09 (0.83) 0.22 (0.97) 0.50 (0.80)
Scroop Task (Incongruent Colors)*
Hypo 1.05(1.43) 0.14(0.89) -0.15(0.64) 0.007 0.000 0.214 0.016 0.025 0.015
Control 0.10(0.60) -0.47 (0.66) -0.66 (0.57)
PASAT 4 second
Hypo -0.79(1.46) -0.06 (0.97) -0.01 (0.87) 0.043 0.000 0.020 0.020 0 113 0.142
Control 0.13(0.81) 0.36(0.61) 0.36 (0.68)
PASAT 2 second
Hypo -0.62 (0.91) -0.25(1.04) 0.10(1.01) 0.073 0.000 0.902 - — —
Control -0.15 (0.82) 0.29 (0.95) 0.63 (0.85)
FDS
Hypo -0.19(0.90) -0.41 (1.10) -0.41 (1.04) 0.014 0.743 0.459 0.167 0.037 0.009
Control 0.30 (0.97) 0.38 (0.78) 0.33 (0.90)
BDS
Hypo -0.35(1.26) -0.31 (0.79) -0.28 (0.82) 0.021 0.233 0.470 0.109 0.013 0.021
Control 0.14(0.89) 0.27 (0.90) 0.53(1.02)
Borkowski Verbal Fluency (total)
Hypo -0.45 (0.92) -0.25 (0.87) 0.13(1.08) 0.188 0.000 0.784 — — —
Control -0.12(1.00) 0.1.1 (0.90) 0.58 (0.99)
TMB*
Hypo 0.59(1.52) 0.08 (1.02) 0.09(1.10) 0.109 0.000 0.293 — — —
Control -0.03 (0.63) -0.29 (0.55) -0.44 (0.57)
LM (immediate recall)
Hypo -0.55 (0.86) 0.42 (1.13) 0.01 (0.78) 0.750 0.000 0.688 — — —
Control -0.31 (0.88) 0.42 (0.93) 0.00(1.09)
LM (delayed recall)
Hypo -0.62 (0.96) 0.34(1.13) 0.07 (0.65) 0.551 0.000 0,733 — — —
Control -0.33(1.19) 0.44(1.11) 0.11 (0.84)
FM
Hypo -0,03 (0.82) 0.01 (0.92) 0.20(1.03) 0.627 0.014 0.289 — — —
Control
IT*
-0.35(1.19) -0.22(1.15) 0.39 (0.76)
11
Hypo 0.37 (1.02) -0.19(0.65) -0.30 (0.54) 0.761 0.004 0.180- — — —
Control 0.15(1.02) 0.05 (0.93) -0.08(1.51)
VCD
Hypo -0.05(1.06) 0.38 (0.97) 0.13(0.98) 0.298 0.014 0.028 0.453 0.065 0.756
Control -0.28 (0.89) -0.22(1.03) 0.03 (1.04)
8-Choice RT (Median
Decision Time)*
Hypo 0.35(1.05) 0.04 (1.01) -0.08 (0.99) 0.647 0.000 0.608 — — -
Control 0.08(1.06) -0.16(0.90) -0.22 (1.01)
8-Choice RT (Median
Movement Time)*
Hypo 0.31 (1.04) 0.05(1.3) -0,01 (1.3) 0 417 0.000 0.802 — — —
Control 0.04(0.71) -0.19(0.82) -0.21 (0.68)
CFSA
Hypo 0.68(1.08) 0.40(1.08) 0.23(1.20) 0.002 0.005 0.445 0.001 0.004 0.021
Control -0.32 (0.59) -0.47 (0.63) -0.52 (0.65)
Data are means ± SD of standardized cognitive test scores [2 scores). *Cognitive test where a lower score indicates better performance, in the remaining tasks, a higher
score indicates belter perfonnance.
308 Diabetes Care, volume 23, number 3, March 2000
Strachan and Associates
Table 4—Mood scale results
P
Time point Hypo vs. Group-by-time Simple effects
Mood scale t. t2 t3 control Time interaction t2 t2 t}
UW1ST Hedonic Tone
Hypo -0.50(1.25) -0.02(0.87) -0.07(1.05) 0.167 0.014 0.082 — —
Control '• 0.15(0.98) 0.40(0.84) 0.03(0.85)
UWIST Tense Arousal
Hypo 0.57(1.09) 0.12(0.99) -0.05(0.97) 0.101 0.006 0.489 — —
Control 0.02(0.99) -0.39(0.85) -0.27(0.94)
UWIST Energetic Arousal
Hypo -0.31 (1.15) -0.19(0.87) 0.01 (0.94) 0.263 0.813 0.053
Control 0.23(1.05) 0.24(1.10) 0.02(0.85)
HAD Anxiety
Hypo 0.63(1.23) 0.15(1.07) 0.07(1.12) 0.049 0.001 0.178 0.017 0.102 0.179
Control -0.17(0.60) -0.32(0.68) -0.36(0.86)
HAD Depression
Hypo 0.41 (0.80) 0.39(0.96) 0.30(1.31) 0.011 0.547 0.994 0.008 0.018 0.036
Control -0.31 (0.84) -0.35 (0.93) -0.43 (0.76)
Data are means ± SD of standardized mood scale scores (Z scores]. Higher scores represent greater levels of the mood parameter.
subjects on the Color-Associated Words (data
not shown; P = 0.014) and Incongruent Col¬
ors (P = 0.007) subtests of the Stroop Task.
Post hoc simple effects analysis demonstrated
that performance on the DS and Stroop Task
was poorer in the hypo subjects at all three
time points (P < 0.05), whereas perfor¬
mance on the FDS and BDS was significantly
poorer in the hypo subjects only at t2 and t3
(P < 0.05). The main effect of group on the
PASAT 2 second (P = 0.073) and BD (P =
0.060) tasks just failed to reach conventional
levels of statistical significance. No significant
main effects of group were demonstrated on
the information processing (IT, VCD, RT),
memory (FM, LM), TMB, and Borkowski
Verbal Fluency tasks (P > 0.05).
Main effects of group on mood scales
Significant main effects of group (hypo vs.
control subjects) were observed on the
HAD Depression (P = 0.011) and HAD
Anxiety (P = 0.049) scales. The hypo sub¬
jects had significantly higher HAD Depres¬
sion scale scores at all three time points
(P < 0.05) and significantly higher HAD
Anxiety scale scores at tj (P = 0.017). No
significant group effects were recorded with
any of the UWIST mood scores (P > 0.05).
Main effects of group on self-rated
cognitive ability
A significant main effect of group (hypo vs.
control subjects) was noted for the CFSA
total score (P = 0.002), with the hypo sub¬
jects having significantly lower levels of self-
rated cognitive ability at all three time points
(P < 0.05). At tj, three subjects in the hypo
group gave a self-rating on the CFSA change
score that suggested that a large deteriora¬
tion in cognitive ability had occurred with
time, eight subjects stated that cognitive
ability had declined slightly with time, and
nine subjects stated that they had experi¬
enced no change. In the control group, 18
subjects indicated that no change in their
cognitive ability had occurred with time,
and 2 subjects recorded a slight decline (P =
0.008). These responses were not signifi¬
cantly different at t2 and t3 (P > 0.05).
Main effects of time
All cognitive tasks, with the exception of the
FDS (P = 0.743) and BDS (P = 0.233) tests,
showed significant learning effects ,(as indi¬
cated by a statistically significant main effect
of time) (P < 0.05). The UWIST Energetic
Arousal scale and the HAD Depression scale
scores did not show a significant effect of
time (P > 0.05), but a time effect was seen
with the. UWIST Hedonic Tone scale (P =
0.014) and Tense Arousal scale (P = 0.006)
scores and the HAD Anxiety scores (P =
0.001). These scores do not affect the inter-
pretability of the effect of the experimental
variable (hypo vs. control subjects) because
they apply to both groups.
Effects of previous episodes of severe
hypoglycemia
After adjusting for severe hypoglycemia his¬
tory, differences in DS, BD, Stroop Task, FDS,
BDS, PASAT 4 second, HAD Anxiety, HAD
Depression, and CFSA scale scores (at time
points where significant simple effects were
obtained) became nonsignificant (P > 0.05).
CONCLUSIONS — To our knowl¬
edge, the present study is the first to
attempt to evaluate changes in moods and
cognitive functions prospectively in
patients with insulin-treated diabetes who
have experienced a spontaneous episode of
acute severe hypoglycemia. In the statistical
analysis, we anticipated that a significant
interaction between group and time effects
may be indicative of a "hangover" effect of
severe hypoglycemia on the cognitive
parameter measured, with performance
improving with time in the hypo subjects
more than in the control subjects. Such an
interaction was statistically significant in
only two cognitive tasks (BD and PASAT 4
second). However, the results for the
PASAT 4 second task can be interpreted as
showing a ceiling effect, with the perfor¬
mance of the control subjects at tt being
very close to maximum with little scope for
scores to improve with time.
Therefore, only 1 (BD) of the 14 cogni¬
tive tasks showed convincing evidence of a
hangover effect, which implies that, in gen¬
eral, any cognitive decrement resulting from
the acute episode of severe hypoglycemia
had recovered by the time of the initial test¬
ing session at 1.5 days. Evidence existed
that some aspects of mood may have taken
longer to recover because happiness and
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energy, as measured by the UWIST scale,
increased with time in the hypo subjects.
However, although such mood alterations
in response to severe hypoglycemia might
be expected, the simple effects for the sta¬
tistical interactions were not significant, and
the interpretation that acute severe hypo¬
glycemia lias a hangover effect on mood
must be made with caution.
The two study groups were well
matched regarding standard demographic
characteristics and premorbid IQ, but sub¬
jects in the hypo group had a previous his¬
tory of significantly more episodes of
severe hypoglycemia. Significant main
effects of group (hypo vs. control subjects)
were observed with several of the psycho¬
metric tests that measure fluid-type intelli¬
gence and attention and concentration
skills. In addition, the hypo subjects had
higher levels on the HAD Depression and
HAD Anxiety scales and had higher self-
rated levels of cognitive impairment
(CFSA), but no significant group effects
were observed with the memory or infor¬
mation processing tasks. Several previous
cross-sectional studies have suggested that
recurrent exposure to episodes of severe
hypoglycemia is associated with cumula¬
tive cognitive impairment (19-23). In the
present study, the differences in cognitive
performance and mood between the two
groups were abolished when we statisti¬
cally adjusted for the number of previous
episodes of severe hypoglycemia experi¬
enced by subjects. In addition, the differ¬
ence in mean IQ decrement index scores
(i.e., the difference in IQ scores as pre¬
dicted by the NART scale and as measured
by the WAIS-R scale) for the hypo and
control subjects was 8.5 points. This is
comparable with the mean difference in IQ
decrement scores of 5.8 points observed by
Langan et al. (20) when comparing dia¬
betic subjects who had a history of severe
hypoglycemia with those who had no his¬
tory of severe hypoglycemia. Therefore,
the difference in cognitive ability noted in
the current study between the hypo and
control subjects may possibly have been a
consequence of the previous exposure of
the former group to many more episodes of
severe hypoglycemia. However, the study
did not have power to investigate this issue
specifically, and the statistical adjustment
for the effects of exposure to previous
severe hypoglycemia should be interpreted
with caution because severe hypoglycemia
was itself a significant variable between the
study groups. The small sample size pre¬
cluded a sufficiently powerful correlational
analysis between cognitive performance
and previous severe hypoglycemia history
in the hypo subjects alone.
The elevated anxiety and depression
scores recorded in the hypo subjects have
been noted previously in diabetic patients
exposed to recurrent severe hypoglycemia
(40,41) and may be either a consequence
or a cause of the previous severe hypogly¬
cemia. Unfortunately, performing a surro¬
gate retrospective assessment of mood in a
similar manner to the use of the NART for
intellectual ability is not possible. Gonder-
Frederick and Cox (42) prospectively mea¬
sured symptoms of depression in 20
subjects who experienced two or more
episodes of severe hypoglycemia during a
6-month period and in 20 control subjects
who experienced no severe hypoglycemia
during that time. Depression scores (as
assessed by the Beck Depression Inven¬
tory) were comparable between the groups
at baseline but at 6 months were signifi¬
cantly higher in the subjects exposed to
severe hypoglycemia (42).
Most of the cognitive tasks showed a
practice effect, despite the fact that subjects
underwent training in the individual cog¬
nitive tasks before the formal test perfor¬
mance. This highlights the importance of a
parallel longitudinal control group in stud¬
ies of this type. The UWIST Tense Arousal
and Hedonic Tone and the HAD Anxiety
scale scores also showed a significant main
effect of time, with levels of tense arousal
and anxiety decreasing with time and lev¬
els of hedonic tone or happiness increasing
with time. This effect is likely to reflect the
natural initial apprehension of subjects
regarding participation in a clinical study.
This study has several limitations.
These include the relatively small sample
size, the absence of prehypoglycemia cog¬
nitive and mood data, and the need for
multiple statistical testing. The small sample
size means that a small hangover effect of
severe hypoglycemia on cognitive function
may not have been detected and precluded
meaningful analysis to determine whether
large individual differences existed regard¬
ing the effect of severe hypoglycemia. Major
difficulty was encountered in recruiting
insulin-treated diabetic patients after severe
hypoglycemia, despite the high frequency
of this problem in clinical practice. Most
episodes of severe hypoglycemia are treated
effectively in the community (43), and only
a small selected group requires hospitaliza¬
tion (44). An attempt to improve recruit¬
ment by advising the patients attending our
clinic and all local general practitioners in
advance that the study was ongoing was
unsuccessful. In addition, as observed pre¬
viously in a local survey of acute severe
hypoglycemia (44), recruitment was ham¬
pered by the fact that many of the diabetic
patients attending the hospital for emer¬
gency treatment were elderly, had concur¬
rent medical disorders, or were infrequent
attendees at the diabetic clinic. Further¬
more, many patients who were eligible for
inclusion were unable to participate in the
study because of the short notice or the time
constraints necessitated by the study design.
The collection of cognitive and mood data
on the hypo subjects before the index
episode of severe hypoglycemia would have
necessitated testing a large number of dia¬
betic subjects and a relatively long period of
follow-up to identify subsequent hypo¬
glycemic episodes. Future studies could
reduce the number of subjects who would
undergo cognitive (pre)testing by studying
subjects who are at high risk for severe
hypoglycemia (e.g., patients who have had
an episode of severe hypoglycemia in the
preceding year or who have impaired hypo¬
glycemia awareness). The large number of
statistical tests that were used in this study
increases the risk of type 1 statistical errors.
At the outset of the study, the specific areas
of cognitive function and mood that may
exhibit a hangover effect were not clear,
and clearly a balance had to be struck
between testing a wide number of cognitive
functions and risking type 1 errors versus
including a limited number of cognitive
measures and potentially missing an effect
in a cognitive domain not tested. Given the
exploratory and preliminary nature of the
present study, the former approach (using a
conventional level of statistical significance)
was adopted, and an illustrative Bonferroni
correction has been included.
In conclusion, these results imply that
acute severe hypoglycemia does not have a
prolonged effect on cognitive functions, and
patients with insulin-treated diabetes may
be reassured that performance of activities
such as work or driving is not likely to be
impaired 36 h after an episode. To deter¬
mine more precisely at what time cognitive
function recovers after severe hypoglycemia
would require further studies within the
period of 1.5 days. However, such investi¬
gations would pose considerable ethical and
practical difficulties. The persistent
impaired cognitive performance and mood
disturbance demonstrated by the hypo sub-
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jects may be a long-term consequence of
repeated exposure to previous episodes of
severe hypoglycemia.
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Abstract
Acute hypoglycemia impairs functions of the central nervous system, but few controlled studies have assessed the impact of
hypoglycemia on the function of the peripheral nervous system. Sixteen non-diabetic humans underwent two separate hyperinsulinemic
glucose clamp procedures on different study days, in a counter-balanced fashion. On one occasion, euglycernia was maintained (blood
glucose, 5.0 mmol 1 ~'), and on the other occasion, hypoglycemia (blood glucose, 2.6 mmol 1 ') was induced. During each condition,
subjects performed a combined psychometric, cognitive-experimental and psychophysical test battery, and measures were made (in the
dominant median and common peroneal nerves) of the motor nerve conduction velocities and the amplitudes of the motor action potentials.
Hypoglycemia caused impaired performance of general cognitive and information processing tasks (P<.05), but nerve conduction
velocities and the amplitudes of motor action potentials were unaffected. Conduction velocities of the common peroneal nerve decreased
from baseline within each experimental condition, perhaps due to hyperinsulinemia. Overall, these results demonstrate that multiple levels of
information processing in the brain may alter while peripheral nerve function remains intact, and imply that peripheral neurons do not have
the same obligate requirement for glucose as a metabolic fuel as neurons of the central nervous system. © 2001 Elsevier Science Inc. All
rights reserved.
Keywords: Hypoglycemia; Cognition; Nerve conduction; Information processing
1. Introduction
Acute hypoglycemia impairs function of the central
nervous system in humans. Controlled studies, with experi¬
mental hypoglycemia induced in a laboratory setting, have
demonstrated that a wide range of mental functions deterio¬
rate when arterialized venous blood glucose concentrations
decline to between 2.8 and 2.4 mmol 1 1 [1], Cognitive
functions that deteriorate include simple and choice reaction
times, speed of arithmetical calculation, verbal fluency, color
identification, trail-making and digit symbol test perfor¬
mance, digit span and other short-term memory indices [1],
Considerably less attention has focused on the effects of
hypoglycemia on the peripheral nervous system, but lim-
Corresponding author. Tel.: +44-131-650-3452; fax: +44-131-650-
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ited evidence in humans supports the existence of a
putative 'hypoglycemic neuropathy' [2], Several studies
in diabetic and non-diabetic rats have demonstrated that
hypoglycemia (blood glucose below 2.5 mmol 1 ') of
prolonged duration (at least 12 h) results in axonal degen¬
eration of peripheral nerves with consequent reduction of
nerve conduction velocities and evoked muscle action
potentials [3-5], In the spontaneously diabetic BB rat,
prolonged hypoglycemia (blood glucose less than 3.0
mmol 1 1 for 6 days) is associated with the development
of a motor peripheral neuropathy characterized by loss of
anterior horn motor neurons, loss of large myelinated fibers
and Wallerian degeneration [6], In humans, peripheral
neuropathy is a rare, but recognized, complication of
insulinoma (a tumor associated with chronic hypoglycemia)
[7-9]. The characteristic findings are those of a predomi¬
nantly motor peripheral neuropathy, which is distal and
symmetrical. Upper limb involvement is generally more
frequent and severe, and neurophysiological studies suggest
0031-9384/01/$ - see front matter © 2001 Elsevier Science Inc. All rights reserved.
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that the axon is the primary site of damage [7]. Following
resection of the insulinoma, weakness improves and sen¬
sory symptoms may resolve completely [7], Earlier obser¬
vations of psychiatric patients undergoing insulin-coma
therapy suggested that peripheral sensory disturbances
and, in some instances, sensory loss followed prolonged
insulin-induced hypoglycemia [10—12], In addition, anec¬
dotal reports exist of peripheral neuropathy being precipi¬
tated by the onset of strict glycemic control in diabetic
patients [13], in whom recurrent episodes of moderate
hypoglycemia are common.
Few data are available on the effects of more moderate
degrees and durations of hypoglycemia on peripheral nerve
function. Tamburrano et al. [14] did not identify any
change in median nerve sensory conduction velocity in
six non-diabetic human subjects in whom mean blood
glucose was maintained at 2.4 mmol 1- 1 for 60 min using
a glucose clamp technique. However, nerve conduction
studies were not performed on nerves in the lower limb,
and motor nerve conduction velocities were not measured.
In a different study, acute hypoglycemia (blood glucose,
2.4 mmol 1_ had no effect on median sensory nerve
conduction velocities in seven patients with insulinoma
[15], However, no information was provided on how, or if,
hypoglycemia was avoided in the period leading up to the
experimental studies, the order of the study sessions
(euglycemia vs. hypoglycemia) was not randomized and,
in the hypoglycemia studies, the neurophysiological read¬
ings were performed immediately after the blood glucose
nadir was reached so that insufficient time may have
elapsed for significant alterations in peripheral nerve func¬
tion to have occurred.
Moderate hypoglycemia is known to have significant
impact on functions of the central nervous system, and any
differential effect of hypoglycemia on the peripheral ner¬
vous system may offer insights into the metabolic require¬
ments of central and peripheral neurons. The primary aim of
the present study was, therefore, to consider the impact of 1
h of hypoglycemia (arterialized blood glucose, 2.6 mmol
1 ~ ') on the motor function of the median and common
peroneal nerves in non-diabetic humans.
A secondary aim of the investigation was, within a single
study, to examine comprehensively the effects of controlled
hypoglycemia on different levels of human information
processing. In a reductionist scheme, from the most com¬
plex to the simplest level, efficiency of information proces¬
sing in humans can be assessed using psychometric tests
(e.g. the processing speed test of the British Ability Scales),
cognitive-experimental tasks (e.g. choice reaction time pro¬
cedures), psychophysical tests (e.g. backward masking pro¬
cedures such as visual inspection time (IT) [16]) and
physiological tests (such as nerve conduction velocity
[17]). Speed of processing at all the above levels of
description is related in normal humans to mental ability
as measured using psychometric (IQ type) tests [18]. By
testing all such levels during hypoglycemia in the same
group of subjects, the lower level processes that may
contribute to the decrements in higher-level mental perfor¬
mance can be investigated.
2. Methods
2.1. Subjects
Sixteen non-diabetic human subjects (eight males) were
recruited from the staff at the Royal Infirmary of Edinburgh.
None had any relevant previous medical history or family
history of diabetes, and none were taking regular medication
(other than the oral contraceptive pill). All subjects had a
corrected visual acuity of 6/6 or better, as measured with a
Snellen chart. The mean age (±S.D.) was 31.1 (±8.3)
years, and the mean body mass index (±S.D.) was 23.1
(±2.2) kg m-2. All of the subjects had above average
intellectual ability as assessed by the National Adult Read¬
ing Test (NART) [19] and the Alice Heim 4 (AII4) Test
[20]. The mean (±S.D.) NART error score for 15 of the 16
subjects was 15.7 (±5.6), which predicted a mean (±S.D.)
intelligence quotient (IQ) of 111.2 ( ± 6.9); the NART was
not administered to one of the subjects whose first language
was not English. 'Hie mean (±S.D.) AH4 score for all 16
subjects was 98.8 (±17.0). Written informed consent was
obtained from all subjects and the study was approved by
the local medical ethics advisory committee.
2.2. Experimental procedure
Subjects attended three study sessions, each separated by
at least 2 weeks. The purpose of the initial visit was to
familiarize subjects with the tests that would be used in the
experimental sessions, so as to reduce the effects of practice
on test results. The results from this session were discarded.
In the following two study sessions, the participants under¬
went the experimental procedures during conditions of
either hypoglycemia or euglycemia (Fig. 1). The subjects
were not informed which condition was being studied at
each visit. Tire subjects completed both experimental con¬
ditions in a counterbalanced fashion, i.e. half of the subjects
underwent the euglycemia study first followed by the
hypoglycemia study and the other half underwent the
studies in the reverse order.
During the two experimental visits, subjects underwent a
glucose clamp procedure. Following a light breakfast at
07:00 hours, subjects were asked to go to the department at
midday. A Teflon cannula was inserted into an ante-cubital
vein in the subject's non-dominant arm under local anes¬
thetic (1% lignocaine). This cannula was used to infuse
human soluble insulin (Actrapid, Novo Nordisk Pharma¬
ceuticals, Crawley, UK) and 10% dextrose. A second
cannula was inserted in a retrograde direction into a vein
on the dorsum of the same hand, which was then placed in a
heated box (Plexiglas) at 60°C to arterialize the venous
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Fig. 1. Schematic representation of study design. Each subject attended two experimental sessions, which comprised 'baseline' (euglyceinia) and 'study'
(euglycemia or hypoglycemia) conditions. The durations of each condition are illustrated on the time scale. I and G represent the times at which insulin and
glucose infusions, respectively, were commenced. The test battery included the cognitive and nerve conduction studies and lasted approximately 1 h; to ensure
stability of the blood glucose concentrations, the battery was preceded by a 10 min period in which no tests were performed.
blood. Arterialized blood samples were obtained throughout
the study for the measurement of whole blood glucose at the
bedside using a glucose oxidase method (Yellow Springs
Instrument 2300 Stat, Yellow Springs, OH, USA). To
maintain patency, both cannulae were flushed frequently
with heparinized saline.
A modified hyperinsulinemic glucose clamp technique
was used to maintain the blood glucose at predetermined
levels [21], After a brief priming regimen, insulin was
infused at a steady rate (based on whole-body surface area)
of 60 mU m ~ min ~ 1 using an IMED Gemini PC 1 pump;
10% dextrose was infused, using an IVAC Site Saver pump,
at a variable rate according to the blood glucose value.
Arterialized blood glucose was initially measured every 3
min, until a stable level had been achieved, and then at 5-
min intervals. Counter-regulatory hormone concentrations
were not estimated.
At each laboratory session, the arterialized blood glu¬
cose concentration was initially stabilized at 5.0 mmol 1 -
for a period of 1 h during which baseline peripheral nerve
conduction velocities were measured and the subject
completed the mental test battery (baseline, Fig. 1). Fol¬
lowing this, the blood glucose concentration was either
maintained at 5.0 mmol 1_1 (euglycemia, Fig. 1) or
lowered to 2.6 mmol 1 ~ (hypoglycemia, Fig. 1) and
maintained at this level for 1 h, during which peripheral
nerve conduction velocities were measured every 30 min
and the neuropsychological test battery was repeated. The
subjects were not informed about their blood glucose
concentration during any phase of the study. A period of
20 min was allowed to elapse between the baseline and the
attainment of euglycemia or hypoglycemia to allow the
blood glucose concentration to stabilize. The target glu¬
cose concentration was maintained for a further 10 min
before the tests were administered.
2.3. Nerve conduction studies
Motor nerve conduction studies were performed by the
same investigator on the dominant-side median and com¬
mon peroneal nerves using a Medelec Sapphire" 2ME
electromyograph (Medelec, Old Woking, Surrey, UK).
Skin surface electrodes were utilized and these remained
in position during the course of each experimental study.
Motor nerves were stimulated orthodromically with supra¬
maximal electrical signals; the sites for nerve stimulation
were marked at the outset of each study session and
remained constant thereafter. Limb temperature was kept
constant at 34°C using a DISA thermostatically-regulated
heater (DISA, Bristol, UK). Recordings were made of the
median and common peroneal nerve motor conduction
velocities (ms ~ ) and of the amplitudes of the motor
action potentials (mV). 1'he ratio of the amplitudes of the
motor action potentials after distal and proximal stimula¬
tions was also calculated as an index of acute conduction
block. If acute conduction block occurred, then this
would give a distal to proximal amplitude ratio of greater
than 1.00. Measurements were made once during the
baseline, at the beginning (TO) of the study session
(hypoglycemia or euglycemia) and after 30 (T30) and
60 (T60) min.
2.4. Cognitive test battery
A combined psychometric, cognitive-experimental and
psychophysical test battery was applied during the baseline
and experimental phases of the euglycemia and hypoglyce¬
mia conditions. The order of the tests remained the same
during each phase of the visit, and the battery was inter¬
rupted only to allow measurement of peripheral nerve
conduction velocities at prerequisite lime points. Symptoms
I
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of hypoglycemia were also measured using the Edinburgh
Hypoglycemia Scale (EHS) [22],
2.4.1. Tests ofgeneral cognitive ability
Two complex psychometric tests were used to assess
general, high-level cognitive function. In many studies,
these have proved sensitive to moderate hypoglycemia:
2.4.1.1. Digit symbol task (DS). This is a subtest of the
Wechsler Adult Intelligence Scale-revised (WAIS-R) [23],
In the task, nine digits were represented by nine differ¬
ent symbols, and subjects were required to write down
the appropriate symbol for each in a given array of
numbers for over 90 s. The number of correct responses
was recorded.
2.4.1.2. Trail-making test B (TMB). This is a test from the
Halstead Reitan Neuropsychological Battery [24], The sub¬
ject had to connect correctly an alternating series of
numbers (113) and letters (A - L) in their respective orders
as quickly as possible. The time taken (in seconds) to
complete the task correctly was recorded.
2.4.2. Tests of information processing
Three tasks were employed to assess the efficiency of
information processing at the psychometric, cognitive-
experimental and psychophysical levels. Nerve conduction
assessed a still more basic level.
2.4.2.1. Speed of information processing (SIP). This is a
subtest of the British Ability Scales [25]. Subjects were
presented with a card on which 25 rows of five numbers
were printed. The complexity of the numbers increased
from the top to the bottom of the page. Subjects were
asked to circle the highest number on each row as
quickly as possible. Two cards were presented to each
subject: one containing 'easy' numbers, which were one
to four digits in length, and the other containing 'difficult'
numbers, which were three to six digits in length. For
each card, 'easy' and 'difficult', the time taken to
complete the task was recorded, as was the number of
errors made.
2.4.2.2. Reaction time (RT). Information processing was
measured at the cognitive-experimental level using a Hick-
type reaction time device [26]. The device, by employing a
'home' button and two clocks, allows the separation of the
decision and movement components of reaction times.
Measures were made of four-choice reaction time. Forty
trials were attempted and the median decision time (DT) and
median movement time (MT) were recorded in millise¬
conds. DT represents the time interval between the stimulus
light onset and the subject lifting his/her hand off the 'home'
button. MT represents the time interval between the subject
lifting his/her hand off the 'home' button and striking the
stimulus light button.
2.4.2.3. Inspection time. This is a two-alternative, forced-
choice discrimination task that utilizes an LED screen and
assesses the efficiency of the early stages of visual informa¬
tion processing using psychophysical procedures. The format
and theoretical basis of the test have been described in detail
[16,27], but, in brief, subjects have to indicate which of two
parallel vertical lines, ofmarkedly different lengths, is longer.
During the test, the experimenter varies the stimulus dura¬
tion, with shorter durations being more difficult. Only cor¬
rectness of response is recorded; response speed was not
measured, and the subject is instructed to respond at leisure to
achieve maximum accuracy. The IT test's adaptive staircase
algorithm measures the stimulus presentation time (in milli¬
seconds) required by each subject to achieve 85% accuracy in
responding (50% representing chance responding).
2.5. Edinburgh Hypoglycemia Scale
This is a subjective self-rating system, using a Likert
scale, [22] in which subjects are presented with a list of
symptoms of hypoglycemia and are asked to score the
severity of each symptom from 1 (not present) to 7 (very
intense). Symptoms scores were summated and classified
into three groups: autonomic (e.g. sweating, tremor, hun¬
ger), neuroglycopenic (e.g. confusion, drowsiness, inability
to concentrate) and nonspecific (nausea and headache).
2.6. Statistical analysis
All data are presented as means ± standard deviation
(S.D.). Each measure of cognitive and peripheral nerve
function was analyzed independently.
The effects of acute hypoglycemia on symptom scores
and cognitive performance were assessed using a mixed-
model analysis of variance (ANOVA). 'Order of session'









Fig. 2. Mean blood glucose concentrations (±S.D.) during the baseline and
study conditions of both the euglycemic (#) and hypoglycemic (■)
glucose clamps. There was no difference in blood glucose concentrations
during the baseline conditions. Blood glucose concentration was approxi¬
mately 5.0 mrnol 1 ~ 1 during the euglycemia experimental condition and
2.6 mmol 1 1 during the hypoglycemia experimental condition.
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Table I
Results of cognitive function tests and symptom scores during euglycemia and hypoglycemia
87
Euglycemia Hypoglycemia
F' P value"Baseline Study Baseline Study
Digit symbol (score)b 12.5 ± 10.8 77.2 ±10.2 72.5 ±10.7 67.0± 13.1 9.3 .009
Trail-making B (s) 26.5 ±10.1 24.6 ±8.0 27.0 ±9.7 33.0± 17.2 4.8 .045
Speed of information processing
Easy numbers (s) 48.1 ±8.2 49.1 ±9.5 51.4 ±14.8 57.6 ±16.8 3.4 .085
Easy errors (no.) 1.0± 1.5 1.2 ±1.3 0.9± 1.7 1.1 ± 1.2 0.3 .873
Difficult numbers (s) 69.7 ±12.3 65.6± 13.0 72.5 ±18.4 83.6±20.8 13.1 .003
Difficult errors (no.) 1.7± 1.8 2.1 ± 1.8 1.4± 1.3 1.9 ±2.5 0.1 .726
Four-choice reaction time
DT (tns) 300.9±22.1 298.5 ±20.8 304.4 ±30.1 328.9±46.5 7.0 .019
MT (ms) 115.1 ±26.5 109.2 ±24.4 117.4 ±24.5 128.9±34.3 9.6 .008
IT (tns) 47.6± 19.1 47.3 ±16.9 50.2 ±20.3 63.4 ±24.1 16.0 .001
Symptom scores
Autonomic 10.3 ±2.0 10.4± 1.5 11.1 ±2.5 21.1 ±7.6 17.1 .001
Neuroglycopenic 10.4± 1.5 10.8±3.3 10.4 ± 1.3 19.9± 12.0 8.0 .013
Malaise 2.0 ±0.0 2.1 ±0.3 2.4 ±1.0 2.5 ± 1.1 0.0 1.000
Results are presented from the baseline and study conditions of the englycemia and hypoglycemia study days (see Fig. 1). Values are means± S D
a F and P values refer to the interaction of 'Time' vs. 'Experimental condition' in ANOVA, i.e. they indicate, with reference to baseline scores, whether
hypoglycemia leads to a deterioration in outcomes by comparison with euglycemia.
b In tire digit symbol task, a higher score represents better performance; in all other cognitive tasks, a lower score indicates better performance. Higher
symptoms scores represent greater levels of hypoglycemia symptomatology.
(euglycemia-hypoglycemia or hypoglycemia-euglycae-
mia). There were two within subjects factors, each with
two levels; 'Experimental condition' (euglycemia vs. hypo¬
glycemia) and 'Time' (baseline vs. experimental). The
principal outcome statistic was any ['Experimental condi¬
tion' x 'Time'] interaction as this indicated the effects of
hypoglycemia on cognitive and symptom parameters and
controlled for day-to-day variation by including baseline
scores. The principal outcome statistic would pick up any
significant shift in outcome variables' scores attributable to
hypoglycemia. Significant main effects for 'Experimental
condition' are not reported, as subjects were euglycemic at
baseline during both the euglycemia and hypoglycemia
condition days, making this effect meaningless; importantly,
main effects of 'Experimental condition' do not indicate a
euglycemia-hypoglycemia difference. Significant main
effects of 'Time' are also not relevant in this context and
are not reported.
A mixed-model ANOVA was also used to assess the
effects of acute hypoglycemia on the median and common
peroneal nerve conduction parameters. 'Order of session'
was used as a between subjects factor with two levels
(euglycemia-hypoglycemia or hypoglycemia-euglycemia).
There were two within subjects factors; factor 1, 'Experi¬
mental condition', had two levels (euglycemia vs. hypogly¬
cemia) and factor 2, 'Time', had four levels (baseline vs. TO,
vs. T30, vs. T60). In addition to the principal outcome
statistic of any ['Experimental condition' x 'Time'] interac¬
tion, the main effects of'Time' and 'Experimental condition'
are also reported.
A P value of < .05 was considered to be significant. All
analyses were performed using SPSS version 7.5.1 for
Windows 95.
3. Results
Stable glycemic plateaus were achieved for every subject
in each condition of the study (Fig. 2). The whole blood
glucose (mean±S.D.) during the baseline euglycemic
clamps was 4.95 ±0.15 mmol 1 '. During the experimental
conditions of euglycemia and hypoglycemia, blood glucose






Fig. 3. Mean motor nerve conduction velocities (±S.D.) in doininant-side
median nerves at four time points — B (baseline), TO, T30, T60 (T=time;
0, 30 and 60 min). (•) Data from the euglycemia study day; (■) Data from
the hypoglycemia study day. Moderate hypoglycemia had no significant
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Fig. 4. Mean motor nerve conduction velocities (±S.D.) in dominant-side
common peroneal nerves at four time points — B (baseline), TO, T30, T60
(T = time; 0, 30 and 60 min). (#) Data from the euglycemia study day; (■)
Data from the hypoglycemia study day. Moderate hypoglycemia had no
significant effect on nerve conduction velocities.
tively. There were no statistically significant effects of order
on any of the outcome variables.
3.1. Symptoms
During the hypoglycemic condition of the study, signifi¬
cant increments occurred both in autonomic and neurogly-
copenic symptom scores (P< .05), but no significant change
was observed in the nonspecific symptoms of malaise
(Table 1).
3.2. General cognitive function tests
Moderate hypoglycemia resulted in a deterioration in
performance of the digit symbol and trail-making B tasks
(both P<.05; Table 1).
3.3. Tests of information processing
The time taken to complete the 'difficult' subset of the
SIP test from the British Ability Scales was prolonged by
acute hypoglycemia (P<.05; Table 1), but the time taken to
complete the 'easy' task failed to reach statistical signifi¬
cance (P=.09). There was no change in the number oferrors
made, which was low in each subtest. Moderate hypogly¬
cemia also resulted in a deterioration in performance of the
IT task and in the DT and MT components of the four choice
reaction time (all P<.05; Table 1).
3.4. Nerve conduction studies
3.4.1. Effects of interaction of 'Experimental condition ' and
'Time' on nerve conduction parameters
Acute hypoglycemia had no significant effect on the
motor nerve conduction velocities of the median and com¬
mon peroneal nerves (Figs. 3 and 4). Similarly, acute
hypoglycemia did not alter the amplitudes of the evoked
action potentials of either nerve after proximal or distal
stimulation, nor did it affect the ratio of the distal to
proximal amplitudes (Table 2).
3.4.2. Main effects of 'Experimental condition' on nerve
conduction parameters
The amplitudes of median nerve evoked potentials after
proximal stimulation were smaller during the hypoglycemia
study day than the euglycemia study day (/J=.02), and there
was also a nonsignificant trend for the amplitudes after
distal stimulation to be smaller during the hypoglycemia
study day ( P=. 11). There were no significant main effects
of 'Experimental condition' on median nerve conduction
velocities or on any of the common peroneal nerve con¬
duction parameters.
3.4.3. Main effects of 'Time' on nerve conduction
parameters
There was a significant main effect of'Time' on common
peroneal nerve conduction velocities (P=.00), i.e. nerve
conduction velocities in both experimental conditions
declined with time within the experimental sessions. No
]± 1 1 1 1
• ■ Eug
■ Hypo
B TO T30 T60
Timepoint
Table 2
Conduction amplitudes in median and common peroneal motor nerve after proximal and distal stimulation
Euglycemia Hypoglycemia
Baseline TO T30 T60 Baseline TO T30 T60 Fa P value'
Median nerve amplitudes (mV)
Proximal 7.3 ±3.4 7.7±3.6 6.4 ±3.7 6.6 ±3.2 5.9 ±3.2 4.8 ±3.1 5.3±3.0 6.5 ±3.2 2.4 .083
Distal 8.6±3.2 8.2 ±3.3 7.4 ±3.9 7.2 ±3.2 6.4 ±3.1 5.0 ±3.2 5.5 ±2.6 6.0 ±2.9 1.4 .246
Ratio (D/P) 1.4 ±0.8 1.2 ±0.6 1.4 ± 1.4 1.2 ±0.4 1.2 ±0.4 1.1 ±0.4 1.2±0.8 0.9 ±0.1 0.2 .882
Peroneal nerve amplitudes (m V)
Proximal 2.4 ±1.6 2.9± 1.7 3.1 ±1.8 2.9± 1.8 2.9± 1.6 2.9±2.8 2.7 ±1.5 3.5 ±3.1 0.6 .595
Distal 2.7 ±1.8 3.1 ±2.3 3.1 ±2.2 3.0±2.2 2.9 ±2.2 2.9 ±2.7 2.6 ±1.6 2.6 ±1.9 0.5 .683
Ratio (D/P) 1.1 ±0.6 1.0 ±0.6 1.0±0.3 1.0 ±0.4 1.0 ±0.3 1.3 ± 1.0 1.0 ±0.5 I.0±0.6 2.1 .120
Results are presented from the baseline and study conditions of the euglycemia and hypoglycemia study days (see Fig. 1). Values are means ±S.D. The ratio
of distal to proximal amplitudes is a measure of acute conduction block, which if present would be expected to result in a ratio of greater than 1.0.
a F and P values refer to the interaction of 'Time' vs. 'Experimental condition' in ANOVA, i.e. they indicate, with reference to baseline scores, whether
hypoglycemia leads to a deterioration in outcomes by comparison with euglycemia.
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main effect of 'Time' was observed on the common per¬
oneal amplitude data, or on any of the median nerve
neurophysiological parameters.
In summary, levels of information processing from
psychometric, through cognitive to psychophysical were
impaired during hypoglycemia, while nerve conduction
velocities were unaffected.
4. Discussion
Neurons of the central nervous system are exquisitely
sensitive to the prevailing blood glucose concentration, with
even moderate hypoglycemia resulting in significant impair¬
ment of neuronal function, as evidenced by the development
of cognitive dysfunction [1], Experimental studies in ani¬
mals [3-6] and anecdotal reports in humans [7-12] have
also suggested that profound and protracted hypoglycemia
adversely affects peripheral nerve function, and may pre¬
cipitate the development of a peripheral neuropathy. The
effects of more moderate degrees and durations of hypogly¬
cemia on peripheral nerve function have not been defini¬
tively ascertained.
Previous studies demonstrated that acute moderate hypo¬
glycemia had no impact on median nerve sensory function
in both non-diabetic subjects [14] and in patients with
insulinoma [15]. However, these studies had significant
methodological limitations, which were described in the
Introduction, and which included very small sample sizes.
The present study has supported and extended these earlier
observations by demonstrating that acute hypoglycemia had
no effect on the motor conduction velocities of the domi¬
nant-side median and common peroneal nerves. The ampli¬
tudes of the action potentials were similarly unaffected, and
there was no evidence of acute conduction block. The
differences observed between the median nerve evoked
potential amplitudes measured on the euglycenria and
hypoglycemia study days (which included the baseline
euglycemic measurements during both days) do not afford
an obvious physiological explanation and might represent a
chance occurrence (i.e. a Type 1 statistical error). The
tendency for the ratio of median nerve distal to proximal
amplitudes to be greater than 1.00 was predictable [28],
since proximal stimulation may give rise to evoked poten¬
tials that are of slightly longer duration and lower amplitude
than those observed following distal stimulation, because
the impulses of slow-conducting fibers lag behind those of
fast-conducting fibers over a long conduction path.
4.1. Methodological considerations
It is reasonable to speculate whether any methodological
issues such as sample size, the depth of hypoglycemia
attained, the nature of the nerves chosen for neurophysio¬
logical study or the nerve conduction studies themselves
could have accounted for this null result.
The present study had ample power to detect differ¬
ences in cognitive function during acute hypoglycemia.
Moreover, because subjects acted as their own controls the
sample size provided approximately 80% power to detect
a 0.75 S.D. change in median nerve conduction velocities
with a P value set at .05. Median and common peroneal
nerve conduction velocities did appear to be consistently
1.0-1.5 m/s slower during hypoglycemia compared with
euglycemia, but these differences were highly nonsignifi¬
cant. It is just conceivable that these differences could
have become statistically significant in a larger study, but
the magnitude of such a difference would be of minimal
clinical relevance.
An arterialized blood glucose concentration of 2.6 ntmol
1 1 was chosen for the hypoglycemia phase of the inves¬
tigations as numerous previous studies have demonstrated
that this blood glucose level is associated with significant
impairment of cognitive functions [1], Therefore, if periph¬
eral nerves had a similar reliance on glucose as a metabolic
fitel as central nervous system neurons, then this level of
hypoglycemia should have been sufficient to demonstrate a
decrement in function. Lower blood glucose concentrations
are associated with increased physical discomfort for sub¬
jects, and it was not ethically justifiable to induce more
profound hypoglycemia.
The common peroneal and median nerves were chosen
for several reasons. Both nerves are readily accessible for
performing neurophysiological studies, and their stimula¬
tion causes minimal discomfort to subjects. Peripheral
neuropathies tend to affect longer nerves rather than
shorter nerves, therefore, the common peroneal nerve
was chosen on the theoretical basis that its long length
may have made it more susceptible to the effects of
moderate hypoglycemia. The median nerve was chosen
since animal and human studies suggested that 'hypogly¬
cemic neuropathy' affects predominantly upper limb
nerves. Sensory neural function was not assessed in this
study on the basis that 'hypoglycemic neuropathy' primar¬
ily affects motor nerves and two previous studies, albeit of
limited methodological quality, had previously shown no
susceptibility of peripheral sensory nerves to acute hypo¬
glycemia [14,15]. In addition, the measurement of sensory
nerve function causes considerably more discomfort to
subjects and is open to greater technical errors because
the amplitudes of the evoked potentials are considerably
smaller (leading to a reduced signal-to-noise ratio) [28],
There was a limited amount of time available in the
context of each clamp study to perform nerve conduction
studies, and it was felt that this would best be utilized
measuring motor nerve function.
In current clinical practice, nerve conduction studies,
and, in particular, the measurement of nerve conduction
velocities and the amplitudes of the evoked potentials,
represent the most effective methodology for assessing the
functions of peripheral nerves [28], It is possible to
measure other electrophysiological parameters, such as F
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waves (which measure conduction time from the peripheral
nerve to the spinal cord and back) and nerve refractory
period (i.e. the shortest time interval between two sequen¬
tial nerve stimuli that generate two sequential evoked
potentials). It was not felt that the measurement of these
parameters would have added considerably to the assess¬
ment of peripheral neural function. In particular, the
measurement of refractory period is a time-consuming
process and in a previous pilot study of four male
Sprague-Dawley rats, acute hypoglycemia (arterial blood
glucose nadir of 1.66 mmol l_l induced by insulin
infusion) had no effect on the refractory period of the
right femoral nerve [29].
The foregoing paragraphs, therefore, suggest that metho¬
dological issues do not account for the results of the present
study and that the inability to detect any significant change in
the neurophysiological parameters of peripheral nerves dur¬
ing hypoglycemia indicates resistance of peripheral neural
function to neuroglycopenia.
4.2. Main effects of 'Time' on common peroneal nerve
conduction velocities
The significant change in common peroneal nerve con¬
duction velocities that occurred with time during the hypo¬
glycemia and euglycemia studies was unexpected and was
not observed in any of the other peripheral nerve neurophy¬
siological measurements. Tamburrano et al. [14] did not
report any impact of hyperinsulinemic euglycemia on med¬
ian sensory nerve conduction velocities in five non-diabetic
subjects, and in a later study on nerve conduction para¬
meters in patients with insulinoma no time course data was
provided |I5]. While this observation could have resulted
by chance, it should be noted that nerve conduction velo¬
cities are generally regarded as being highly reproducible
within individual subjects (in contrast to amplitude mea¬
surements) [30]. It is, therefore, tempting to speculate that
hyperinsulinemia per se affected the common peroneal
nerve conduction velocities, although the reason for a lack
of effect on median nerve conduction velocities would
require explanation. One possibility would be that the
greater length of the common peroneal nerve may have
made it more susceptible to metabolic perturbation. The
institution of intensive insulin therapy in diabetic patients
with poor glycemic control can promote the development of
a peripheral neuropathy [13], but, of course, in observational
studies such as this, and others that have looked at 'hypo¬
glycemic neuropathy', it is not possible to separate a
potential direct toxic effect of insulin itself from its hypo¬
glycemic actions. Greene et al. [31], however, reported no
direct toxic effects of insulin on isolated endoneural pre¬
parations of rat peripheral nerve. Therefore, the observation
that common peroneal motor nerve conduction velocities
changed with time and the speculation that this may be
related to hyperinsulinemia must be re-assessed in future
appropriately controlled studies.
4.3. Symptoms of hypoglycemia
Acute hypoglycemia predictably caused an increase in
autonomic and neuroglycopenic symptoms of hypoglyce¬
mia, but did not affect the 'nonspecific' symptoms of nausea
and malaise. The insensitivity of the 'nonspecific' symp¬
toms to hypoglycemia has been identified in other studies
[27,32]. The three-factor model of hypoglycemic symptoms,
which is utilized in the EMS, is based on a multifactor
confirmatory factor analysis of symptoms of hypoglycemia
that were retrospectively recalled by two large groups of
diabetic subjects [33], Therefore, the relative insensitivity of
the 'nonspecific' symptoms, in the present and previous
studies, suggests that this model may not be appropriate for
symptoms of hypoglycemia induced during hyperinsuline-
mic clamp studies.
4.4. Implications for understanding human intelligence
differences
By contrast to its effects on the peripheral nervous
system, acute hypoglycemia caused significant disruption
of central neural function as evidenced by impaired perfor¬
mance in the majority of tasks in the cognitive test battery.
The time taken to complete the 'easy' subtest of the SIP task
just failed to reach statistical significance, but moderate
hypoglycemia had no significant effect on the number of
errors made in either the 'easy' or the 'difficult' subtests of
this task. These findings are consistent with previous studies
suggesting that hypoglycemia causes greater impairment of
complex cognitive tasks than simple tasks [1,27,32], and
that accuracy of performance of a given task tends to be
preserved at the expense of speed [34,35],
A significant correlation of low effect size (r< .2) exists
between peripheral nerve conduction velocity and psycho¬
metric intelligence test scores [36], It has been hypothesized
that this association might explain some of the covariation
found between mental ability differences and speed-of-
information-processing indices such as reaction times [37]
and IT [38], i.e. that more intelligent people have faster
central neuronal functioning and that peripheral nerve con¬
duction velocities may be a surrogate marker of this. A
partial refutation of this hypothesis arises from studies that
have found no reduction in correlations between psycho¬
metric intelligence and reaction times after statistically
controlling for nerve conduction velocity differences (using
partial correlation) [39,40], The present study adds further
evidence that may be interpreted as a refutation of the
premise that differences in peripheral nerve conduction
velocity form a partial basis for the association between
psychometric intelligence and measures of information
processing efficiency. Moderate hypoglycemia impaired
psychometric ability test scores, reaction times and visual
information processing, but peripheral nerve conduction
velocity was unaffected. Of course, it remains perfectly
feasible that speed of neuronal conduction within the central
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nervous system could still relate to speed of information
processing and intelligence, but further studies are clearly
required to investigate this in more detail.
4.5. Explaining the differential sensitivity of the central and
peripheral nervous systems to acute hypoglycemia
The marked disparity in the effects of acute hypogly¬
cemia on peripheral and central neural system function
implies that peripheral nerves do not have the same
reliance on prevailing blood glucose concentrations as is
demonstrated by neurons of the central nervous system.
Neural components of peripheral nerves are separated
from plasma and general extracellular fluid by endoneural
capillaries and the perineural membrane, which form a
'blood-nerve' barrier that has similar properties to the
blood-brain barrier in preventing the passive transfer of
large molecules [41,42], As with neurons in the central
nervous system, glucose is the major substrate for energy
production in peripheral neural tissue, when plasma con¬
centrations of ketone bodies are not elevated [31]. Incuba¬
tion of isolated nerve fascicles in a glucose-deficient
medium produces a profound fall in glucose in nerve
tissue, with reduced oxygen uptake and decrements in
neural oxygen and ATP levels [31]. Glucose utilization in
peripheral nerves does not appear to be regulated directly
by insulin [31], which is also the case with neurons in the
central nervous system. Peripheral neurons can, however,
adapt to prolonged exposure to a low blood glucose. This
was demonstrated by an elegant study of non-diabetic rats
in which the anterograde fast component of axonal trans¬
port in peripheral neural tissue was reduced by 36%
following the induction of acute hypoglycemia (blood
glucose ~ 1.5 mmol 1 ~ 1 for 2 h) [43], The reduction in
axonal transport was prevented, however, by pretreatment
of the animals for 3 days with insulin to induce prolonged
moderate hypoglycemia [43], The mechanisms behind this
adaptive response to hypoglycemia are not clear, but it is
also recognized that the brains of rats adapt gradually to
chronic hypoglycemia over a period of days, by up-
regulation of the GLUT 1 blood-brain barrier glucose
transport protein [44], This acts to increase extraction of
glucose from the circulation during periods of hypoglyce¬
mia [45], In human studies of non-diabetic and diabetic
subjects, a similar adaptive mechanism has been demon¬
strated, preserving cerebral function at lower blood glu¬
cose concentrations than normal [46,47], However, short-
term adaptation of cerebral function to 1 h of hypoglyce¬
mia does not occur [48], indicating that this is a relatively
slow process.
There are, therefore, several possible explanations
whereby peripheral neural tissue may be unaffected by
moderate hypoglycemia. Peripheral neurons have stores of
glycogen, and these may provide sufficient energy to
sustain neural metabolism during periods of short-lived,
moderate hypoglycemia [31]. Alternatively, peripheral
neurons may utilize other energy substrates, such as
ketone bodies, fructose, lactate, amino acids and free fatty
acids [31,49] more efficiently than the brain. It is also
possible that the 'blood-nerve' barrier may have a con-
stitutively greater ability at extracting glucose from the
circulation, or that peripheral neurons have a lower overall
glucose requirement.
5. Conclusions
In summary, acute hypoglycemia caused predictable
disruption of cognitive functions as assessed by tasks of
general cognitive ability and multiple levels of speed of
information processing. However, acute hypoglycemia had
no demonstrable effect on the function of peripheral nerves
in healthy adult volunteers. This implies that neurons of
the peripheral nervous system do not have the same
obligate requirement for glucose as a metabolic fuel as
neurons of the central nervous system. The data also
partially refute the hypothesis that speed of conduction
within the peripheral nervous system may be used as a
marker of speed of nerve conduction within the central
nervous system, and thus be a measure of speed of
information processing and intelligence.
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